CONTENTS

NUMBER 1, JANUARY, 1956

Relation of Circulating Red Cell Volume to Body Density and Obesity. REX L. HUFF AND D. D. FELLER 1
The Effect of Certain Chelating Substances (EDTA) upon Cholesterol Metabolism in the Rat. RAY H. ROSENMAN AND MALCOLM K. SMITH 11
Observations on the Metabolic Effects of the Carbonic Anhydrase Inhibitor Diamox®: Mode and Rate of Recovery from the Drug's Action. T. HANLEY AND M. M. PLATTS 20
The Distribution of Chlormerodrin (Neohydrin®) in Tissues of the Rat and Dog. R. R. M. BORGHGRAEF AND R. F. PITTS 31
Distribution of Radiomercury Administered as Labelled Chlormerodrin (Neohydrin®) in the Kidneys of Rats and Dogs. ROGER L. GREIF, W. JAMES SULLIVAN, GLORIA S. JACOBS, AND ROBERT F. PITTS 38
Studies on the Metabolism of Plasma Proteins in the Nephrotic Syndrome. I. Albumin, γ-Globulin and Iron-Binding Globulin. DAVID GITLIN, CHARLES A. JANEWAY, AND LEE E. FARR 44
Response to Triiodothyronine as Index of Persistence of Disease in the Thyroid Remnant of Patients in Remission from Hyperthyroidism. SIDNEY C. WERNER 57
The Metabolic Response to Burns. ERIC REISS, ELINOR PEARSON, AND CURTIS P. ARTZ 62
Studies in Calcium Metabolism. The Fate of Intravenously Injected Radiocalcium in Human Beings. FELIX BRONNER, ROBERT S. HARRIS, CONSTANTINE J. MALETSKOS, AND CLEMENS E. BENDA 78
The Anemia of Infection. XX. The Kinetics of Iron Metabolism in the Anemia Associated with Chronic Infection. J. A. BUSH, HELEN ASHENBRUCKER, G. E. CARTWRIGHT, AND M. M. WINTROBE 89
The Response of Bone, Connective Tissue, and Muscle to Acute Acidosis. MARVIN F. LEVITT, LOUIS B. TURNER, AVRON Y. SWEET, AND DEMETRA PANDIRI 98
Chromatographic Purification of Human Serum Accelerator Globulin. FREDERICK M. COX, GERARD F. LANCHANTIN, AND ARNOLD G. WARE 106
Excretion of Sodium and Potassium in Human Sweat. IRVING L. SCHWARTZ AND JØRN HESS THAYSEN 114
The Effect of Plasma on the *In Vitro* Uptake or Binding by Human Red Cells of Radioactive I-131 Labeled L-Thyroxine and L-Triiodothyronine. K. R. CRISPELL, SHIRLEY KAHANA, AND HARRY HYER 121
A Relation between Hemodynamic and Plasma Volume Alterations during General Anesthesia in Man. HENRY L. PRICE, MARTIN HELRICH, AND EUGENE H. CONNER 125

NUMBER 2, FEBRUARY, 1956

Lipoproteins in Primary Biliary Cirrhosis. ELLA M. RUSS, JULIE RAYMUNT, AND DAVID P. BARR 133
An Asolectin Adsorbed Substrate for Proaccelerin Assay. ARTHUR J. SEAMAN AND PAUL A. OWREN 145
A Relation between Non-Esterified Fatty Acids in Plasma and the Metabolism of Glucose. VINCENT P. DOLE 150
Response to Mercurial Diuretics during Alkalosis: A Comparison of Acute Metabolic and Chronic Hypokalemic Alkalosis in the Dog. GILBERT H. MUDGE AND BYRON HARDIN 155
A Study of the Rate of Protein Synthesis before and during the Administration of L-Triiodothyronine to Patients with Myxedema and Healthy Volunteers Using N-15 Glycine. K. R. CRISPELL, WILLIAM PARSON, AND GUY HOLLIFIELD 164

Insulin-I^{131} Metabolism in Human Subjects: Demonstration of Insulin Binding Globulin in the Circulation of Insulin Treated Subjects. SOLOMON A. BERSON, ROSALYN S. YALOW, ARTHUR BAUMAN, MARCUS A. ROTHSCHILD, AND KATHARINA NEWERLY 170
The Effect of Sodium Glutamate on Hepatic Coma. LESLIE T. WEBSTER, JR., AND CHARLES S. DAVIDSON 191
Immunity in Volunteers Recovered from Nonbacterial Gastroenteritis. IRVING GORDON, PAUL R. PATTERSON, AND ELINOR WHITNEY 200
Unesterified Fatty Acid in Human Blood Plasma. ROBERT S. GORDON, JR., AND AMELIA CHERKES 206
Virilizing Adrenal Hyperplasia; A Genetic and Hormonal Study. BARTON CHILDS, MELVIN M. GRUMBACH, AND JUDSON J. VAN WYK 213
The Mechanism of the Excretion of Ammonia in the Dog. JACK ORLOFF AND ROBERT W. BERLINER 223
Certain Aspects of Tyrosine Metabolism in the Young. I. The Development of the Tyrosine Oxidizing System in Human Liver. NORMAN KRETCHMER, S. Z. LEVINE, HELEN MCNAMARA, AND HENRY L. BARNETT 236
The Acute Effects in Man of a Rapid Intravenous Infusion of Hypertonic Sodium Bicarbonate Solution. II. Changes in Respiration and Output of Carbon Dioxide. R. B. SINGER, R. C. DEERING, AND J. K. CLARK 245
Metabolism of Salt-Retaining Hormone by Surviving Liver Slices. JEROME J. CHART, EDGAR S. GORDON, PHYLLIS HELMER, AND MARJORIE LESHER 254
Evaluation of Respiratory Compensation in Metabolic Alkalosis. KATHLEEN E. ROBERTS, J. W. POPPELL, PARKER VANAMEE, ROBERT BEALS, AND HENRY T. RANDALL 261

NUMBER 3, MARCH, 1956

Postural Effect on Renal Tubular Activity. A. SURTSHIN AND H. L. WHITE 267
The Hemodynamics of Thyrotoxicosis in Man with Special Reference to Coronary Blood Flow and Myocardial Oxygen Metabolism. GEORGE G. ROWE, JOHN H. HUSTON, ARVIN B. WEINSTEIN, HERMAN TUCHMAN, JOHN F. BROWN, AND CHARLES W. CRUMPTON 272
The Fate of Sodium Glucuronate and Glucuronolactone in Man. ROBERT M. DOWBEN 277
The Permeability of Capillaries to Serum Cholesterol. GEORG GEYER, FRANZ S. M. HERBST, H. THALER, AND WALTER F. LEVER 281
The Dynamics of Leukopoiesis and Leukocytosis, as Studied by Leukopheresis and Isotopic Techniques. CHARLES G. CRADDOCK, JR., SEYMOUR PERRY, AND JOHN S. LAWRENCE 285
The Effect of Nor-Epinephrine on the Electrolyte Composition of Arterial Smooth Muscle. LOUIS TOBIAN AND ADACIE FOX 297
The Physiologic Explanation of the Changes in the Coronary Circulation Following Prolonged Aortico-Coronary Sinus Anastomosis. ALVIN A. BAKST, ROSARIO MANIGLIA, AND CHARLES P. BAILEY 302
Studies of the Antidiuresis of Quiet Standing: Observations upon Electrolyte and Acid-Base Excretion during Sulfate Diuresis. FRANKLIN H. EPSTEIN, CHARLES R. KLEEMAN, EZRA LAMDIN, AND MILTON E. RUBINI 308
Studies on Myocardial Metabolism. V. The Effects of Lanatoside-C on the Metabolism of the Human Heart. J. M. BLAIN, E. E. EDDLEMAN, A. SIEGEL, AND R. J. BING 314
A Rapid Plethysmographic Method for Measuring Thoracic Gas Volume: A Comparison with a Nitrogen Washout Method for Measuring Functional Residual Capacity in Normal Subjects. ARTHUR B. DUBOIS, STELLA Y. BOTELHO, GEORGE N. BEDELL, ROBERT MARSHALL, AND JULIUS H. COMROE, JR. 322

A New Method for Measuring Airway Resistance in Man Using a Body Plethysmograph: Values in Normal Subjects and in Patients with Respiratory Disease. ARTHUR B. DUBOIS, STELLA Y. BOTELHO, AND JULIUS H. COMROE, JR. 327
Measurement of the Volume of Gas in the Gastro-Intestinal Tract. Values in Normal Subjects and Ambulatory Patients. GEORGE N. BEDELL, ROBERT MARSHALL, ARTHUR B. DUBOIS, AND JOHN H. HARRIS 336
The Fat, Protein and Nucleic Acid Content of the Liver in Malnourished Human Infants. J. C. WATERLOW AND T. WEISZ 346

NUMBER 4, APRIL, 1956

Studies on Platelets. XIV. Human Platelets as Source of Antifibrinolysin. MARIO STEFANINI AND IRENE S. MURPHY 355
The Induction of Gross Myocardial Lesions by a Coxsackie (Pleurodynia) Virus and Cortisone. EDWIN D. KILBOURNE, CHARLES B. WILSON, AND DOROTHY PERRIER 362
Asolectin Separation of Prothrombin from Proconvertin. ARTHUR J. SEAMAN AND PAUL A. OWREN 371
Effect of a Phenylbutazone Analog (4-[Phenylthioethyl]-1,2-Diphenyl 3,5-Pyrazolidinedione) on Urate Clearance and Other Discrete Renal Functions in Gouty Subjects. Evaluation as Uricosuric Agent. T. F. YÜ, BRUCE C. PATON, THEODORE CHENKIN, J. J. BURNS, BERNARD B. BRODIE, AND ALEXANDER B. GUTMAN 374
Studies on Alcohol Diuresis. III. The Response to Ethyl Alcohol in Certain Disease States Characterized by Impaired Water Tolerance. EZRA LAMDIN, CHARLES R. KLEEMAN, MILTON RUBINI, AND FRANKLIN H. EPSTEIN 386
The Physical Properties of the Lung in Chronic Obstructive Pulmonary Emphysema. REUBEN M. CHERNIACK 394
The Fractionation of Cholesterol in Body Fluids by Means of Solvent Extraction. SANFORD O. BYERS AND MEYER FRIEDMAN 405
Familial Hypoglycemia Precipitated by Amino Acids. W. A. COCHRANE, W. W. PAYNE, M. J. SIMPKISS, AND L. I. WOOLF 411
The Effect of Estrogen on Water and Electrolyte Metabolism. I. The Normal. JOHN R. K. PREEDY AND ELSIE H. AITKEN 423
The Effect of Estrogen on Water and Electrolyte Metabolism. II. Hepatic Disease. JOHN R. K. PREEDY AND ELSIE H. AITKEN 430
The Effect of Estrogen on Water and Electrolyte Metabolism. III. Cardiac and Renal Disease. JOHN R. K. PREEDY AND ELSIE H. AITKEN 443

NUMBER 5, MAY, 1956

The Properdin System and Immunity. IV. The Hemolysis of Erthrocytes from Patients with Paroxysmal Nocturnal Hemoglobinuria. CARL F. HINZ, JR., WILLIAM S. JORDAN, JR., AND LOUIS PILLEMER 453
The Production and Identification of Antibodies to Insulin and Their Use in Assaying Insulin. EDWARD R. ARQUILLA AND ABRAM B. STAVITSKY 458
Evidence for the Insulin-Directed Specificity of Rabbit Anti-Insulin Serum. EDWARD R. ARQUILLA AND ABRAM B. STAVITSKY 467
A Study of the Relative Binding Capacity of Plasma Proteins, Intact Human Red Cells, and Human Red Cell Stroma for Radioactive I-131 Labeled L-Thyroxine. K. R. CRISPELL AND JOSEPH COLEMAN 475
The Effect of Acute Elevation of the Plasma Chloride Concentration on the Renal Excretion of Bicarbonate during Acute Respiratory Acidosis. JAMES G. HILTON, NICHOLAS E. CAPECI, GEORGE T. KISS, OSCAR R. KRUESI, VINCENT V. GLAVIANO, AND RENÉ WÉGRIA 481

Placental Passage of 17-Hydroxycorticosteroids: Comparison of the Levels in Maternal and Fetal Plasma and Effect of ACTH and Hydrocortisone Administration. CLAUDE J. MIGEON, HARRY PRYSTOWSKY, MELVIN M. GRUMBACH, AND MARGARET C. BYRON..... 488
The Effect of Glucagon on Carbohydrate Metabolism in Normal Human Beings. PHILIP K. BONDY AND LEO R. CARDILLO..... 494
Gastrointestinal Water and Electrolytes. I. The Equilibration of Radiosodium in Gastrointestinal Contents and the Proportion of Exchangeable Sodium (Na_e) in the Gastrointestinal Tract. I. S. EDELMAN AND N. J. SWEET..... 502
Gastrointestinal Water and Electrolytes. II. The Equilibration of Radiopotassium in Gastrointestinal Contents and the Proportion of Exchangeable Potassium (K_e) in the Gastrointestinal Tract. J. NADELL, N. J. SWEET, AND I. S. EDELMAN..... 512
The Causal Role of Plasma Albumin Deficiency in Experimental Nephrotic Hyperlipemia and Hypercholesteremia. RAY H. ROSENMAN, MEYER FRIEDMAN, AND SANFORD O. BYERS.. 522
The Action of Heparin in the Prevention of Prothrombin Conversion. A. S. DOUGLAS..... 533
Bilirubin-Protein Linkages in Serum and Their Relationship to the Van den Bergh Reaction. GERALD KLATSKIN AND LUITGARD BUNGARDS..... 537
The Miscible Pool and Turnover Rate of Hydrocortisone in Man. RALPH E. PETERSON AND JAMES B. WYNGAARDEN..... 552
Erythrocyte Preservation. VI. The Storage of Blood with Purine Nucleosides. DENNIS M. DONOHUE, CLEMENT A. FINCH, AND BEVERLY WESCOTT GABRIO..... 562
A Comparison of the Metabolic and Circulatory Effects of Epinephrine, Nor-Epinephrine, and Insulin Hypoglycemia with Observations on the Influence of Autonomic Blocking Agents. R. J. DISALVO, WALTER L. BLOOM, ALBERT A. BRUST, ROBERT W. FERGUSON, AND EUGENE B. FERRIS..... 568

NUMBER 6, JUNE, 1956

Excretion of Hydroxyproline in Patients with Rheumatic and Non-Rheumatic Diseases. MORRIS ZIFF, ANDRE KIBRICK, ELLIS DRESNER, AND H. JOEL GRIBETZ..... 579
On the Presence of Ferritin in the Peripheral Blood of Patients with Hepatocellular Disease. KURT R. REISSMANN AND MARY R. DIETRICH..... 588
Total Sodium, Potassium and Chloride in Adult Man. GILBERT B. FORBES AND ANNE M. LEWIS..... 596
Observations on the Early Elevation of Serum Potassium During Respiratory Alkalosis. JOHN B. HICKAM, WILLIAM P. WILSON, AND REGINA FRAYSER..... 601
Distribution of Sulfate Ion Across Semi-Permeable Membranes. ROY C. SWAN, HOWARD M. FEINSTEIN, AND HARRY MADISSO..... 607
The Relationship of Pulmonary Compliance to Pulmonary Vascular Pressures in Patients with Heart Disease. GEORGE A. SAXTON, JR., MURRAY RABINOWITZ, LEWIS DEXTER, AND FLORENCE HAYNES..... 611
Diminished Phenylketonuria in Phenylpyruvic Oligophrenia after Administration of L-Glutamine, L-Glutamate or L-Asparagine. ALTON MEISTER, SIDNEY UDENFRIEND, AND SAMUEL P. BESSMAN..... 619
An Experimental Test of the Glucostatic Theory of Regulation of Food Intake. LIONEL M. BERNSTEIN AND MORTON I. GROSSMAN..... 627
Sites of Water Exchange Between the Maternal System and the Amniotic Fluid of Rabbits. WILLIAM M. PAUL, THEODORE ENNS, SAMUEL R. M. REYNOLDS, AND FRANCIS P. CHINARD 634
The α_2 Lipoproteins of Human Serum. Correlation of Ultracentrifugal and Electrophoretic Properties. HENRY G. KUNKEL AND RODES TRAUTMAN..... 641
Effect of Cervico-Thoracic Ganglionectomy on the Adrenaline and Noradrenaline Content in the Mammalian Heart. McC. GOODALL AND N. KIRSHNER..... 649

Erythrocyte Preservation. VII. Acid-Citrate-Dextrose-Inosine (ACDI) as a Preservative for Blood During Storage at 4°C. BEVERLY WESCOTT GABRIO, DENNIS M. DONOHUE, F. M. HUENNEKENS, AND CLEMENT A. FINCH 657
Plethysmographic Determination of thé Volume of Gas Trapped in the Lungs. GEORGE N. BEDELL, ROBERT MARSHALL, ARTHUR B. DUBOIS, AND JULIUS H. COMROE, JR. 664
The Quantitatively Minor Role of Carbohydrate in Oxidative Metabolism by Skeletal Muscle in Intact Man in the Basal State. Measurements of Oxygen and Glucose Uptake and Carbon Dioxide and Lactate Production in the Forearm. REUBEN ANDRES, GORDON CADER, AND KENNETH L. ZIERLER 671
Proceedings of the Forty-Eighth Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N. J., April 30, 1956 683

NUMBER 7, JULY, 1956

The Effect of Variations in Solute Excretion and Glomerular Filtration on Water Diuresis. CHARLES R. KLEEMAN, FRANKLIN H. EPSTEIN, AND COLIN WHITE 749
The Interaction of Glucagon and Insulin on Blood Glucose. H. ELRICK, C. J. HLAD, JR., Y. ARAI, AND A. SMITH 757
Alterations in Body Composition with Sodium Loading and Potassium Restriction in the Rat: The Total Body Sodium, Nitrogen, Magnesium and Calcium. DONALD B. CHEEK AND CLARK D. WEST 763
The Distribution of Hg^{203}-Labeled Mercaptomerin in Human Tissues. JERRY K. AIKAWA AND REGINALD H. FITZ 775
Total Body Water and Total Exchangeable Sodium in Edematous States Due to Cardiac, Renal or Hepatic Disease. SAUL J. FARBER AND ROBERT J. SOBERMAN 779
Thyroxine Metabolism in the Nephrotic Syndrome. HOWARD RASMUSSEN 792
Physicochemical Estimation of Aldosterone in Urine. ROBERT NEHER AND ALBERT WETTSTEIN 800
Radiothyroxine Turnover Studies in Myxedema, Thyrotoxicosis, and Hypermetabolism without Endocrine Disease. KENNETH STERLING AND ROBERT B. CHODOS 806
Characterization of the Synovial Fluid Proteins. K. SCHMID AND MARGARET B. MCNAIR 814
Comparison of Liver Blood Flow Values Estimated by the Bromsulphalein and by the Radiogold Method. HERBERT VETTER, GEORG GRABNER, RUDOLF HÖFER, ANTON NEUMAYR, AND OTTO PARZER 825

NUMBER 8, AUGUST, 1956

The Influence of Chelation on Radiomanganese Excretion in Man and Mouse. LAURENCE S. MAYNARD AND SIDNEY FINK 831
The Chemical Estimation of Epinephrine and Norepinephrine in Human and Canine Plasma. I. A Critique of the Ethylenediamine Condensation Method. ARTHUR DE T. VALK, JR. AND HENRY L. PRICE 837
Clinical Determination of the Sites of Red Cell Sequestration in Hemolytic Anemias. JAMES H. JANDL, MORTIMER S. GREENBERG, ROBERT H. YONEMOTO, AND WILLIAM B. CASTLE 842
Renal Participation in Enhanced Pressor Responses to Noradrenaline in Patients Given Hexamethonium. A. C. CORCORAN, WILLIAM E. WAGNER, AND IRVINE H. PAGE 868
The Effect of Thyroid Disease on Calcium Metabolism in Man. STEPHEN M. KRANE, GORDON L. BROWNELL, JOHN B. STANBURY, AND HELEN CORRIGAN 874
The Renal Tubular Reponse to Amino Acid Loading. PAUL D. DOOLAN, HAROLD A. HARPER, MAXINE E. HUTCHIN, AND EDWARD L. ALPEN 888

The Experimental Production of Ascites in the Dog with Diabetes Insipidus. JOHN H. LARAGH, H. B. VAN DYKE, JULIUS JACOBSON, KARLIS ADAMSONS, JR., AND STAMFORD L. ENGEL 897
The Mechanics of Breathing in Different Body Positions. I. In Normal Subjects. ERNST O. ATTINGER, R. GRIER MONROE, AND MAURICE S. SEGAL 904
The Mechanics of Breathing in Different Body Positions. II. In Cardiopulmonary Disease. ERNST O. ATTINGER, J. AARON HERSCHFUS, AND MAURICE S. SEGAL 912
A Constant-Change (Single Injection) Method for the Estimation of the Volume of Distribution of Substances in Body Fluid Compartments. PETER P. POULOS 921

NUMBER 9, SEPTEMBER, 1956

The Effect in Humans of Extracellular pH Change on the Relationship between Serum Potassium Concentration and Intracellular Potassium. JAMES M. BURNELL, MARIO F. VILLAMIL, BEN T. UYENO, AND BELDING H. SCRIBNER 935
Prolonged Hypothermia in Experimental Pneumococcal Peritonitis. B. EISEMAN, W. G. MALETTE, R. S. WOTKYNS, W. B. SUMMERS, AND J. L. TONG 940
The Urinary Excretion of Sodium and Potassium During the Pyrogenic Reaction in Man. WILLOUGHBY LATHEM 947
Studies on the Physiology of Hunger. I. The Effect of Intravenous Administration of Glucose on Gastric Hunger Contractions in Man. ALBERT J. STUNKARD AND HAROLD G. WOLFF 954
Determination of the Life Span of Human Blood Platelets Using Labelled Diisopropylfluorophosphonate. C. H. W. LEEKSMA AND J. A. COHEN 964
The Relationship of Cardiovascular and Renal Hemodynamic Function to Sodium Excretion in Patients With Severe Heart Disease but Without Edema. WILLIAM HOLLANDER AND WALTER E. JUDSON 970
A Study of Serum Lipoproteins in Normal and Atherosclerotic Patients by Paper Electrophoretic Techniques. WILLIAM P. JENCKS, MARION R. HYATT, MERA R. JETTON, THOMAS W. MATTINGLY, AND E. L. DURRUM 980
Carbohydrate Metabolism in Intact Skeletal Muscle in Man During the Night. KENNETH L. ZIERLER AND REUBIN ANDRES 991
Hyposthenuria in Sickle Cell Anemia: A Reversible Renal Defect. H. G. KEITEL, D. THOMPSON, AND H. A. ITANO 998
The Diffusing Capacity of the Lungs in Patients with Mitral Stenosis Studied Post-Operatively. R. L. RILEY, C. J. JOHNS, G. COHEN, J. E. COHN, D. G. CARROLL, AND R. H. SHEPARD 1008
An Evaluation of Potassium Iodide as a Therapeutic Agent in the Treatment of Experimental Hypercholesteremia and Atherosclerosis. MEYER FRIEDMAN, RICHARD HOMER, AND SANFORD O. BYERS 1015
The Metabolism of Chylomicra. I. The Removal of Palmitic Acid-1-C^{14} Labeled Chylomicra from Dog Plasma. RICHARD J. HAVEL AND DONALD S. FREDRICKSON 1025
Tracer Studies of the Absorption and Fate of Steroid Hormones in Man. LEON HELLMAN, H. LEON BRADLOW, E. L. FRAZELL, AND T. F. GALLAGHER 1033
The Effects of Compound A (11-Dehydrocorticosterone) and Compound F (17-Hydroxycorticosterone) on Total Body Fat. LAURENCE H. KYLE, RICHARD J. MEYER, MARCUS SCHAAF, AND EDWARD J. WERDEIN 1045
Plasma Regression, Distribution and Excretion of Radiomercury in Relation to Diuresis Following the Intravenous Administration of Hg^{203} Labelled Chlormerodrin to the Dog. R. R. M. BORGHGRAEF, R. H. KESSLER, AND R. F. PITTS 1055

NUMBER 10, OCTOBER, 1956

Biocolloids of Urine in Health and in Calculous Disease. III. The Mucoprotein Matrix of Urinary Calculi. WILLIAM H. BOYCE AND NORMAN M. SULKIN 1067
Studies of the Effects of Large Doses of Bacterial Pyrogen in the Dog. I. The Renal Handling of Salt and Water. J. LEONARD BRANDT, BARNETT ZUMOFF, LEONARD CASTLEMAN, HERMAN D. RUSKIN, AUDREY JONES, AND SEYMOUR ZUCKERMAN 1080
Certain Aspects of Tyrosine Metabolism in the Young. II. The Tyrosine Oxidizing System of Fetal Rat Liver. NORMAN KRETCHMER AND HELEN MCNAMARA 1089
Changes in Body Composition in Acute Renal Failure. L. W. BLUEMLE, JR., H. P. POTTER, AND J. R. ELKINTON 1094
Interrelationships of Some Metabolic Effects of Testosterone Propionate in Normal Males during Restricted Sodium Intake. E. RAYMOND BORUN AND ERNEST GEIGER 1109
Experiences with Radiosulfate in the Estimation of Physiologic Extracellular Water in Healthy and Abnormal Man. ROBERT J. RYAN, LUKE R. PASCAL, TOHRU INOYE, AND LIONEL BERNSTEIN 1119
Quantitative Urinary Coproporphyrin Excretion and Its Relation to Edathamil Calcium Disodium Administration in Children with Acute Lead Intoxication. J. JULIAN CHISOLM, JR., AND HAROLD E. HARRISON 1131
Studies on the Kinetics of Glucose Utilization. C. J. HLAD, JR., H. ELRICK, AND T. A. WITTEN 1139
Some Studies on the Naturally Occurring Leucocyte Agglutinins. JOHN J. BUTLER 1150
Comparative Studies on the Turnover of Serum Albumin in Normal Human Subjects. SHELDON MARGEN AND HAROLD TARVER 1161
Physical Activity and the Diet in Populations Differing in Serum Cholesterol. ANCEL KEYS, JOSEPH T. ANDERSON, MARIO ARESU, GUNNAR BIÖRCK, JOHN F. BROCK, B. BRONTE-STEWART, FLAMINIO FIDANZA, MARGARET HANEY KEYS, HAQVIN MALMROS, ARRIGO POPPI, TEODORO POSTELI, BENGT SWAHN, AND ALFONSO DEL VECCHIO 1173

NUMBER 11, NOVEMBER, 1956

Studies on the Clot-Promoting Activity of Glass. ELEAZAR SHAFRIR AND ANDRE DE VRIES .. 1183
Studies on the Circulatory Changes in the Dog Produced by Endotoxin from Gram-Negative Microorganisms. MAX H. WEIL, LLOYD D. MACLEAN, MAURICE B. VISSCHER, AND WESLEY W. SPINK 1191
Multiple Serum Protein Deficiencies in Congenital and Acquired Agammaglobulinemia. DAVID GITLIN, WALTER H. HITZIG, AND CHARLES A. JANEWAY 1199
Oxygen Consumption in Dogs as Influenced by the Altered Metabolism of Diabetes Mellitus. HAROLD G. DANFORD, ROBERT D. GALVIN, AND AKIRA HORITA 1205
Heat Stability of Protein Solutions Obtained from Human Plasma by Different Ethanol Concentrations and Temperatures. DWIGHT J. MULFORD AND EDWARD H. MEALEY ... 1213
Myocardial Transfer of Sodium and Potassium: Effect of Acetyl Strophanthidin in Normal Dogs. TIMOTHY J. REGAN, FREDERICK N. TALMERS, AND HARPER K. HELLEMS 1220
The Cause of Hypercalcuria in Sarcoid and Its Treatment with Cortisone and Sodium Phytate. PHILIP H. HENNEMAN, ELEANOR F. DEMPSEY, EVELYN L. CARROLL, AND FULLER ALBRIGHT 1229
Carotenoids in Man. The Distribution of Epiphasic Carotenoids in Atherosclerotic Lesions. DAVID H. BLANKENHORN, DAVID G. FREIMAN, AND HARVEY C. KNOWLES, JR. 1243
Studies of the Anemia and Iron Metabolism in Cancer. AARON MILLER, ROBERT B. CHODOS, CHARLES P. EMERSON, AND JOSEPH F. ROSS 1248

Thyroxine-Binding by Sera of Pregnant Women, New-Born Infants, and Women with Spontaneous Abortion. J. Thomas Dowling, Norbert Freinkel, and Sidney H. Ingbar.. 1263
Renal Circulatory Dynamics and Urinary Protein Excretion during Infusions of *l*-Norepinephrine and *l*-Epinephrine in Patients with Renal Disease. Willoughby Lathem..... 1277
The Effect of Obstruction to Breathing on the Ventilatory Response to CO_2. R. M. Cherniack, and D. P. Snidal..... 1286
A Study on the Narcotic Action of the Short Chain Fatty Acids. Frederick E. Samson, Jr., Nancy Dahl, and Dennis R. Dahl..... 1291
The Effect of Changes in Body Sodium on Extracellular Fluid Volume and Aldosterone and Sodium Excretion by Normal and Edematous Men. Leroy E. Duncan, Jr., Grant W. Liddle, and Frederic C. Bartter..... 1299
The Regulation of Aldosterone Secretion in Man: The Role of Fluid Volume. Frederic C. Bartter, Grant W. Liddle, Leroy E. Duncan, Jr., Joan K. Barber, and Catherine Delea..... 1306
A Laboratory Study of the Carrier State in Classic Hemophilia. Alvin Margolius, Jr. and Oscar D. Ratnoff..... 1316

Number 12, December, 1956

Desoxyribonuclease I Activity in Pancreatic Disease. O. D. Kowlessar and R. K. McEvoy. 1325
Metabolism of 4-C^{14}-Testosterone in Human Subjects. I. Distribution in Bile, Blood, Feces and Urine. Avery A. Sandberg and W. Roy Slaunwhite, Jr..... 1331
The Adaptation of the Nitrous Oxide Method to the Determination of Renal Blood Flow and *In Vivo* Renal Weight in Man. Archer P. Crosley, Jr., John F. Brown, John H. Huston, Dean A. Emanuel, Herman Tuchman, Cesar Castillo, and George G. Rowe..... 1340
Total Free Tocopherols in the Serum of Patients with Thyroid Disease. Sholem Postel... 1345
Renal Function in Primary Aldosteronism. Harriet P. Dustan, A. C. Corcoran, and Irvine H. Page..... 1357
Studies on the Functional Capacity of a Denervated Homotransplanted Kidney in an Identical Twin with Parallel Observations in the Donor. Neal S. Bricker, Warren R. Guild, John B. Reardan, and John P. Merrill..... 1364
The Role of the Kidney in the Etiology of Renal Hyperlipemia. N. R. Di Luzio and C. Riley Houck..... 1381
The Hematocrit of the Lesser Circulation in Man. Lawrence S. Lilienfield, Renato D. Kovach, Paul A. Marks, Lee M. Hershenson, Gerald P. Rodnan, Frank G. Ebaugh, and Edward D. Freis..... 1385
The Pulmonary Blood Volume in Mitral Stenosis. Elliot Rapaport, Hiroshi Kuida, Florence W. Haynes, and Lewis Dexter..... 1393
The Phosphate Partition of the Erythrocytes of Normal Newborn Infants and of Infants with Hemolytic Disease. Tibor J. Greenwalt and Valborg Elizabeth Ayers..... 1404
The Pressor Effect of the Antidiuretic Principle of the Posterior Pituitary in Orthostatic Hypotension. Henry N. Wagner, Jr. and Eugene Braunwald..... 1412
Rheologic Studies on Synovial Fluid. Milton G. Levine and David H. Kling..... 1419
Binding of Corticosteroids by Plasma Proteins. I. Dialysis Equilibrium and Renal Clearance Studies. William H. Daughaday..... 1428
Binding of Corticosteroids by Plasma Proteins. II. Paper Electrophoresis and Equilibrium Paper Electrophoresis. William H. Daughaday..... 1434
Author Index to Volume XXXV..... 1439
Subject Index to Volume XXXV..... 1457

AUTHOR INDEX

(Page numbers in italics refer to abstracts)

A

Abernathy, Robert S., and **Spink, Wesley W.** Protection against Brucella with heterologous endotoxins *687*

Adamsons, Karlis, Jr. See LARAGH, VAN DYKE, JACOBSON, ADAMSONS, and ENGEL 897

Adelstein, S. James. See WACKER, ADELSTEIN, ULMER, and VALLEE *741*

Aikawa, Jerry K., and **Fitz, Reginald H.** The distribution of Hg^{203}-labeled mercaptomerin in human tissues 775

Aitken, Elsie H. See PREEDY and AITKEN 423

—. See PREEDY and AITKEN 430

—. See PREEDY and AITKEN 443

Albright, Edwin C., Larson, Frank C., Tomita, Kenkichi, and **Lardy, Henry A.** Formation of tetraiodothyroacetic acid from thyroxine by rat kidney mitochondria *687*

Albright, Fuller. See HENNEMAN, DEMPSEY, CARROLL, and ALBRIGHT 1229

Alkjaersig, Norma. See SHERRY and ALKJAERSIG *735*

Alpen, Edward L. See DOOLAN, HARPER, HUTCHIN, and ALPEN 888

Anderson, Elizabeth A. See ISSELBACHER, ANDERSON, and KALCKAR *714*

Anderson, Joseph T. See KEYS, ANDERSON, ARESU, BIÖRCK, BROCK, BRONTE-STEWART, FIDANZA, KEYS, MALMROS, POPPI, POSTELI, SWAHN, and DEL VECCHIO 1173

Andres, Reubin, Cader, Gordon, and **Zierler, Kenneth L.** The quantitatively minor role of carbohydrate in oxidative metabolism by skeletal muscle in intact man in the basal state. Measurements of oxygen and glucose uptake and carbon dioxide and lactate production in the forearm 671

—. See ZIERLER and ANDRES *747*

—. See ZIERLER and ANDRES 991

Antonowicz, Irena. See METCOFF, FRENK, GORDILLO, GOMEZ, GALVAN, and ANTONOWICZ *723*

Appelboom, Johannes W. See BRODSKY, DENNIS, REHM, APPELBOOM, and DIAMOND *694*

Arai, Y. See ELRICK, HLAD, ARAI, and SMITH 757

Aresu, Mario. See KEYS, ANDERSON, ARESU, BIÖRCK, BROCK, BRONTE-STEWART, FIDANZA, KEYS, MALMROS, POPPI, POSTELI, SWAHN, and DEL VECCHIO 1173

Arquilla, Edward R., and **Stavitsky, Abram B.** The production and identification of antibodies to insulin and their use in assaying insulin 458

—, and **Stavitsky, Abram B.** Evidence for the insulin-directed specificity of rabbit anti-insulin serum 467

Artz, Curtis P. See REISS, PEARSON, and ARTZ 62

Ashenbrucker, Helen. See BUSH, ASHENBRUCKER, CARTWRIGHT, and WINTROBE 89

Atkinson, Michael, Kramer, Philip, Wyman, Stanley M., and **Ingelfinger, Franz J.** Pharyngeal swallowing mechanisms in normal subjects and in patients with neuromuscular dysphagia *687*

Attinger, Ernst O., Monroe, R. Grier, and **Segal, Maurice S.** The mechanics of breathing in different body positions. I. In normal subjects 904

—, **Herschfus, J. Aaron**, and **Segal, Maurice S.** The mechanics of breathing in different body positions. II. In cardiopulmonary disease 912

Auchincloss, J. Howland. See FALOON, AUCHINCLOSS, EICH, and GILBERT *701*

Ayers, Valborg Elizabeth. See GREENWALT and AYERS 1404

B

Baeder, David. See STEIGER, ZARAFONETIS, MILLER, SEIFTER, and BAEDER *737*

Bailey, Charles P. See BAKST, MANIGLIA, and BAILEY 302

Bain, Thomas H. See PATTERSON, MULLINAX, BAIN, and KRUEGER *728*

Baker, Winfield H. See DOYLE, DELALLA, BAKER, HESLIN, and BROWN *699*

Bakst, Alvin A., Maniglia, Rosario, and **Bailey, Charles P.** The physiologic explanation of the changes in the coronary circulation following prolonged aortico-coronary sinus anastomosis 302

Ballon, Jonathan D. See WESSLER, BALLON, and GILBERT *743*

Bally, Peter R. Studies on phospholipid and cholesterol metabolism in liver and kidney of rats with experimental nephrotic syndrome *688*

Barber, Joan K. See BARTTER, LIDDLE, DUNCAN, BARBER, and DELEA 1306

Barnett, Henry L. See KRETCHMER, LEVINE, MCNAMARA, and BARNETT 236

Barr, David P. See RUSS, RAYMUNT, and BARR 133

Bartholomay, Anthony F. The sequential probability ratio test, a new statistical procedure for clinical investigation; its validation in a study of serum zinc concentrations in Laennec's cirrhosis *688*

Bartter, Frederic C., Liddle, Grant W., Duncan, Leroy E., and **Delea, Catherine.** The role of extracellular fluid volume in the control of aldosterone secretion in man *688*

—, **Liddle, Grant W., Duncan, Leroy E., Jr., Barber, Joan K.**, and **Delea, Catherine.** The regulation of aldosterone secretion in man: The role of fluid volume 1306

—. See SCHWARTZ, BENNETT, CURELOP, and BARTTER *734*

—. See DUNCAN, LIDDLE, and BARTTER 1299

Bashour, Fouad. The conversion of reduced uroporphyrin I to coproporphyrin and protoporphyrin by dog liver homogenate *689*

Batten, John C. See MCCUNE, DINEEN, and BATTEN *723*

Bauld, William S., Milne, Ian G., and **Givner, Morris L.** Abnormality of estrogen metabolism in men with myocardial infarction *689*

Bauman, Arthur. See BERSON, YALOW, BAUMAN, ROTHSCHILD, and NEWERLY 170

Baxter, James H., Goodman, Howard C., and **Orloff, Jack.** Nephrosis in adults: results of steroid therapy. *689*

Beals, Robert. See ROBERTS, POPPELL, VANAMEE, BEALS, and RANDALL 261

Bedell, George N., Marshall, Robert, DuBois, Arthur B., and **Harris, John H.** Measurement of the volume of gas in the gastro-intestinal tract. Values in normal subjects and ambulatory patients 336
—, **Marshall, Robert, DuBois, Arthur B.,** and **Comroe, Julius H., Jr.** Plethysmographic determination of the volume of gas trapped in the lungs 664
—. See DuBois, Botelho, Bedell, Marshall, and Comroe 322
Benda, Clemens E. See Bronner, Harris, Maletskos, and Benda 78
Benjamin, A. D. See Lathem and Benjamin *719*
Benjamin, Naomi R. See Crosby and Benjamin *698*
Bennett, T. E. See Tarail and Bennett *738*
Bennett, Warren. See Schwartz, Bennett, Curelop, and Bartter *734*
Bergenstal, D. M. See Li, Bergenstal, and Parrott *721*
Berliner, Robert W., and **Davidson, Douglas G.** Production of hypertonic urine in the absence of pituitary antidiuretic hormone *690*
—. See Orloff and Berliner 223
Bernstein, Lionel M., and **Grossman, Morton I.** An experimental test of the glucostatic theory of regulation of food intake *627*
—. See Ryan, Pascal, Inoye, and Bernstein 1119
Berson, Solomon A., Yalow, Rosalyn S., Bauman, Arthur, Rothschild, Marcus A., and **Newerly, Katharina.** Insulin-I^{131} metabolism in human subjects: Demonstration of insulin binding globulin in the circulation of insulin treated subjects 170
—. See Yalow and Berson *746*
Bessman, Samuel P. The reduction of blood ammonia levels by certain amino acids *690*
—. See Meister, Udenfriend, and Bessman 619
Best, Maurice M. See Duncan and Best *700*
Beutler, Ernest. *In vitro* studies of the stability of red cell glutathione: A new test for drug sensitivity *690*
Biehl, J. Park, and **Hughes, Hettie B.** The inactivation of isoniazid and its relationship to the emergence of isoniazid resistance *691*
Bierman, Howard R., Kelly, Keith H., Cordes, Fauno, and **Byron, Ralph L., Jr.** Leukocyte production and delivery in the leukemias of man *691*
Bing, R. J. See Blain, Eddleman, Siegel, and Bing 314
Biörck, Gunnar. See Keys, Anderson, Aresu, Biörck, Brock, Bronte-Stewart, Fidanza, Keys, Malmros, Poppi, Posteli, Swahn, and del Vecchio 1173
Bishop, Jonathan. See Marks and Bishop *722*
Blain, J. M., Eddleman, E. E., Siegel, A., and **Bing, R. J.** Studies on myocardial metabolism. V. The effects of lanatoside-C on the metabolism of the human heart 314
Blake, William D. Salt excretion and the control of glomerular filtration *691*
Blakemore, William S. See Conn, Heiman, Blakemore, Kuo, and Langfeld *697*
—. See Kuo, Schnabel, Blakemore, and Langfeld *719*
Blankenhorn, David H., and **Freiman, David G.** A study of carotenoids: Colored lipids which infiltrate the human aorta *692*
—, **Freiman, David G.,** and **Knowles, Harvey C., Jr.** Carotenoids in man. The distribution of epiphasic carotenoids in atherosclerotic lesions 1243
Block, Matthew. Passive transfer of non-thrombocytopenic purpura *692*
Bloom, Walter L. See DiSalvo, Bloom, Brust, Ferguson, and Ferris 568
Bluemle, L. W., Jr., Potter, H. P., and **Elkinton, J. R.** Changes in body composition in acute renal failure 1094
Boand, Arthur V. See Jackson and Boand *715*
Bondurant, Stuart, and **Hickam, John B.** Pulmonary and circulatory effects of acute pulmonary vascular engorgement in normal subjects *692*
Bondy, Philip K., and **Cardillo, Leo R.** The effect of glucagon on carbohydrate metabolism in normal human beings 494
Bongiovanni, Alfred M., and **Eberlein, Walter R.** A defect in steroid biogenesis in man associated with hypertension *693*
Borghgraef, R. R. M., and **Pitts, R. F.** The distribution of chlormerodrin (Neohydrin®) in tissues of the rat and dog 31
—, **Kessler, R. H.,** and **Pitts, R. F.** Plasma regression, distribution and excretion of radiomercury in relation to diuresis following the intravenous administration of Hg^{203} labelled chlormerodrin to the dog 1055
Borun, E. Raymond, and **Geiger, Ernest.** Interrelationships of some metabolic effects of testosterone propionate in normal males during restricted sodium intake 1109
Botelho, Stella Y. See DuBois, Botelho, Bedell, Marshall, and Comroe 322
—. See DuBois, Botelho, and Comroe *327*
Bothwell, Thomas H., Pribilla, Walther, Hurtado, Arnold V., and **Finch, Clement A.** Regulation of iron transport *693*
Boyce, William H., and **Sulkin, Norman M.** Biocolloids of urine in health and in calculous disease. III. The mucoprotein matrix of urinary calculi 1067
Bradley, S. E. See Wheeler, Combes, Childs, and Bradley *744*
Bradlow, H. Leon. See Hellman, Bradlow, Frazell, and Gallagher 1033
Brandt, J. Leonard, Zumoff, Barnett, Castleman, Leonard, Ruskin, Herman D., Jones, Audrey, and **Zuckerman, Seymour.** Studies of the effects of large doses of bacterial pyrogen in the dog. I. The renal handling of salt and water 1080
Braude, A. I., and **Zalesky, M.** A study of the intermittent character of fever during infection *693*
Braunwald, Eugene. See Wagner and Braunwald *742*
—. See Wagner and Braunwald 1412
Brewer, Spencer S., Jr. See Rundles and Brewer *733*
Bricker, Neal S., Guild, Warren R., Reardan, John B., and **Merrill, John P.** Studies on the functional capacity of a denervated homotransplanted kidney with parallel observations on the identical twin donor *694*
—, **Guild, Warren R., Reardan, John B.,** and **Merrill, John P.** Studies on the functional capacity of a denervated homotransplanted kidney in an identical twin with parallel observations in the donor 1364
Brock, John F. See Keys, Anderson, Aresu, Biörck, Brock, Bronte-Stewart, Fidanza, Keys, Malmros, Poppi, Posteli, Swahn, and del Vecchio 1173
Brodie, Bernard B. See Yü, Paton, Chenkin, Burns, Brodie, and Gutman 374

Brodsky, William A., Dennis, Warren H., Rehm, Warren S., Appelboom, Johannes W., and **Diamond, Israel.** The problem of isotonic versus hypertonic cell fluid in the light of cryoscopic measurements of tissue homogenates *694*

Bronner, Felix, Harris, Robert S., Maletskos, Constantine J., and **Benda, Clemens E.** Studies in calcium metabolism. The fate of intravenously injected radiocalcium in human beings 78

Bronte-Stewart, B. See KEYS, ANDERSON, ARESU, BIÖRCK, BROCK, BRONTE-STEWART, FIDANZA, KEYS, MALMROS, POPPI, POSTELI, SWAHN, and DEL VECCHIO 1173

Brown, John F. See ROWE, HUSTON, WEINSTEIN, TUCHMAN, BROWN, and CRUMPTON 272

—. See CROSLEY, BROWN, HUSTON, EMANUEL, TUCHMAN, CASTILLO, and ROWE 1340

Brown, Ray K. See DOYLE, DELALLA, BAKER, HESLIN, and BROWN *699*

Brownell, Gordon L. See KRANE, BROWNELL, STANBURY, and CORRIGAN 874

Brunson, Joel G. See VERNIER, FARQUHAR, BRUNSON, and GOOD *741*

Brust, Albert A. See DISALVO, BLOOM, BRUST, FERGUSON, and FERRIS 568

—. See WILBER and BRUST *744*

Bungards, Luitgard. See KLATSKIN and BUNGARDS 537

Burnell, James M., Villamil, Mario F., Uyeno, Ben T., and **Scribner, Belding H.** The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium 935

Burns, J. J. See YÜ, PATON, CHENKIN, BURNS, BRODIE, and GUTMAN 374

Burnside, Charles R. See YOUNG, BURNSIDE, and KNOWLES *747*

Burrows, Belton A. See HOLLANDER, REILLY, and BURROWS *713*

Bush, J. A., Ashenbrucker, Helen, Cartwright, G. E., and **Wintrobe, M. M.** The anemia of infection. XX. The kinetics of iron metabolism in the anemia associated with chronic infection 89

Butler, John J. Some studies on the naturally occurring leucocyte agglutinins 1150

Byers, Sanford O., and **Friedman, Meyer.** The fractionation of cholesterol in body fluids by means of solvent extraction 405

—. See ROSENMAN, FRIEDMAN, and BYERS 522

—. See ROSENMAN, BYERS, and FRIEDMAN *732*

—. See FRIEDMAN, HOMER, and BYERS 1015

Byron, Margaret C. See MIGEON, PRYSTOWSKY, GRUMBACH, and BYRON 488

Byron, Ralph L., Jr. See BIERMAN, KELLY, CORDES, and BYRON *691*

C

Cader, Gordon. See ANDRES, CADER, and ZIERLER 671

Callaway, Enoch, III, and **Finesinger, Jacob E.** "Uncertainty" measurements in psychopharmacology *694*

Campbell, Edmund W., and **Small, Walter J.** Metabolic function of human platelets *695*

Campbell, James A., Graettinger, John S., Muenster, Joseph J., and **Checcia, Carlo S.** Hemodynamics of congestive failure associated with peripheral arteriovenous fistulae *695*

Capeci, Nicholas E. See HILTON, CAPECI, KISS, KRUESI, GLAVIANO, and WÉGRIA 481

Caputto, Ranwel. See JOHNSON, RICHMOND, CAPUTTO, and WOLF *716*

Cardillo, Leo R. See BONDY and CARDILLO 494

Carey, James B., Jr. The serum dihydroxytrihydroxy bile acid ratio in liver and biliary tract disease *695*

Carroll, D. G. See RILEY, JOHNS, COHEN, COHN, CARROLL, and SHEPARD 1008

Carroll, Evelyn L. See HENNEMAN, DEMPSEY, CARROLL, and ALBRIGHT 1229

Carroll, Hugh J. See FARBER and CARROLL *702*

Carroll, R. T. See HOLBURN, SCHWARTZ, CARROLL, and WEISS *712*

Cartwright, G. E. See BUSH, ASHENBRUCKER, CARTWRIGHT, and WINTROBE 89

Casserd, Frederick. See MOTULSKY, CASSERD, and GIBLETT *725*

Castillo, Cesar. See CROSLEY, BROWN, HUSTON, EMANUEL, TUCHMAN, CASTILLO, and ROWE 1340

Castle, William B. See JANDL, GREENBERG, YONEMOTO, and CASTLE 842

Castleman, Leonard. See BRANDT, ZUMOFF, CASTLEMAN, RUSKIN, JONES, and ZUCKERMAN 1080

Chart, Jerome J., Gordon, Edgar S., Helmer, Phyllis, and **LeSher, Marjorie.** Metabolism of salt-retaining hormone by surviving liver slices 254

Checcia, Carlo S. See CAMPBELL, GRAETTINGER, MUENSTER, and CHECCIA *695*

Cheek, Donald B., and **West, Clark D.** Alterations in body composition with sodium loading and potassium restriction in the rat: The total body sodium, nitrogen, magnesium and calcium *763*

Cheng, Samuel, and **Stanley, Malcolm.** Variations in gastrointestinal cholesterol exchange in man with acute changes in diet *696*

Chenkin, Theodore. See YÜ, PATON, CHENKIN, BURNS, BRODIE, and GUTMAN 374

Cherkes, Amelia. See GORDON and CHERKES 206

Cherniack, Reuben M. The physical properties of the lung in chronic obstructive pulmonary emphysema 394

—, and **Snidal, D. P.** The effect of obstruction to breathing on the ventilatory response to CO_2 1286

Childs, A. W. See WHEELER, COMBES, CHILDS, and BRADLEY *744*

Childs, Barton, Grumbach, Melvin M., and **Van Wyk, Judson J.** Virilizing adrenal hyperplasia; a genetic and hormonal study 213

Chinard, Francis P., Enns, Theodore, and **Nolan, Mary F.** Relative renal excretion patterns of glomerular substances, sodium and water; effects of mercurial diuretics *696*

—. See PAUL, ENNS, REYNOLDS, and CHINARD 634

Chisolm, J. Julian, Jr., and **Harrison, Harold E.** Quantitative urinary coproporphyrin excretion and its relation to edathamil calcium disodium administration in children with acute lead intoxication 1131

Chodos, Robert B. See STERLING and CHODOS *737*

—. See STERLING and CHODOS 806

—. See MILLER, CHODOS, EMERSON, and ROSS 1248

Christensen, Raymond C. See HELLEMS, REGAN, TALMERS, CHRISTENSEN, and WADA *710*

Clark, J. K. See SINGER, DEERING, and CLARK 245

Clifton, James A. The effect of cortisone and hydrocortisone on hepatic excretory function *696*

Cochrane, W. A., Payne, W. W., Simpkiss, M. J., and **Woolf, L. I.** Familial hypoglycemia precipitated by amino acids 411

Cohen, G. See RILEY, JOHNS, COHEN, COHN, CARROLL, and SHEPARD 1008
Cohen, Henry W. See ROSENBAUM, PAPPER, and COHEN *732*
Cohen, J. A. See LEEKSMA and COHEN 964
Cohn, J. E. See RILEY, JOHNS, COHEN, COHN, CARROLL, and SHEPARD 1008
Coleman, Joseph. See CRISPELL and COLEMAN 475
—. See CRISPELL, COLEMAN, and HYER *698*
Combes, B. See WHEELER, COMBES, CHILDS, and BRADLEY *744*
Comroe, Julius H., Jr. See DUBOIS, POTELHO, BEDELL, MARSHALL, and COMROE *322*
—. See DUBOIS, POTELHO, and COMROE *327*
—. See BEDELL, MARSHALL, DUBOIS, and COMROE 664
Condit, Paul T. Metabolism of folic acid in man *697*
Conn, Hadley L., Jr., Heiman, Donald F., Blakemore, William S., Kuo, Peter T., and Langfeld, Stephen B. Radiopotassium dilution studies from the "left" circulation in patients with rheumatic mitral valvular disease *697*
Conner, Eugene H. See PRICE, HELRICH, and CONNER 125
Connor, Thomas B., Thomas, William C., Jr., and Howard, John Eager. The etiology of hypercalcemia associated with lung carcinoma *697*
Corbus, Howard F. See MILLER, CORBUS, and SULLIVAN *724*
Corcoran, A. C., Wagner, William E., and Page, Irvine H. Renal participation in enhanced pressor responses to noradrenaline in patients given hexamethonium 868
—. See DUSTAN, CORCORAN, and PAGE 1357
Cordes, Fauno. See BIERMAN, KELLY, CORDES, and BYRON *691*
Cornwell, David. See GITLIN and CORNWELL *706*
Corrigan, Helen. See KRANE, BROWNELL, STANBURY, and CORRIGAN 874
Cottier, P. T., Hoobler, S. W., and Weller, J. M. Effect of a sodium chloride-load on renal hemodynamics and electrolyte excretion in essential hypertension *698*
Couch, Nathan P. See DAMMIN, MURRAY, and COUCH *699*
Cournand, A. See FRITTS, FILLER, FISHMAN, and COURNAND *705*
Cox, Frederick M., Lanchantin, Gerard F., and Ware, Arnold G. Chromatographic purification of human serum accelerator globulin 106
Crabbe, Jean. See RENOLD, CRABBE, ROSS, HERNANDO-AVENDANO, NELSON, and THORN *731*
Craddock, Charles G., Jr., Perry, Seymour, and Lawrence, John S. The dynamics of leukopoiesis and leukocytosis, as studied by leukopheresis and isotopic techniques 285
Craig, John. See SCHWARTZ and CRAIG *734*
Crary, H. I. See MILNOR and CRARY *725*
Crispell, K. R., Kahana, Shirley, and Hyer, Harry. The effect of plasma on the *in vitro* uptake or binding by human red cells of radioactive I-131 labeled l-thyroxine and l-triiodothyronine 121
—, **Parson, William, and Hollifield, Guy.** A study of the rate of protein synthesis before and during the administration of l-triiodothyronine to patients with myxedema and healthy volunteers using N-15 glycine 164
—, and **Coleman, Joseph.** A study of the relative binding capacity of plasma proteins, intact human red cells, and human red cell stroma for radioactive I-131 labeled l-thyroxine 475
—, **Coleman, Joseph, and Hyer, Harry J.** A comparison of the effect of human plasma and albumin on the *in vitro* uptake by human erythrocytes of I^{131} labeled thyroid hormones *698*
Crosby, William H., and Benjamin, Naomi R. An abnormal hemolytic system associated with disseminated malignant disease *698*
Crosley, Archer P., Jr., Brown, John F., Huston, John H., Emanuel, Dean A., Tuchman, Herman, Castillo, Cesar, and Rowe, George G. The adaptation of the nitrous oxide method to the determination of renal blood flow and *in vivo* renal weight in man 1340
Crumpton, Charles W. See ROWE, HUSTON, WEINSTEIN, TUCHMAN, BROWN, and CRUMPTON *272*
Curelop, Sidney. See SCHWARTZ, BENNETT, CURELOP, and BARTTER *734*
Currens, James H. See MYERS, CURRENS, FRIEDLICH, and SCANNELL *727*

D

Dahl, Dennis R. See SAMSON, DAHL, and DAHL 1291
Dahl, Nancy. See SAMSON, DAHL, and DAHL 1291
Dammin, Gustave J., Murray, Joseph E., and Couch, Nathan P. Tissue transplantation: Prolonged skin homograft survival in recipients with chronic uremia *699*
Danford, Harold, G., Galvin, Robert D., and Horita, Akira. Oxygen consumption in dogs as influenced by the altered metabolism of diabetes mellitus 1205
Daughaday, William H. Binding of corticosteroids by plasma proteins. I. Dialysis equilibrium and renal clearance studies 1428
—. Binding of corticosteroids by plasma proteins. II. Paper electrophoresis and equilibrium paper electrophoresis 1434
—. See SALMON and DAUGHADAY *733*
Daum, Kate. See THORNTON, HODGES, LUBIN, WILSON, and DAUM *739*
Davidson, Charles S. See WEBSTER and DAVIDSON 191
—. See WEBSTER and DAVIDSON *742*
Davidson, Douglas G. See BERLINER and DAVIDSON *690*
Davignon, André. See GENEST, LEMIEUX, DAVIGNON, KOIW, NOWACZYNSKI, and STEYERMARK *706*
Deering, R. C. See SINGER, DEERING, and CLARK 245
DeLalla, Louis S. See DOYLE, DELALLA, BAKER, HESLIN, and BROWN *699*
Delea, Catherine. See BARTTER, LIDDLE, DUNCAN, and DELEA *688*
—. See BARTTER, LIDDLE, DUNCAN, BARBER, and DELEA 1306
del Vecchio, Alfonso. See KEYS, ANDERSON, ARESU, BIÖRCK, BROCK, BRONTE-STEWART, FIDANZA, KEYS, MALMROS, POPPI, POSTELI, SWAHN, and DEL VECCHIO 1173
Dempsey, Eleanor F. See HENNEMAN and DEMPSEY *711*
—. See HENNEMAN, DEMPSEY, CARROLL, and ALBRIGHT 1229
Dennis, Warren H. See BRODSKY, DENNIS, REHM, APPELBOOM, and DIAMOND *694*

De T. Valk, Arthur, Jr., and **Price, Henry L.** The chemical estimation of epinephrine and norepinephrine in human and canine plasma. I. A critique of the ethylenediamine condensation method 837

de Vries, Andre. See SHAFRIR and DE VRIES 1183

Dexter, Lewis. See SAXTON, RABINOWITZ, DEXTER, and HAYNES 611

—. See RAPAPORT, KUIDA, HAYNES, and DEXTER 1393

Diamond, Israel. See BRODSKY, DENNIS, REHM, APPELBOOM, and DIAMOND *694*

Dickens, Janet. See GOLDBERG, SMITH, DICKENS, RABER, and WALDOW *706*

Dietrich, Mary R. See REISSMANN and DIETRICH 588

Di Luzio, N. R., and **Houck, C. Riley.** The role of the kidney in the etiology of renal hyperlipemia 1381

Dineen, P. A. Peter. See MCCUNE, DINEEN, and EATTEN *723*

DiSalvo, R. J., Bloom, Walter L., Brust, Albert A., Ferguson, Robert W., and **Ferris, Eugene B.** A comparison of the metabolic and circulatory effects of epinephrine, nor-epinephrine and insulin hypoglycemia with observations on the influence of autonomic blocking agents 568

Dole, Vincent P. A relation between non-esterified fatty acids in plasma and the metabolism of glucose 150

Donohue, Dennis M., Finch, Clement A., and **Gabrio, Beverly Wescott.** Erythrocyte preservation. VI. The storage of blood with purine nucleosides 562

—. See GABRIO, DONOHUE, HUENNEKENS, and FINCH 657

Doolan, Paul D., Harper, Harold A., Hutchin, Maxine E., and **Alpen, Edward L.** The renal tubular response to amino acid loading 888

Doscherholmen, Alfred, and **Hagen, Paul S.** Radioactive vitamin B_{12} absorption studies: Results of direct measurement of radioactivity in the blood *699*

Douglas, A. S. The action of heparin in the prevention of prothrombin conversion 533

Dowben, Robert M. The fate of sodium glucuronate and glucuronolactone in man 277

Dowling, J. Thomas, Freinkel, Norbert, and **Ingbar, Sidney H.** Thyroxine-binding by sera of pregnant women, new-born infants, and women with spontaneous abortion 1263

—. See INGBAR, FREINKEL, DOWLING, and KUMAGAI *714*

Doyle, Joseph T., DeLalla, Louis S., Baker, Winfield H., Heslin, A. Sandra, and **Brown, Ray K.** Blood lipoprotein patterns in preclinical and in clinical coronary artery disease *699*

Dreifus, L. See STAMLER, DREIFUS, MARCUS, WONG, HASBROUCK, SHERIDAN, MAIER, and ELLIS *737*

Dresner, Ellis. See ZIFF, KIBRICK, DRESNER, and GRIBETZ 579

Dreyfuss, L., and **Pick, A.** A clinical correlative study of the electrocardiogram in electrolyte imbalance *700*

DuBois, Arthur B., Botelho, Stella Y., Bedell, George N., Marshall, Robert, and **Comroe, Julius H., Jr.** A rapid plethysmographic method for measuring thoracic gas volume: A comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects 322

—, **Botelho, Stella Y.**, and **Comroe, Julius H., Jr.** A new method for measuring airway resistance in man using a body plethysmograph: Values in normal subjects and in patients with respiratory disease *327*

—. See BEDELL, MARSHALL, DUBOIS, and HARRIS *336*

—. See BEDELL, MARSHALL, DUBOIS, and COMROE *664*

Duncan, Charles H., and **Best, Maurice M.** Comparative effects of free and esterified sitosterol on serum and liver cholesterol in rats *700*

Duncan, Leroy E., Jr., Liddle, Grant W., and **Bartter, Frederic C.** The effect of changes in body sodium on extracellular fluid volume and aldosterone and sodium excretion by normal and edematous men 1299

—. See BARTTER, LIDDLE, DUNCAN, and DELEA *688*

—. See BARTTER, LIDDLE, DUNCAN, BARBER, and DELEA 1306

Durrum, E. L. See JENCKS, HYATT, JETTON, MATTINGLY, and DURRUM 980

Dustan, Harriet P., Corcoran, A. C., and **Page, Irvine H.** Renal function in primary aldosteronism 1357

E

Ebaugh, Franklin G., Jr. See LILIENFIELD, KOVACH, MARKS, HERSHENSON, RODNAN, EBAUGH, and FREIS 1385

Eberlein, Walter R. See BONGIOVANNI and EBERLEIN *693*

Eckstein, John W. See WOOD and ECKSTEIN *746*

Eddleman, E. E. See BLAIN, EDDLEMAN, SIEGEL, and BING 314

Edelman, I. S., and **Sweet, N. J.** Gastrointestinal water and electrolytes. I. The equilibration of radiosodium in gastrointestinal contents and the proportion of exchangeable sodium (Na_e) in the gastrointestinal tract 502

—. See NADELL, SWEET, and EDELMAN 512

Eich, Robert. See FALOON, AUCHINCLOSS, EICH, and GILBERT *701*

Eiseman, B., Malette, W. G., Wotkyns, R. S., Summers, W. B., and **Tong, J. L.** Prolonged hypothermia in experimental pneumococcal peritonitis 940

Eisenberg, Seymour, and **Sensenbach, Willis.** Cerebral blood flow and metabolism in mentally confused subjects with congestive heart failure *700*

Eliel, Leonard P., and **Heaney, Robert P.** The relationship of chemotherapeutic specificity to metabolic and cytochemical changes in patients with leukemia and lymphosarcoma *701*

Elkinton, J. R. See BLUEMLE, POTTER, and ELKINTON 1094

Ellenbogen, Eric. See OLSON, ELLENBOGEN, STERN, and LIANG *727*

Ellis, A. See STAMLER, DREIFUS, MARCUS, WONG, HASBROUCK, SHERIDAN, MAIER, and ELLIS *737*

Ellis, F. Henry, Jr. See WOOD, WOODWARD, SWAN, and ELLIS *745*

Elrick, H., Hlad, C. J., Jr., Arai, Y., and **Smith, A.** The interaction of glucagon and insulin on blood glucose 757

—. See HLAD, HUFFMAN, WHIPPLE, and ELRICK *712*

—. See HLAD, ELRICK, and WITTEN 1139

Emanuel, Dean A. See CROSLEY, BROWN, HUSTON, EMANUEL, TUCHMAN, CASTILLO, and ROWE 1340

Emerson, Charles P. Quantitative aspects of osmotic hemolysis and its significance in hereditary spherocytosis *701*
—. See MILLER, CHODOS, EMERSON, and ROSS 1248
Engel, Stamford L. See LARAGH, VAN DYKE, JACOBSON, ADAMSONS, and ENGEL 897
Enns, Theodore. See PAUL, ENNS, REYNOLDS, and CHINARD 634
—. See CHINARD, ENNS, and NOLAN *696*
Epstein, Franklin H., Kleeman, Charles R., Lamdin, Ezra, and **Rubini, Milton E.** Studies of the antidiuresis of quiet standing: observations upon electrolyte and acid-base excretion during sulfate diuresis 308
—. See LAMDIN, KLEEMAN, RUBINI, and EPSTEIN 386
—. See KLEEMAN, EPSTEIN, and WHITE 749
Estes, E. H., Jr. See WEISSLER, MCINTOSH, ESTES, and WARREN *743*

F

Faloon, William W., Auchincloss, J. Howland, Eich, Robert, and **Gilbert, Robert.** Ammonia metabolism in cirrhotic patients with portacaval shunts *701*
Farber, Saul J., and **Carroll, Hugh J.** The arteriovenous difference of potassium in a patient with periodic paralysis *702*
—, and **Soberman, Robert J.** Total body water and total exchangeable sodium in edematous states due to cardiac, renal or hepatic disease 779
Farquhar, Marilyn G. See VERNIER, FARQUHAR, BRUNSON, and GOOD *741*
Farr, Lee E. See GITLIN, JANEWAY, and FARR 44
Feinstein, Howard M. See SWAN, FEINSTEIN, and MADISSO 607
Feldman, Harry A., and **Pillemer, Louis.** Toxoplasma antibody and the properdin system *702*
Feller, D. D. See HUFF and FELLER 1
Felts, William R., Jr., and **Talbott, Edmund J.** Clinical study of host-parasite relationship in loa-loa *702*
Ferguson, Robert W. See DISALVO, BLOOM, BRUST, FERGUSON, and FERRIS 568
Ferris, Eugene B. See DISALVO, BLOOM, BRUST, FERGUSON, and FERRIS 568
Fidanza, Flaminio. See KEYS, ANDERSON, ARESU, BIÖRCK, BROCK, BRONTE-STEWART, FIDANZA, KEYS, MALMROS, POPPI, POSTELI, SWAHN, and DEL VECCHIO 1173
Field, James B., and **Stetten, DeWitt, Jr.** Observations on the causes and mechanism of insulin resistance during diabetic acidosis *703*
Filler, J. See FRITTS, FILLER, FISHMAN, and COURNAND *705*
Finch, Clement A. See DONOHUE, FINCH, and GABRIO 562
—. See GABRIO, DONOHUE, HUENNEKENS, and FINCH 657
—. See BOTHWELL, PRIBILLA, HURTADO, and FINCH *693*
Finesinger, Jacob E. See CALLAWAY and FINESINGER *694*
Fink, Sidney. See MAYNARD and FINK 831
Fishman, A. P. See FRITTS, FILLER, FISHMAN, and COURNAND *705*
Fitz, Reginald H. See AIKAWA and FITZ 775
Fletcher, Anthony P., Johnson, Alan J., and **McCarty, W. Ross.** Effects of purified streptokinase injected intravenously into patients *703*
Forbes, Gilbert B., and **Lewis, Anne M.** Total sodium, potassium and chloride in adult man 596
—, and **Lewis, Anne.** Relation of exchangeable sodium, potassium and chloride to total body content in man *703*
Fox, Adacie. See TOBIAN and FOX *297*
Franklin, Edward C., and **Kunkel, Henry G.** The role of the basic fraction of gamma globulin in the flocculation reactions *704*
Franks, J. J., and **Reeve, E. B.** Errors in measurements with serum proteins labelled with I^{131} *704*
Frayser, Regina. See HICKAM, WILSON, and FRAYSER 601
Frazell, E. L. See HELLMAN, BRADLOW, FRAZELL, and GALLAGHER 1033
Fredrickson, Donald S. See HAVEL and FREDRICKSON 1025
Freiman, David G. See BLANKENHORN and FREIMAN *692*
—. See BLANKENHORN, FREIMAN, and KNOWLES 1243
Freinkel, Norbert. See INGBAR, FREINKEL, DOWLING, and KUMAGAI *714*
—. See DOWLING, FREINKEL, and INGBAR 1263
Freis, Edward D., Schnaper, Harold W., Kovach, Renato D., Porfido, Frank A., and **Lilienfield, Lawrence S.** Bidirectional exchange of permeable substances across the capillaries of the human forearm *704*
—. See LILIENFIELD, KOVACH, MARKS, HERSHENSON, RODNAN, EBAUGH, and FREIS 1385
Fremont-Smith, Kenneth, and **Iber, Frank L.** The application of I-131 labeled albumin to the study of acute changes in protein metabolism in man *705*
Frenk, Silvestre. See METCOFF, FRENK, GORDILLO, GOMEZ, GALVAN, and ANTONOWICZ *723*
Friedlich, Allan L. See MYERS, CURRENS, FRIEDLICH, and SCANNELL *727*
Friedman, Meyer, Homer, Richard, and **Byers, Sanford O.** An evaluation of potassium iodide as a therapeutic agent in the treatment of experimental hypercholesteremia and atherosclerosis 1015
—. See BYERS and FRIEDMAN 405
—. See ROSENMAN, FRIEDMAN, and BYERS 522
—. See ROSENMAN, BYERS, and FRIEDMAN *732*
Friend, C. See WRÓBLEWSKI, FRIEND, NYDICK, RUEGSEGGER, and LADUE *746*
Fritts, H. W., Jr., Filler, J., Fishman, A. P., and **Cournand, A.** The efficiency of ventilation during voluntary hyperpnea of patients with chronic obstructive emphysema *705*
Fudenberg, Hugh, and **Mahoney, John P.** The relation of spleen size to the body hematocrit/venous hematocrit ratio *705*

G

Gabrio, Beverly Wescott, Donohue, Dennis M., Huennekens, F. M., and **Finch, Clement A.** Erythrocyte preservation. VII. Acid-citrate-dextrose-inosine (ACDI) as a preservative for blood during storage at 4° C 657
—. See DONOHUE, FINCH, and GABRIO *562*
Gallagher, T. F. See HELLMAN, BRADLOW, FRAZELL, and GALLAGHER 1033

Galvan, Rafael Ramos. See METCOFF, FRENK, GORDILLO, GOMEZ, GALVAN, and ANTONOWICZ *723*
Galvin, Robert D. See DANFORD, GALVIN, and HORITA 1205
Geiger, Ernest. See BORUN and GEIGER 1109
Gelfand, Mathew. See GOLDSTEIN, GELFAND, SANDERS, and ROSEN *707*
Genest, Jacques, Lemieux, Guy, Davignon, André, Koiw, Erich, Nowaczynski, Wojciech, and **Steyermark, Paul.** Aldosterone and human arterial hypertension *706*
Gerst, P. H. See PETERSON and GERST *729*
Geyer, Georg, Herbst, Franz S. M., Thaler, H., and **Lever, Walter F.** The permeability of capillaries to serum cholesterol 281
Gibbons, Donald M. See WESTON, ISAACS, ROSENBLUM, GIBBONS, and GROSSMAN *744*
Giblett, Eloise. See MOTULSKY, CASSERD, and GIBLETT *725*
Gibson, William. See ZOLL, LINENTHAL, GIBSON, PAUL, and NORMAN *748*
Gilbert, Marvin. See WESSLER, BALLON, and GILBERT *743*
Gilbert, Robert. See FALOON, AUCHINCLOSS, EICH, and GILBERT *701*
Gilbertsen, A. Sigrid. See KENNEDY and GILBERTSEN *717*
Gillespie, Louis, Jr. See INKLEY, GILLESPIE, and KOLETSKY *714*
Gitlin, David, Janeway, Charles A., and **Farr, Lee E.** Studies on the metabolism of plasma proteins in the nephrotic syndrome. I. Albumin, γ-globulin and iron-binding globulin 44
—, and **Cornwell, David.** Plasma lipoprotein metabolism in normal individuals and in children with the nephrotic syndrome *706*
—, **Hitzig, Walter H.,** and **Janeway, Charles A.** Multiple serum protein deficiencies in congenital and acquired agammaglobulinemia 1199
Givner, Morris L. See BAULD, MILNE, and GIVNER *689*
Glaviano, Vincent V. See HILTON, CAPECI, KISS, KRUESI, GLAVIANO, and WÉGRIA 481
Goldberg, Harry, Smith, Ralph, Dickens, Janet, Raber, George, and **Waldow, Asher.** Simultaneous catheterization of left and right heart *706*
Goldstein, Robert, Gelfand, Mathew, Sanders, Martin, and **Rosen, Robert.** Anticoagulant appearing in plasma thromboplastin component (PTC) deficiency *707*
Gomez, Federico. See METCOFF, FRENK, GORDILLO, GOMEZ, GALVAN, and ANTONOWICZ *723*
Good, Robert A. See VERNIER, FARQUHAR, BRUNSON, and GOOD *741*
Goodall, McC., and **Kirshner, N.** Effect of cervicothoracic ganglionectomy on the adrenaline and noradrenaline content in the mammalian heart 649
Goodman, Howard C. See BAXTER, GOODMAN, and ORLOFF *689*
Gordillo, Gustavo. See METCOFF, FRENK, GORDILLO, GOMEZ, GALVAN, and ANTONOWICZ *723*
Gordon, Edgar S. See CHART, GORDON, HELMER, and LESHER 254
Gordon, Irving, Patterson, Paul R., and **Whitney, Elinor.** Immunity in volunteers recovered from non-bacterial gastroenteritis 200
Gordon, Robert S., Jr., and **Cherkes, Amelia.** Unesterified fatty acid in human blood plasma 206
Grabner, Georg. See VETTER, GRABNER, HÖFER, NEUMAYR, and PARZER 825
Graettinger, John S. See CAMPBELL, GRAETTINGER, MUENSTER, and CHECCIA *695*
Gray, Seymour J., Ramsey, Colin G., and **Thorn, George W.** Adrenal influences on the stomach: Peptic ulcer in Addison's disease during adrenal steroid therapy *707*
Greenberg, Mortimer S., and **Kass, Edward H.** Alkali in the treatment of painful crises in patients with sickle cell anemia *707*
—. See JANDL, GREENBERG, YONEMOTO, and CASTLE 842
Greenwalt, Tibor J., and **Ayers, Valborg Elizabeth.** The phosphate partition of the erythrocytes of normal newborn infants and of infants with hemolytic disease 1404
Greif, Roger L., Sullivan, W. James, Jacobs, Gloria S., and **Pitts, Robert F.** Distribution of radiomercury administered as labelled chlormerodrin (Neohydrin®) in the kidneys of rats and dogs 38
Gribetz, Donald. See LEVITT, HALPERN, SWEET, and GRIBETZ *720*
Gribetz, H. Joel. See ZIFF, KIBRICK, DRESNER, and GRIBETZ 579
—. See ZIFF, GRIBETZ, and LOSPALLUTO *747*
Grob, David, Liljestrand, Ake, and **Johns, Richard J.** Role of potassium gradient in neuromuscular function in normal subjects and periodic paralysis *708*
Grossman, Jacob. See WESTON, ISAACS, ROSENBLUM, GIBBONS, and GROSSMAN *744*
Grossman, Morton I. See BERNSTEIN and GROSSMAN *627*
Grumbach, Melvin M. See CHILDS, GRUMBACH, and VAN WYK 213
—. See MIGEON, PRYSTOWSKY, GRUMBACH, and BYRON 488
Guild, Warren R. See BRICKER, GUILD, REARDAN, and MERRILL *694*
—. See BRICKER, GUILD, REARDAN, and MERRILL 1364
Gutman, Alexander B. See YÜ, PATON, CHENKIN, BURNS, BRODIE, and GUTMAN 374

H

Hadju, Stephen, and **Leonard, Edward.** The action of human plasma on the isolated frog heart: Observations on subjects with and without essential hypertension *708*
Hagen, Paul S. See DOSCHERHOLMEN and HAGEN *699*
Halpern, Mark H. See LEVITT, HALPERN, SWEET, and GRIBETZ *720*
Hamolsky, Milton W. Further studies on the plasma protein-thyroid hormone complex in various thyroid states in man *708*
Hanley, T., and **Platts, M. M.** Observations on the metabolic effects of the carbonic anhydrase inhibitor Diamox®: Mode and rate of recovery from the drug's action 20
Hardin, Byron. See MUDGE and HARDIN 155
Harper, Harold A. See DOOLAN, HARPER, HUTCHIN, and ALPEN 888
Harris, John H. See BEDELL, MARSHALL, DUBOIS, and HARRIS 336

Harris, John W., Price, James M., Whittington, Richard M., Weisman, Russell, Jr., and **Horrigan, Daniel L.** Pyridoxine responsive anemia in the adult human *709*

Harris, Robert S. See BRONNER, HARRIS, MALETSKOS, and BENDA 78

Harrison, Harold E. See CHISOLM and HARRISON 1131

Harvey, A. McGehee. The individual in medical research and the rôle of the university center in his training *683*

Hasbrouck, E. E. See STAMLER, DREIFUS, MARCUS, WONG, HASBROUCK, SHERIDAN, MAIER, and ELLIS *737*

Havel, Richard J., and **Fredrickson, Donald S.** The metabolism of chylomicra. I. The removal of palmitic acid-1-C^{14} labeled chylomicra from dog plasma 1025

Haynes, Florence W. See SAXTON, RABINOWITZ, DEXTER, and HAYNES 611

—. See KUIDA, RAPAPORT, and HAYNES *719*

—. See RAPAPORT, KUIDA, HAYNES, and DEXTER 1393

Heaney, Robert P. See ELIEL and HEANEY *701*

Hecht, Hans H., and **Lange, Ramon L.** Four chamber catheterization for quantitation of valvular deformities with particular reference to mitral stenosis *709*

Heiman, Donald F. See CONN, HEIMAN, BLAKEMORE, KUO, and LANGFELD *697*

Hellems, Harper K., Regan, Timothy J., Talmers, Frederick N., Christensen, Raymond C., and **Wada, Taskashi.** The mode of action of acetyl strophanthidin on the failing human heart *710*

—. See REGAN, TALMERS, and HELLEMS 1220

Hellman, Leon, and **Numerof, Paul.** The metabolism of reserpine in man *710*

—, **Bradlow, H. Leon, Frazell, E. L.,** and **Gallagher, T. F.** Tracer studies of the absorption and fate of steroid hormones in man 1033

Helmer, Phyllis. See CHART, GORDON, HELMER, and LESHER 254

Helrich, Martin. See PRICE, HELRICH, and CONNER 125

Henley, Keith S., Wiggins, Hugh S., and **Pollard, H. Marvin.** The effect of oral ethanol on the hepatic glutamic pyruvic transaminase activity in the rat *710*

Henneman, Philip H. and **Dempsey, Eleanor F.** Factors determining fecal electrolyte excretion *711*

—, **Dempsey, Eleanor F., Carroll, Evelyn L.,** and **Albright, Fuller.** The cause of hypercalcuria in sarcoid and its treatment with cortisone and sodium phytate 1229

Herbst, Franz S. M. See GEYER, HERBST, THALER, and LEVER 281

Hernando-Avendano, Luis. See RENOLD, CRABBE, ROSS, HERNANDO-AVENDANO, NELSON, and THORN *731*

Herschfus, J. Aaron. See ATTINGER, HERSCHFUS, and SEGAL 912

Hershenson, Lee M. See LILIENFIELD, KOVACH, MARKS, HERSHENSON, RODNAN, EBAUGH, and FREIS 1385

Heslin, A. Sandra. See DOYLE, DELALLA, BAKER, HESLIN, and BROWN *699*

Hibbett, Lester L. See HILL, HOLLEY, STARNES, and HIBBETT *711*

Hickam, John B., Wilson, William P., and **Frayser, Regina.** Observations on the early elevation of serum potassium during respiratory alkalosis 601

—. See BONDURANT and HICKAM *692*

Higgins, John A. See REITEMEIER, HIGGINS, LEE, and SCHOLER *730*

Hill, S. Richardson, Jr., Holley, Howard L., Starnes, Willard R., and **Hibbett, Lester L.** Studies on the diurnal pattern and ratio of urinary 17-hydroxycorticosteroid and 17-ketosteroid excretion in patients with rheumatoid arthritis and non-rheumatic chronic diseases *711*

Hilton, James G., Capeci, Nicholas E., Kiss, George T., Kruesi, Oscar R., Glaviano, Vincent V., and **Wégria, René.** The effect of acute elevation of the plasma chloride concentration on the renal excretion of bicarbonate during acute respiratory acidosis 481

Hinz, Carl F., Jr., Jordan, William S., Jr., and **Pillemer, Louis.** The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria 453

Hirschowitz, Basil I., Wiggins, Hugh S., London, John, and **Pollard, H. Marvin.** The secretion of pepsin by the human stomach *711*

Hitzig, Walter H. See GITLIN, HITZIG, and JANEWAY 1199

Hlad, C. J., Jr., Huffman, E. R., Whipple, N., and **Elrick, H.** Sodium "space" studies: The effect of certain hormones *712*

—, **Elrick, H.,** and **Witten, T. A.** Studies on the kinetics of glucose utilization 1139

—. See ELRICK, HLAD, ARAI, and SMITH *757*

Hodges, R. E. See THORNTON, HODGES, LUBIN, WILSON, and DAUM *739*

Höfer, Rudolf. See VETTER, GRABNER, HÖFER, NEUMAYR, and PARZER 825

Holburn, R. R., Schwartz, I. R., Carroll, R. T., and **Weiss, A.** Electrophoretic separation of anticoagulants from human plasma *712*

Hollander, William, and **Michelson, Alan L.** The effects of serotonin and antiserotonins in hypertensive man *712*

—, **Reilly, Paul,** and **Burrows, Belton A.** Lymphatic flow in human subjects as indicated by the disappearance of I^{131} labelled albumin from the subcutaneous tissues *713*

—, and **Judson, Walter E.** The relationship of cardiovascular and renal hemodynamic function to sodium excretion in patients with severe heart disease but without edema 970

—. See MICHELSON and HOLLANDER *724*

Hollander, W., Jr., Winters, R. W., Williams, T. F., Holliday, M., Oliver, J., and **Welt, L. G.** The renal concentrating defect in potassium depleted rats *713*

Holley, Howard L. See HILL, HOLLEY, STARNES, and HIBBETT *711*

Holliday, M. See HOLLANDER, WINTERS, WILLIAMS, HOLLIDAY, OLIVER, and WELT *713*

Hollifield, Guy. See CRISPELL, PARSON, and HOLLIFIELD 164

Homer, Richard. See FRIEDMAN, HOMER, and BYERS 1015

Hoobler, S. W. See COTTIER, HOOBLER, and WELLER *698*

Horita, Akira. See DANFORD, GALVIN, and HORITA 1205
Horrigan, Daniel L. Isolation from crude liver of a substance effective in therapy of a nutritional hypochromic anemia *713*
—. See HARRIS, PRICE, WHITTINGTON, WEISMAN, and HORRIGAN *709*
Houck, C. Riley. See DI LUZIO and HOUCK 1381
Howard, John Eager. See CONNOR, THOMAS, and HOWARD *697*
Huennekens, F. M. See GABRIO, DONOHUE, HUENNEKENS, and FINCH 657
Huff, Rex L., and **Feller, D. D.** Relation of circulating red cell volume to body density and obesity 1
Huffman, E. R. See HLAD, HUFFMAN, WHIPPLE, and ELRICK *712*
Hughes, Hettie B. See BIEHL and HUGHES *691*
Hurtado, Arnold V. See BOTHWELL, PRIBILLA, HURTADO, and FINCH *693*
Huston, John H. See ROWE, HUSTON, WEINSTEIN, TUCHMAN, BROWN, and CRUMPTON *272*
—. See CROSLEY, BROWN, HUSTON, EMANUEL, TUCHMAN, CASTILLO, and ROWE 1340
Hutchin, Maxine E. See DOOLAN, HARPER, HUTCHIN, and ALPEN 888
Hyatt, Marion R. See JENCKS, HYATT, JETTON, MATTINGLY, and DURRUM 980
Hyer, Harry. See CRISPELL, KAHANA, and HYER 121
—. See CRISPELL, COLEMAN, and HYER *698*

I

Iber, Frank L. See FREMONT-SMITH and IBER *705*
Ingbar, Sidney H., Freinkel, Norbert, Dowling, James T., and **Kumagai, Lindy F.** Abnormalities of iodine metabolism in euthyroid relatives of patients with Graves' disease *714*
—. See DOWLING, FREINKEL, and INGBAR 1263
Ingelfinger, Franz J. See ATKINSON, KRAMER, WYMAN, and INGELFINGER *687*
Inkley, Scott R., Gillespie, Louis, Jr., and **Koletsky, Simon.** Pulmonary lesions in rabbits following intravenous injections of thromboplastin *714*
Inoye, Tohru. See RYAN, PASCAL, INOYE, and BERNSTEIN 1119
Isaacs, Marian C. See WESTON, ISAACS, ROSENBLUM, GIBBONS, and GROSSMAN *744*
Isselbacher, Kurt J., Anderson, Elizabeth A., and **Kalckar, Herman M.** Demonstration of the specific enzymatic defect in galactosemia *714*
Itano, H. A. See KEITEL, THOMPSON, and ITANO 998
Itoh, Shinji. See SCHWARTZ and ITOH *733*

J

Jackson, George Gee, and **Boand, Arthur V.** Protection from viral infections by inhibitors in human nasal secretion *715*
Jacobs, Gloria S. See GREIF, SULLIVAN, JACOBS, and PITTS 38
Jacobson, Julius. See LARAGH, VAN DYKE, JACOBSON, ADAMSONS, and ENGEL 897
Jaenike, John R., Schreiner, Bernard F., Jr., and **Waterhouse, Christine.** A comparative study of the dextran and radioiodinated albumin spaces in normal and edematous subjects *715*
Jandl, James H. Elongated macromolecules for detecting and characterizing red cell sensitization in acquired hemolytic anemia *715*
—, **Greenberg, Mortimer S., Yonemoto, Robert H.,** and **Castle, William B.** Clinical determination of the sites of red cell sequestration in hemolytic anemias 842
Janeway, Charles A. See GITLIN, JANEWAY, and FARR 44
—. See GITLIN, HITZIG, and JANEWAY 1199
Jarcho, Leonard W., and **Tyler, Frank H.** Myxedema, myotonia and pseudomyotonia *716*
Jencks, William P., Hyatt, Marion R., Jetton, Mera R., Mattingly, Thomas W., and **Durrum, E. L.** A study of serum lipoproteins in normal and atherosclerotic patients by paper electrophoretic techniques 980
Jetton, Mera R. See JENCKS, HYATT, JETTON, MATTINGLY, and DURRUM 980
Johns, C. J. See RILEY, JOHNS, COHEN, COHN, CARROLL, and SHEPARD 1008
Johns, Richard J. See GROB, LILJESTRAND, and JOHNS *708*
Johnson, Alan J. See FLETCHER, JOHNSON, and MCCARTY *703*
Johnson, B. B. See MULROW, LIEBERMAN, JOHNSON, and LUETSCHER *726*
Johnson, Phillip C., Richmond, Virginia, Caputto, Ranwel, and **Wolf, Stewart.** Fractionation of human gastric content: The separation of intrinsic factor activity *716*
Johnson, Robert L., Jr. See MILLER, JOHNSON, and WU *724*
Jones, Audrey. See BRANDT, ZUMOFF, CASTLEMAN, RUSKIN, JONES, and ZUCKERMAN 1080
Jones, Philip N., and **Mills, Elizabeth H.** The effect of liver disease on serum vitamin B_{12} concentrations *716*
Jordan, William S., Jr. See HINZ, JORDAN, and PILLEMER 453
Judson, Walter E. See HOLLANDER and JUDSON 970

K

Kahana, Shirley. See CRISPELL, KAHANA, and HYER 121
Kalckar, Herman M. See ISSELBACHER, ANDERSON, and KALCKAR *714*
Kark, Robert M., Pollak, Victor E., Pirani, Conrad L., and **Muehrcke, Robert C.** The relationship of renal structural changes to renal function in lupus nephritis *717*
Karnofsky, David A. See MURPHY and KARNOFSKY *726*
Kass, Edward H. See GREENBERG and KASS *707*
Keitel, H. G., Thompson, D., and **Itano, H. A.** Hyposthenuria in sickle cell anemia: A reversible renal defect 998
Kelley, Robert T. See ROSE, MCDERMOTT, LILIENFIELD, PORFIDO, and KELLEY *731*
Kelly, Keith H. See BIERMAN, KELLY, CORDES, and BYRON *691*
Kennedy, B. J., and Gilbertsen, A. Sigrid. Increased erythropoiesis induced by androgenic hormones *717*
Kessler, R. H. See BORGHGRAEF, KESSLER, and PITTS 1055

Keys, Ancel, Anderson, Joseph T., Aresu, Mario, Biörck, Gunnar, Brock, John F., Bronte-Stewart, B., Fidanza, Flaminio, Keys, Margaret Haney, Malmros, Haqvin, Poppi, Arrigo, Posteli, Teodoro, Swahn, Bengt, and **del Vecchio, Alfonso.** Physical activity and the diet in populations differing in serum cholesterol 1173

Keys, Margaret Haney. See KEYS, ANDERSON, ARESU, BIÖRCK, BROCK, BRONTE-STEWART, FIDANZA, KEYS, MALMROS, POPPI, POSTELI, SWAHN, and DEL VECCHIO 1173

Kibrick, Andre. See ZIFF, KIBRICK, DRESNER, and GRIBETZ 579

Kilbourne, Edwin D., Wilson, Charles B., and **Perrier, Dorothy.** The induction of gross myocardial lesions by a coxsackie (pleurodynia) virus and cortisone 362

Kirkendall, Walter M. See PETERSON, O'TOOLE, and KIRKENDALL *730*

Kirshner, N. See GOODALL and KIRSHNER 649

Kiss, George T. See HILTON, CAPECI, KISS, KRUESI, GLAVIANO, and WÉGRIA 481

Klatskin, Gerald, and **Bungards, Luitgard.** Bilirubin-protein linkages in serum and their relationship to the Van den Bergh reaction 537

Kleeman, Charles R., Epstein, Franklin H., and **White, Colin.** The effect of variations in solute excretion and glomerular filtration on water diuresis 749

—. See EPSTEIN, KLEEMAN, LAMDIN, and RUBINI 308

—. See LAMDIN, KLEEMAN, RUBINI, and EPSTEIN. 386

Kleinerman, Jerome, and **Sancetta, Salvatore M.** Effect of mild, steady state exercise on general and cerebral hemodynamics of patients with aortic stenosis *717*

Kleinfeld, Morris, Stein, Edward, and **Magin, John.** Electrical alternans in single ventricular fibers of the frog heart *718*

Kling, David H. See LEVINE and KLING 1419

Knowles, Harvey C., Jr. See YOUNG, BURNSIDE, and KNOWLES *747*

—. See BLANKENHORN, FREIMAN, and KNOWLES 1243

Koch-Weser, Dieter. The influence of the metabolic state of tubercle bacilli upon the action of isoniazid *"in vitro"* *718*

Koiw, Erich. See GENEST, LEMIEUX, DAVIGNON, KOIW, NOWACZYNSKI, and STEYERMARK *706*

Koletsky, Simon. See INKLEY, GILLESPIE, and KOLETSKY *714*

Kovach, Renato D. See FREIS, SCHNAPER, KOVACH, PORFIDO, and LILIENFIELD *704*

—. See LILIENFIELD, KOVACH, MARKS, HERSHENSON, RODNAN, EBAUGH, and FREIS 1385

Kowlessar, O. D., and **McEvoy, R. K.** Desoxyribonuclease I activity in pancreatic disease 1325

Kramer, Philip. See ATKINSON, KRAMER, WYMAN, and INGELFINGER *687*

Krane, Stephen M., Brownell, Gordon L., Stanbury, John B., and **Corrigan, Helen.** The effect of thyroid disease on calcium metabolism in man 874

Kretchmer, Norman, Levine, S. Z., McNamara, Helen, and **Barnett, Henry L.** Certain aspects of tyrosine metabolism in the young. I. The development of the tyrosine oxidizing system in human liver 236

—, and **McNamara, Helen.** Certain aspects of tyrosine metabolism in the young. II. The tyrosine oxidizing system of fetal rat liver 1089

Krueger, John J. See PATTERSON, MULLINAX, BAIN, and KRUEGER *728*

Kruesi, Oscar R. See HILTON, CAPECI, KISS, KRUESI, GLAVIANO, and WÉGRIA 481

Kuida, Hiroshi, Rapaport, Elliot, and **Haynes, Florence W.** The effect of large doses of adrenocortical hormones on the high output of Paget's disease *719*

—. See RAPAPORT, KUIDA, HAYNES, and DEXTER 1393

Kumagai, Lindy F. See INGBAR, FREINKEL, DOWLING, and KUMAGAI *714*

Kunkel, Henry G., and **Trautman, Rodes.** The α_2 lipoproteins of human serum. Correlation of ultracentrifugal and electrophoretic properties 641

—. See FRANKLIN and KUNKEL *704*

Kuo, Peter T., Schnabel, Truman G., Jr., Blakemore, William S., and **Langfeld, Stephen B.** Relationship of gallop sounds to intracardiac pressures *719*

—. See CONN, HEIMAN, BLAKEMORE, KUO, and LANGFELD *697*

Kyle, Laurence H., Meyer, Richard J., Schaaf, Marcus, and **Werdein, Edward J.** The effects of compound A (11-dehydrocorticosterone) and compound F (17-hydroxycorticosterone) on total body fat 1045

L

LaDue, J. S. See WRÓBLEWSKI, FRIEND, NYDICK, RUEGSEGGER, and LADUE *746*

Lambertsen, Christian J. See WENDEL, LAMBERTSEN, and LONGENHAGEN *743*

Lamdin, Ezra, Kleeman, Charles R., Rubini, Milton, and **Epstein, Franklin H.** Studies on alcohol diuresis. III. The response to ethyl alcohol in certain disease states characterized by impaired water tolerance 386

—. See EPSTEIN, KLEEMAN, LAMDIN, and RUBINI 308

Lanchantin, Gerard F. See COX, LANCHANTIN, and WARE 106

Lange, Ramon L. See HECHT and LANGE *709*

Langfeld, Stephen B. See CONN, HEIMAN, BLAKEMORE, KUO, and LANGFELD *697*

—. See KUO, SCHNABEL, BLAKEMORE, and LANGFELD *719*

Laragh, John H., Van Dyke, H. B., Jacobson, Julius, Adamsons, Karlis, Jr., and **Engel, Stamford L.** The experimental production of ascites in the dog with diabetes insipidus 897

Lardy, Henry A. See ALBRIGHT, LARSON, TOMITA, and LARDY *687*

Larson, Frank C. See ALBRIGHT, LARSON, TOMITA, and LARDY *687*

Lathem, Willoughby, and **Benjamin, A. D.** Intrarenal circulatory dynamics and glomerular permeability to hemoglobin in dogs *719*

—. The urinary excretion of sodium and potassium during the pyrogenic reaction in man 947

—. Renal circulatory dynamics and urinary protein excretion during infusions of *l*-norepinephrine and *l*-epinephrine in patients with renal disease 1277

Lavender, A. R. See PAGE and LAVENDER *728*

Lawrence, John S. See CRADDOCK, PERRY, and LAWRENCE 285

Leaf, Alexander, and **Renshaw, Alan.** Tissue metabolism and ion transport *720*

Lee, Philip R. See REITEMEIER, HIGGINS, LEE, and SCHOLER *730*

Leeksma, C. H. W., and **Cohen, J. A.** Determination of the life span of human blood platelets using labelled diisopropylfluorophosphonate 964
Lemieux, Guy. See GENEST, LEMIEUX, DAVIGNON, KOIW, NOWACZYNSKI, and STEYERMARK *706*
Leonard, Edward. See HAJDU and LEONARD *708*
Lepow, Irwin H., Ratnoff, Oscar D., and **Pillemer, Louis.** Studies on the pro-enzymatic activity of the first component of human complement (C'1) *720*
LeSher, Marjorie. See CHART, GORDON, HELMER, and LESHER 254
Lever, Walter F. See GEYER, HERBST, THALER, and LEVER 281
Levine, Milton G., and **Kling, David H.** Rheologic studies on synovial fluid 1419
Levine, S. Z. See KRETCHMER, LEVINE, MCNAMARA, and BARNETT 236
Levitt, Marvin F., Turner, Louis B., Sweet, Avron Y., and **Pandiri, Demetra.** The response of bone, connective tissue, and muscle to acute acidosis 98
—, **Halpern, Mark H., Sweet, Avron Y.,** and **Gribetz, Donald.** The effect of intravenous calcium infusion on electrolyte excretion in man *720*
Lewis, Anne M. See FORBES and LEWIS 596
—. See FORBES and LEWIS *703*
Ley, Allyn B., and **Mayer, Klaus.** The analysis of Cr^{51} erythrocyte survival curves *721*
Li, M. C., Bergenstal, D. M., and **Parrott, R. H.** Paradoxical electrolyte effects of delta 1-9 fluorohydrocortisone in hypocorticoid subjects *721*
Liang, Maria M. L. See OLSON, ELLENBOGEN, STERN, and LIANG *727*
Liddle, Grant W. See BARTTER, LIDDLE, DUNCAN, and DELEA *688*
—. See DUNCAN, LIDDLE, and BARTTER 1299
—. See BARTTER, LIDDLE, DUNCAN, BARBER, and DELEA 1306
Lieberman, A. H. See MULROW, LIEBERMAN, JOHNSON, and LUETSCHER *726*
Lilienfield, Lawrence S., Porfido, Frank A., and **Rose, John C.** The hematocrit of the dog kidney: Differences in red blood cell and plasma transit times *721*
—, **Kovach, Renato D., Marks, Paul A., Hershenson, Lee M., Rodnan, Gerald P., Ebaugh, Franklin G., Jr.,** and **Freis, Edward D.** The hematocrit of the lesser circulation in man 1385
—. See FREIS, SCHNAPER, KOVACH, PORFIDO, and LILIENFIELD *704*
—. See ROSE, MCDERMOTT, LILIENFIELD, PORFIDO, and KELLEY *731*
Liljestrand, Ake. See GROB, LILJESTRAND, and JOHNS *708*
Linenthal, Arthur J. See ZOLL, LINENTHAL, GIBSON, PAUL, and NORMAN *748*
Lipkin, Martin, and **Sleisenger, Marvin H.** Measurement of the threshold to visceral pain induced by distension of the large intestine *722*
Lipson, Martha J., Robbins, Frederick C., and **Woods, Wilna A.** The influence of vaccination upon intestinal infection of family contacts of poliomyelitis patients *722*
London, John. See HIRSCHOWITZ, WIGGINS, LONDON, and POLLARD *711*
Longenhagen, John B. See WENDEL, LAMBERTSEN, and LONGENHAGEN *743*
Lospalluto, Joseph. See ZIFF, GRIBETZ, and LOSPALLUTO *747*
Lubin, R. I. See THORNTON, HODGES, LUBIN, WILSON, and DAUM *739*
Luetscher, J. A., Jr. See MULROW, LIEBERMAN, JOHNSON, and LUETSCHER *726*

Mc

McCarty, W. Ross. See FLETCHER, JOHNSON, and MCCARTY *703*
McCune, Robert M., Dineen, P. A. Peter, and **Batten, John C.** The use of microbial enumeration techniques in the evaluation of antibacterial agents in the treatment of experimental staphylococcal infections of mice *723*
McDermott, Thomas F. See ROSE, MCDERMOTT, LILIENFIELD, PORFIDO, and KELLEY *731*
McEvoy, R. K. See KOWLESSAR and MCEVOY 1325
McIntosh, H. D. See WEISSLER, MCINTOSH, ESTES, and WARREN *743*
McNamara, Helen. See KRETCHMER, LEVINE, MCNAMARA, and BARNETT 236
—. See KRETCHMER and MCNAMARA 1089

M

Mach, René S. See MULLER, RIONDEL, MANNING, and MACH *725*
MacLean, Lloyd D. See WEIL, MACLEAN, VISSCHER, and SPINK 1191
MacNair, Margaret B. See SCHMID and MACNAIR 814
Madisso, Harry. See SWAN, FEINSTEIN, and MADISSO 607
Magin, John. See KLEINFELD, STEIN, and MAGIN *718*
Mahoney, John P. See FUDENBERG and MAHONEY *705*
Maier, K. See STAMLER, DREIFUS, MARCUS, WONG, HASBROUCK, SHERIDAN, MAIER, and ELLIS *737*
Maletskos, Constantine J. See BRONNER, HARRIS, MALETSKOS, and BENDA 78
Malette, W. G. See EISEMAN, MALETTE, WOTKYNS, SUMMERS, and TONG 940
Malmros, Haqvin. See KEYS, ANDERSON, ARESU, BIÖRCK, BROCK, BRONTE-STEWART, FIDANZA, KEYS, MALMROS, POPPI, POSTELI, SWAHN, and DEL VECCHIO 1173
Maniglia, Rosario. See BAKST, MANIGLIA, and BAILEY 302
Manning, Elizabeth L. See MULLER, RIONDEL, MANNING, and MACH *725*
Marcus, E. See STAMLER, DREIFUS, MARCUS, WONG, HASBROUCK, SHERIDAN, MAIER, and ELLIS *737*
Margen, Sheldon, and **Tarver, Harold.** Comparative studies on the turnover of serum albumin in normal human subjects 1161
Margolius, Alvin, Jr., and **Ratnoff, Oscar D.** A laboratory study of the carrier state in classic hemophilia 1316
Marks, Paul A., and **Bishop, Jonathan.** Glucose metabolism in human subjects with neoplastic diseases *722*
—. See LILIENFIELD, KOVACH, MARKS, HERSHENSON, RODNAN, EBAUGH, and FREIS 1385
Marshall, Robert. See DUBOIS, BOTELHO, BEDELL, MARSHALL, and COMROE 322
—. See BEDELL, MARSHALL, DUBOIS, and HARRIS 336
—. See BEDELL, MARSHALL, DUBOIS, and COMROE 664
Mattingly, Thomas W. See JENCKS, HYATT, JETTON, MATTINGLY, and DURRUM 980
Mayer, Klaus. See LEY and MAYER *721*

Maynard, Laurence S., and **Fink, Sidney.** The influence of chelation on radiomanganese excretion in man and mouse 831
Mealey, Edward H. See MULFORD and MEALEY 1213
Meister, Alton, Udenfriend, Sidney, and **Bessman, Samuel P.** Diminished phenylketonuria in phenylpyruvic oligophrenia after administration of l-glutamine, l-glutamate or l-asparagine 619
Merrill, John P. See BRICKER, GUILD, REARDAN, and MERRILL *694*
—. See BRICKER, GUILD, REARDAN, and MERRILL 1364
Metcoff, Jack, Frenk, Silvestre, Gordillo, Gustavo, Gomez, Federico, Galvan, Rafael Ramos, and **Antonowicz, Irena.** On intracellular edema and renal adjustment in severe chronic malnutrition *723*
Meyer, Richard J. See KYLE, MEYER, SCHAAF, and WERDEIN 1045
Michelson, Alan L., and **Hollander, William.** The effect of serotonin on respiration in asthmatic and non-asthmatic subjects *724*
—. See HOLLANDER and MICHELSON *712*
Migeon, Claude J., Prystowsky, Harry, Grumbach, Melvin M., and **Byron, Margaret C.** Placental passage of 17-hydroxycorticosteroids: Comparison of the levels in maternal and fetal plasma and effect of ACTH and hydrocortisone administration 488
Miller, Aaron, Corbus, Howard F., and **Sullivan, John F.** The plasma disappearance, excretion and tissue distribution of intravenous cobalt^{60} vitamin B_{12} in normal subjects and patients with chronic myelogenous leukemia *724*
—, **Chodos, Robert B., Emerson, Charles P.,** and **Ross, Joseph F.** Studies of the anemia and iron metabolism in cancer 1248
Miller, Gladys M. See STEIGER, ZARAFONETIS, MILLER, SEIFTER, and BAEDER *737*
Miller, William F., Johnson, Robert L., Jr., and **Wu, Nancy.** The relationships between components of the rapid expiratory flow and volume curves to pulmonary viscous resistance *724*
Mills, Elizabeth H. See JONES and MILLS *716*
Milne, Ian G. See BAULD, MILNE, and GIVNER *689*
Milnor, W. R., and **Crary, H. I.** The disappearance of T-1824 from the circulation in heart failure *725*
Money, William L. See SONENBERG and MONEY *736*
Monroe, R. Grier. See ATTINGER, MONROE, and SEGAL 904
Motulsky, Arno G., Casserd, Frederick, and **Giblett, Eloise.** *In vivo* measurement of splenic circulation: A rapid method for the demonstration of splenic red cell sequestration *725*
Mudge, Gilbert H., and **Hardin, Byron.** Response to mercurial diuretics during alkalosis: A comparison of acute metabolic and chronic hypokalemic alkalosis in the dog 155
Muehrcke, Robert C. See KARK, POLLAK, PIRANI, and MUEHRCKE *717*
Muenster, Joseph J. See CAMPBELL, GRAETTINGER, MUENSTER, and CHECCIA *695*
Mulford, Dwight J., and **Mealey, Edward H.** Heat stability of protein solutions obtained from human plasma by different ethanol concentrations and temperatures 1213
Muller, Alex F., Riondel, Anne M., Manning, Elizabeth L., and **Mach, René S.** Regulation of the secretion of aldosterone in man *725*
Mullinax, P. Franklin, Jr. See PATTERSON, MULLINAX, BAIN, and KRUEGER *728*
Mulrow, P. J., Lieberman, A. H., Johnson, B. B., and **Luetscher, J. A., Jr.** Potassium to sodium ratio as an index of aldosterone output *726*
Murdaugh, H. V., Jr. Production of diuresis in hyponatremic edematous states with alcohol *726*
Murphy, Irene S. See STEFANINI and MURPHY 355
Murphy, M. Lois, and **Karnofsky, David A.** Teratogenic and toxic effects of antimetabolites in the rat: With special reference to 6-diazo-5-oxo-l-norleucine (DON) *726*
Murray, Joseph E. See DAMMIN, MURRAY, and COUCH *699*
Myers, Gordon S., Currens, James H., Friedlich, Allan L., and **Scannell, J. Gordon.** The circulatory effects of protoveratrines on hypertensive patients with and without congestive heart failure *727*

N

Nadell, J., Sweet, N. J., and **Edelman, I. S.** Gastrointestinal water and electrolytes. II. The equilibration of radiopotassium in gastrointestinal contents and the proportion of exchangeable potassium (K_e) in the gastrointestinal tract 512
Neher, Robert, and **Wettstein, Albert.** Physicochemical estimation of aldosterone in urine 800
Nelson, Don H. See RENOLD, CRABBE, ROSS, HERNANDO-AVENDANO, NELSON, and THORN *731*
Nelson, Robert A., Jr., and **Taverne, Janice.** Immune-adherence with *poliovirus hominis* *727*
Neumayr, Anton. See VETTER, GRABNER, HÖFER, NEUMAYR, and PARZER 825
Newerly, Katharina. See BERSON, YALOW, BAUMAN, ROTHSCHILD, and NEWERLY 170
Nolan, Mary F. See CHINARD, ENNS, and NOLAN *696*
Norman, Leona R. See ZOLL, LINENTHAL, GIBSON, PAUL, and NORMAN *748*
Nowaczynski, Wojciech. See GENEST, LEMIEUX, DAVIGNON, KOIW, NOWACZYNSKI, and STEYERMARK *706*
Numerof, Paul. See HELLMAN and NUMEROF *710*
Nydick, I. See WRÓBLEWSKI, FRIEND, NYDICK, RUEGSEGGER, and LADUE *746*

O

Oliver, J. See HOLLANDER, WINTERS, WILLIAMS, HOLLIDAY, OLIVER, and WELT *713*
Olson, Robert E., Ellenbogen, Eric, Stern, Howard, and **Liang, Maria M. L.** An abnormality of cardiac myosin associated with chronic congestive heart failure in the dog *727*
Orloff, Jack, and **Berliner, Robert W.** The mechanism of the excretion of ammonia in the dog 223
—. See BAXTER, GOODMAN, and ORLOFF *689*
O'Toole, James J. See PETERSON, O'TOOLE, and KIRKENDALL *730*
Owren, Paul A. See SEAMAN and OWREN 145
—. See SEAMAN and OWREN 371

P

Page, Irvine H. See CORCORAN, WAGNER, and PAGE 868
—. See DUSTAN, CORCORAN, and PAGE 1357

Page, Robert G., and **Lavender, A. R.** Effect of hydrocortisone and prednisone on patients with "controlled" congestive heart failure. Preliminary report *728*
Pandiri, Demetra. See LEVITT, TURNER, SWEET, and PANDIRI 98
Papper, Solomon, and **Saxon, Lawrence.** The influence of intravenous infusions of sodium chloride solutions on the renal excretion of sodium in patients with cirrhosis of the liver *728*
—. See ROSENBAUM, PAPPER, and COHEN *732*
Parrott, R. H. See LI, BERGENSTAL, and PARROTT *721*
Parson, William. See CRISPELL, PARSON, and HOLLIFIELD 164
Parzer, Otto. See VETTER, GRABNER, HÖFER, NEUMAYR, and PARZER 825
Pascal, Luke R. See RYAN, PASCAL, INOYE, and BERNSTEIN 1119
Paton, Bruce C. See YÜ, PATON, CHENKIN, BURNS, BRODIE, and GUTMAN 374
Patterson, John L., Jr., Mullinax, P. Franklin, Jr., Bain, Thomas H., and **Krueger, John J.** Carbon dioxide-induced dyspnea in a patient with complete respiratory paralysis *728*
Patterson, Paul R. See GORDON, PATTERSON, and WHITNEY 200
Paul, Milton H. See ZOLL, LINENTHAL, GIBSON, PAUL, and NORMAN *748*
Paul, William M., Enns, Theodore, Reynolds, Samuel R. M., and **Chinard, Francis P.** Sites of water exchange between the maternal system and the amniotic fluid of rabbits 634
Payne, W. W. See COCHRANE, PAYNE, SIMPKISS, and WOOLF 411
Pearson, Elinor. See REISS, PEARSON, and ARTZ 62
Pensky, Jack, and **Weisberger, Austin S.** Studies on the glutathione reductase of leukemic leukocytes *729*
Perrier, Dorothy. See KILBOURNE, WILSON, and PERRIER 362
Perry, Seymour. See CRADDOCK, PERRY, and LAWRENCE 285
Peterson, Lysle H., and **Gerst, P. H.** On the significance of arterial pressure pulse distortion and hemodynamics *729*
Peterson, Ralph E., and **Wyngaarden, James B.** The miscible pool and turnover rate of hydrocortisone in man 552
Peterson, Richard E., O'Toole, James J., and **Kirkendall, Walter M.** The variability of extracellular fluid space (sucrose) in man during a 24-hour period *730*
Pick, A. See DREYFUSS and PICK *700*
Pillemer, Louis. See HINZ, JORDAN, and PILLEMER 453
—. See FELDMAN and PILLEMER *702*
—. See LEPOW, RATNOFF, and PILLEMER *720*
Pirani, Conrad L. See KARK, POLLAK, PIRANI, and MUEHRCKE *717*
Pitts, Robert F. See BORGHGRAEF and PITTS 31
—. See GREIF, SULLIVAN, JACOBS, and PITTS 38
—. See BORGHGRAEF, KESSLER, and PITTS 1055
Platts, M. M. See HANLEY and PLATTS 20
Pollak, Victor E. See KARK, POLLAK, PIRANI, and MUEHRCKE *717*
Pollard, H. Marvin. See HENLEY, WIGGINS, and POLLARD *710*
—. See HIRSCHOWITZ, WIGGINS, LONDON, and POLLARD *711*
Poppell, J. William. See ROBERTS, POPPELL, VANAMEE, BEALS, and RANDALL 261
—. See VANAMEE, POPPELL, RANDALL, and ROBERTS *740*
Poppi, Arrigo. See KEYS, ANDERSON, ARESU, BIÖRCK, BROCK, BRONTE-STEWART, FIDANZA, KEYS, MALMROS, POPPI, POSTELI, SWAHN, and DEL VECCHIO 1173
Porfido, Frank A. See FREIS, SCHNAPER, KOVACH, PORFIDO, and LILIENFIELD *704*
—. See LILIENFIELD, PORFIDO, and ROSE *721*
—. See ROSE, MCDERMOTT, LILIENFIELD, PORFIDO, and KELLEY *731*
Postel, Sholem. Total free tocopherols in the serum of patients with thyroid disease 1345
Posteli, Teodoro. See KEYS, ANDERSON, ARESU, BIÖRCK, BROCK, BRONTE-STEWART, FIDANZA, KEYS, MALMROS, POPPI, POSTELI, SWAHN, and DEL VECCHIO 1173
Potter, H. P. See BLUEMLE, POTTER, and ELKINTON 1094
Poulos, Peter P. A constant-change (single injection) method for the estimation of the volume of distribution of substances in body fluid compartments 921
Preedy, John R. K., and **Aitken, Elsie H.** The effect of estrogen on water and electrolyte metabolism. I. The normal 423
—, and **Aitken, Elsie H.** The effect of estrogen on water and electrolyte metabolism. II. Hepatic disease 430
—, and **Aitken, Elsie H.** The effect of estrogen on water and electrolyte metabolism. III. Cardiac and renal disease 443
Pribilla, Walther. See BOTHWELL, PRIBILLA, HURTADO, and FINCH *693*
Price, Henry L., Helrich, Martin, and **Conner, Eugene H.** A relation between hemodynamic and plasma volume alterations during general anesthesia in man 125
—. See DE T. VALK and PRICE 837
Price, James M. See HARRIS, PRICE, WHITTINGTON, WEISMAN, and HORRIGAN *709*
Prystowsky, Harry. See MIGEON, PRYSTOWSKY, GRUMBACH, and BYRON 488

R

Raber, George. See GOLDBERG, SMITH, DICKENS, RABER, and WALDOW *706*
Rabinowitz, Murray. See SAXTON, RABINOWITZ, DEXTER, and HAYNES 611
Ramsey, Colin G. See GRAY, RAMSEY, and THORN *707*
Randall, Henry T. See ROBERTS, POPPELL, VANAMEE, BEALS, and RANDALL 261
—. See VANAMEE, POPPELL, RANDALL, and ROBERTS *740*
Rapaport, Elliot, Kuida, Hiroshi, Haynes, Florence W., and **Dexter, Lewis.** The pulmonary blood volume in mitral stenosis 1393
—. See KUIDA, RAPAPORT, and HAYNES *719*
Rasmussen, Howard. Thyroxine metabolism in the nephrotic syndrome 792
Ratnoff, Oscar D. See LEPOW, RATNOFF, and PILLEMER *720*
—. See MARGOLIUS and RATNOFF 1316
Raymunt, Julie. See RUSS, RAYMUNT, and BARR 133
Reardan, John B. See BRICKER, GUILD, REARDAN, and MERRILL *694*
—. See BRICKER, GUILD, REARDAN, and MERRILL 1364

Recant, Lillian. An abnormality in thyroxine-binding in nephrosis *730*
Reeve, E. B. See FRANKS and REEVE *704*
Regan, Timothy J., Talmers, Frederick N., and **Hellems, Harper K.** Myocardial transfer of sodium and potassium: Effect of acetyl strophanthidin in normal dogs 1220
—. See HELLEMS, REGAN, TALMERS, CHRISTENSEN, and WADA *710*
Rehm, Warren S. See BRODSKY, DENNIS, REHM, APPELBOOM, and DIAMOND *694*
Reilly, Paul. See HOLLANDER, REILLY, and BURROWS *713*
Reiss, Eric, Pearson, Elinor, and **Artz, Curtis P.** The metabolic response to burns 62
Reissmann, Kurt R., and **Dietrich, Mary R.** On the presence of ferritin in the peripheral blood of patients with hepatocellular disease 588
Reitemeier, Richard J., Higgins, John A., Lee, Philip R., and **Scholer, John F.** The absorption of water and sodium from the small bowel of patients with nontropical sprue *730*
Renold, Albert E., Crabbe, Jean, Ross, Eric J., Hernando-Avendano, Luis, Nelson, Don H., and **Thorn, George W.** Inhibition of aldosterone secretion by amphenone in man *731*
Renshaw, Alan. See LEAF and RENSHAW *720*
Reynolds, Samuel R. M. See PAUL, ENNS, REYNOLDS, and CHINARD 634
Richmond, Virginia. See JOHNSON, RICHMOND, CAPUTTO, and WOLF *716*
Riley, R. L., Johns, C. J., Cohen, G., Cohn, J. E., Carroll, D. G., and **Shepard, R. H.** The diffusing capacity of the lungs in patients with mitral stenosis studied post-operatively 1008
Riondel, Anne M. See MULLER, RIONDEL, MANNING, and MACH *725*
Robbins, Frederick C. See LIPSON, ROBBINS, and WOODS *722*
Roberts, Kathleen E., Poppell, J. W., Vanamee, Parker, Beals, Robert, and **Randall, Henry T.** Evaluation of respiratory compensation in metabolic alkalosis 261
—. See VANAMEE, POPPELL, RANDALL, and ROBERTS *740*
Rodnan, Gerald P. See LILIENFIELD, KOVACH, MARKS, HERSHENSON, RODNAN, EBAUGH, and FREIS 1385
Rogers, David E. Studies on the persistence of staphylococcal bacteremia in rabbits *731*
Rose, John C., McDermott, Thomas F., Lilienfield, Lawrence S., Porfido, Frank A., and **Kelley, Robert T.** Circulatory changes due to hypothermia in anesthetized man *731*
—. See LILIENFIELD, PORFIDO, and ROSE *721*
Rosen, Robert. See GOLDSTEIN, GELFAND, SANDERS, and ROSEN *707*
Rosenbaum, Jack D., Papper, Solomon, and **Cohen, Henry W.** The influence of alcohol ingestion upon maintained water diuresis *732*
Rosenblum, Robert. See WESTON, ISAACS, ROSENBLUM, GIBBONS, and GROSSMAN *744*
Rosenman, Ray H., and **Smith, Malcolm K.** The effect of certain chelating substances (EDTA) upon cholesterol metabolism in the rat 11
—, **Friedman, Meyer,** and **Byers, Sanford O.** The causal role of plasma albumin deficiency in experimental nephrotic hyperlipemia and hypercholesteremia 522
—, **Byers, Sanford O.,** and **Friedman, Meyer.** Plasma albumin deficiency: The cause of hyperlipemia and hypercholesteremia in experimental nephrosis *732*
Ross, Eric J. See RENOLD, CRABBE, ROSS, HERNANDO-AVENDANO, NELSON, and THORN *731*
Ross, Joseph F. See MILLER, CHODOS, EMERSON, and Ross 1248
Ross, Richard S., and **Walker, W. Gordon.** Decreased permeability of capillaries to protein in chronic congestive heart failure *732*
Rothschild, Marcus A. See BERSON, YALOW, BAUMAN, ROTHSCHILD, and NEWERLY 170
Rowe, George G., Huston, John H., Weinstein, Arvin B., Tuchman, Herman, Brown, John F., and **Crumpton, Charles W.** The hemodynamics of thyrotoxicosis in man with special reference to coronary blood flow and myocardial oxygen metabolism 272
—. See CROSLEY, BROWN, HUSTON, EMANUEL, TUCHMAN, CASTILLO, and ROWE 1340
Rubini, Milton E. See EPSTEIN, KLEEMAN, LAMDIN, and RUBINI 308
—. See LAMDIN, KLEEMAN, RUBINI, and EPSTEIN 386
Ruegsegger, P. See WRÓBLEWSKI, FRIEND, NYDICK, RUEGSEGGER, and LADUE *746*
Rundles, R. Wayne, and **Brewer, Spencer S., Jr.** The metabolic role of vitamin B_{12} in pernicious anemia *733*
Ruskin, Herman D. See BRANDT, ZUMOFF, CASTLEMAN, RUSKIN, JONES, and ZUCKERMAN 1080
Russ, Ella M., Raymunt, Julie, and **Barr, David P.** Lipoproteins in primary biliary cirrhosis 133
Ryan, Robert J., Pascal, Luke R., Inoye, Tohru, and **Bernstein, Lionel.** Experiences with radiosulfate in the estimation of physiologic extracellular water in healthy and abnormal man 1119

S

Salmon, William D., Jr., and **Daughaday, William H.** Sulfation factor, a serum component mediating the action of growth hormone in stimulating incorporation of sulfate into cartilage *733*
Samson, Frederick E., Jr., Dahl, Nancy, and **Dahl, Dennis R.** A study of the narcotic action of the short chain fatty acids 1291
Sancetta, Salvatore M. See KLEINERMAN and SANCETTA *717*
Sandberg, Avery A., and **Slaunwhite, W. Roy, Jr.** Metabolism of 4-C^{14}-testosterone in human subjects. I. Distribution in bile, blood, feces and urine 1331
Sanders, Martin. See GOLDSTEIN, GELFAND, SANDERS, and ROSEN *707*
Saxon, Lawrence. See PAPPER and SAXON *728*
Saxton, George A., Jr., Rabinowitz, Murray, Dexter, Lewis, and **Haynes, Florence.** The relationship of pulmonary compliance to pulmonary vascular pressures in patients with heart disease 611
Scannell, J. Gordon. See MYERS, CURRENS, FRIEDLICH, and SCANNELL *727*
Schaaf, Marcus. See KYLE, MEYER, SCHAAF, and WERDEIN 1045
Schmid, K., and **MacNair, Margaret B.** Characterization of the proteins of human synovial fluid in certain disease states 814
Schnabel, Truman G., Jr. See KUO, SCHNABEL, BLAKEMORE, and LANGFELD *719*

Schnaper, Harold W. See Freis, Schnaper, Kovach, Porfido, and Lilienfield *704*
Scholer, John F. See Reitemeier, Higgins, Lee, and Scholer *730*
Schreiner, Bernard F., Jr. See Jaenike, Schreiner, and Waterhouse *715*
Schwartz, Irving L., and **Thaysen, Jørn Hess.** Excretion of sodium and potassium in human sweat 114
—, and **Itoh, Shinji.** Fatigue of the sweat glands in heat stroke *733*
Schwartz, I. R. See Holburn, Schwartz, Carroll, and Weiss *712*
Schwartz, Robert, and **Craig, John.** The effect of diet on potassium deficiency and acid-base balance *734*
Schwartz, William B., Bennett, Warren, Curelop, Sidney, and **Bartter, Frederic C.** Studies on the mechanism of a sodium-losing syndrome in two patients with mediastinal tumors *734*
Scribner, Belding H. See Burnell, Villamil, Uyeno, and Scribner 935
Seaman, Arthur J., and **Owren, Paul A.** An asolectin adsorbed substrate for proaccelerin assay 145
—, and **Owren, Paul A.** Asolectin separation of prothrombin from proconvertin 371
Segal, Maurice S. See Attinger, Monroe, and Segal 904
—. See Attinger, Herschfus, and Segal 912
Seiden, George E. Application of a new quantitative method for studying the QRS complex of the EKG in cardiac patients *734*
Seifter, Joseph. See Steiger, Zarafonetis, Miller, Seifter, and Baeder *737*
Sensenbach, Willis. See Eisenberg and Sensenbach *700*
Shafrir, Eleazar, and **de Vries, Andre.** Studies on the clot-promoting activity of glass 1183
Shepard, R. H. See Riley, Johns, Cohn, Carroll, and Shepard 1008
Sheridan, J. T. See Stamler, Dreifus, Marcus, Wong, Hasbrouck, Sheridan, Maier, and Ellis *737*
Sherry, Sol, and **Alkjaersig, Norma.** Studies on the activation of human plasminogen (profibrinolysin) *735*
Shulman, N. Raphael. The role of a new anticoagulant proteolytic inhibitor in blood coagulation *735*
Siegel, A. See Blain, Eddleman, Siegel, and Bing 314
Simpkiss, M. J. See Cochrane, Payne, Simpkiss, and Woolf 411
Singer, R. B., Deering, R. C., and **Clark, J. K.** The acute effects in man of a rapid intravenous infusion of hypertonic sodium bicarbonate solution. II. Changes in respiration and output of carbon dioxide 245
Siri, William E. Body composition and blood volume in normal and disease states *735*
Slaunwhite, W. Roy, Jr. See Sandberg and Slaunwhite 1331
Sleisenger, Marvin H. See Lipkin and Sleisenger *722*
Small, Walter J. See Campbell and Small *695*
Smith, A. See Elrick, Hlad, Arai, and Smith *757*
Smith, Hubbard W. See Texter and Smith *739*
Smith, J. M., and **Vickers, A. B.** Staphylococcal septicemia: The importance of host factors *736*
Smith, Malcolm K. See Rosenman and Smith 11
Smith, Ralph. See Goldberg, Smith, Dickens, Raber, and Waldow *706*
Snidal, D. P. See Cherniack and Snidal 1286
Soberman, Robert J. See Farber and Soberman 779
Sonenberg, Martin, and **Money, William L.** Inhibition of pituitary activity following administration of derivatives of pituitary preparations *736*
Spaet, Theodore H. Anticoagulant effect of excess platelets *736*
Spink, Wesley W. See Abernathy and Spink *687*
—. See Weil, MacLean, Visscher, and Spink 1191
Stamler, J., Dreifus, L., Marcus, E., Wong, S., Hasbrouck, E. E., Sheridan, J. T., Maier, K., and **Ellis, A.** Studies on receptor-effector mechanisms influencing renal hemodynamics and water-sodium exchanges in intact, diabetes insipidus, ascitic and renal-denervated dogs *737*
Stanbury, John B. See Krane, Brownell, Stanbury, and Corrigan 874
Stanley, Malcolm. See Cheng and Stanley *696*
Starnes, Willard R. See Hill, Holley, Starnes, and Hibbett *711*
Stavitsky, Abram B. See Arquilla and Stavitsky 458
—. See Arquilla and Stavitsky 467
Stefanini, Mario, and **Murphy, Irene S.** Studies on platelets. XIV. Human platelets as source of antifibrinolysin 355
Steiger, William A., Zarafonetis, Chris J. D., Miller, Gladys M., Seifter, Joseph, and **Baeder, David.** Preliminary report on the effects of a plasma lipid mobilizing factor in man *737*
Stein, Edward. See Kleinfeld, Stein, and Magin *718*
Sterling, Kenneth, and **Chodos, Robert B.** Radiothyroxine turnover studies in myxedema, thyrotoxicosis, and hypermetabolism without endocrine disease *737*
—, and **Chodos, Robert B.** Radiothyroxine turnover studies in myxedema, thyrotoxicosis, and hypermetabolism without endocrine disease 806
Stern, Howard. See Olson, Ellenbogen, Stern, and Liang *727*
Stetten, DeWitt, Jr. See Field and Stetten *703*
Steyermark, Paul. See Genest, Lemieux, Davignon, Koiw, Nowaczynski, and Steyermark *706*
Stunkard, Albert J., and **Wolff, Harold G.** Studies on the physiology of hunger. I. The effect of intravenous administration of glucose on gastric hunger contractions in man 954
Sulkin, Norman M. See Boyce and Sulkin 1067
Sulkowitch, Hirsh. The urinary excretion of the epinephrines in anxiety states *738*
Sullivan, John F. See Miller, Corbus, and Sullivan *724*
Sullivan, W. James. See Greif, Sullivan, Jacobs, and Pitts 38
Summers, W. B. See Eiseman, Malette, Wotkyns, Summers, and Tong 940
Surtshin, A., and **White, H. L.** Postural effects on renal tubular activity *267*
Swahn, Bengt. See Keys, Anderson, Aresu, Biörck, Brock, Bronte-Stewart, Fidanza, Keys, Malmros, Poppi, Posteli, Swahn, and del Vecchio 1173
Swan, H. J. C. See Wood, Woodward, Swan, and Ellis *745*

Swan, Roy C., Feinstein, Howard M., and **Madisso, Harry.** Distribution of sulfate ion across semipermeable membranes 607
Sweet, Avron Y. See LEVITT, TURNER, SWEET, and PANDIRI 98
—. See LEVITT, HALPERN, SWEET, and GRIBETZ *720*
Sweet, N. J. See EDELMAN and SWEET 502
—. See NADELL, SWEET, and EDELMAN 512
Swisher, Scott N. Nonspecific adherence of platelets and leukocytes to antibody-sensitized red cells: A mechanism producing thrombocytopenia and leukopenia during incompatible transfusions *738*

T

Talbott, Edmund J. See FELTS and TALBOTT *702*
Talmers, Frederick N. See HELLEMS, REGAN, TALMERS, CHRISTENSEN, and WADA *710*
—. See REGAN, TALMERS, and HELLEMS 1220
Tarail, R., and **Bennett, T. E.** Ultrafiltrability of electrolytes after death *738*
Tarver, Harold. See MARGEN and TARVER 1161
Taverne, Janice. See NELSON and TAVERNE *727*
Texter, E. Clinton, Jr., and **Smith, Hubbard W.** Quantitative study of gastrointestinal motor activity *739*
Thaler, H. See GEYER, HERBST, THALER, and LEVER 281
Thaysen, Jørn Hess. See SCHWARTZ and THAYSEN 114
Thomas, Lewis, and **Zweifach, Benjamin W.** Hyperreactivity to adrenalin as a possible mechanism in endotoxin shock *739*
Thomas, William C., Jr. See CONNOR, THOMAS, and HOWARD *697*
Thompson, D. See KEITEL, THOMPSON, and ITANO 998
Thorn, George W. See GRAY, RAMSEY, and THORN *707*
—. See RENOLD, CRABBE, ROSS, HERNANDO-AVENDANO, NELSON, and THORN *731*
Thornton, G. H. M., Hodges, R. E., Lubin, R. I., Wilson, W. R., and **Daum, Kate.** Studies on pantothenic acid and potassium *739*
Tobian, Louis, and **Fox, Adacie.** The effect of norepinephrine on the electrolyte composition of arterial smooth muscle *297*
—. The effect of desoxycorticosterone with either high or low sodium diets on the electrolyte composition of arterial wall *740*
Tomita, Kenkichi. See ALBRIGHT, LARSON, TOMITA, and LARDY *687*
Tong, J. L. See EISEMAN, MALETTE, WOTKYNS, SUMMERS, and TONG 940
Trautman, Rodes. See KUNKEL and TRAUTMAN 641
Tuchman, Herman. See ROWE, HUSTON, WEINSTEIN, TUCHMAN, BROWN, and CRUMPTON *272*
—. See CROSLEY, BROWN, HUSTON, EMANUEL, TUCHMAN, CASTILLO, and ROWE 1340
Turino, Gerard M. Pulmonary distensibility in mitral stenosis and congenital heart disease *740*
Turner, Louis B. See LEVITT, TURNER, SWEET, and PANDIRI 98
Tyler, Frank H. See JARCHO and TYLER *716*

U

Udenfriend, Sidney. See MEISTER, UDENFRIEND, and BESSMAN 619
Ulmer, David D. See WACKER, ADELSTEIN, ULMER, and VALLEE *741*
Uyeno, Ben T. See BURNELL, VILLAMIL, UYENO, and SCRIBNER 935

V

Vallee, Bert L. See WACKER, ADELSTEIN, ULMER, and VALLEE *741*
Vanamee, Parker, Poppell, J. William, Randall, Henry T., and **Roberts, Kathleen E.** Effects of elevated blood ammonium concentration on respiratory exchange *740*
—. See ROBERTS, POPPELL, VANAMEE, BEALS, and RANDALL 261
Van Dyke, H. B. See LARAGH, VAN DYKE, JACOBSON, ADAMSONS, and ENGEL 897
Van Wyk, Judson J. See CHILDS, GRUMBACH, and VAN WYK 213
Vernier, Robert L., Farquhar, Marilyn G., Brunson, Joel G., and **Good, Robert A.** Studies on familial nephrosis: Evidence for a unitarian concept *741*
Vester, John W. Oxidative phosphorylation in the hepatic mitochondria of normal, diabetic, and insulin treated cats *741*
Vetter, Herbert, Grabner, Georg, Höfer, Rudolf, Neumayr, Anton, and **Parzer, Otto.** Comparison of liver blood flow values estimated by the bromsulphalein and by the radiogold method 825
Vickers, A. B. See SMITH and VICKERS *736*
Villamil, Mario F. See BURNELL, VILLAMIL, UYENO, and SCRIBNER 935
Vilter, Richard W. See WILL and VILTER *745*
Visscher, Maurice B. See WEIL, MACLEAN, VISSCHER, and SPINK 1191

W

Wacker, Warren E. C., Adelstein, S. James, Ulmer, David D., and **Vallee, Bert L.** The relation of copper to ceruloplasmin activity and zinc to malic and lactic dehydrogenase activity and zinc to malic and lactic dehydrogenase activity in acute myocardial infarction *741*
Wada, Taskashi. See HELLEMS, REGAN, TALMERS, CHRISTENSEN, and WADA *710*
Wagner, Henry N., Jr., and **Braunwald, Eugene.** The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension *742*
—, and **Braunwald, Eugene.** The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension 1412
Wagner, William E. See CORCORAN, WAGNER, and PAGE 868
Waldow, Asher. See GOLDBERG, SMITH, DICKENS, RABER, and WALDOW *706*
Walker, W. Gordon. See Ross and WALKER *732*
Ware, Arnold G. See COX, LANCHANTIN, and WARE 106
Warren, J. V. See WEISSLER, MCINTOSH, ESTES, and WARREN *743*
Waterhouse, Christine. See JAENIKE, SCHREINER, and WATERHOUSE *715*
Waterlow, J. C., and **Weisz, T.** The fat, protein and nucleic acid content of the liver in malnourished human infants 346
Webster, Leslie T., Jr., and **Davidson, Charles S.** The effect of sodium glutamate on hepatic coma 191

—, and **Davidson, Charles S.** Sources of blood ammonium after feeding protein to patients with hepatic cirrhosis *742*
Wégria, René. See HILTON, CAPECI, KISS, KRUESI, GLAVIANO, and WÉGRIA 481
Weil, Max H., MacLean, Lloyd D., Visscher, Maurice B., and **Spink, Wesley W.** Studies on the circulatory changes in the dog produced by endotoxin from gram-negative microorganisms 1191
Weinstein, Arvin B. See ROWE, HUSTON, WEINSTEIN, TUCHMAN, BROWN, and CRUMPTON *272*
Weinstein, H. G. See ZIMMERMAN and WEINSTEIN *748*
Weisberger, Austin S. See PENSKY and WEISBERGER *729*
Weisman, Russell, Jr. See HARRIS, PRICE, WHITTINGTON, WEISMAN, and HORRIGAN *709*
Weiss, A. See HOLBURN, SCHWARTZ, CARROLL, and WEISS *712*
Weissler, A. M., McIntosh, H. D., Estes, E. H., Jr., and **Warren, J. V.** Vasodepressor syncope: Acute circulatory disorganization *743*
Weisz, T. See WATERLOW and WEISZ 346
Weller, J. M. See COTTIER, HOOBLER, and WELLER *698*
Welt, L. G. See HOLLANDER, WINTERS, WILLIAMS, HOLLIDAY, OLIVER, and WELT *713*
Wendel, Herbert, Lambertsen, Christian J., and **Longenhagen, John B.** The effect of chlorpromazine and meperidine, alone and combined, upon respiration in man *743*
Werdein, Edward J. See KYLE, MEYER, SCHAAF, and WERDEIN 1045
Werner, Sidney C. Response to triiodothyronine as index of persistence of disease in the thyroid remnant of patients in remission from hyperthyroidism 57
Wessler, Stanford, Ballon, Jonathan D., and **Gilbert, Marvin.** The role of convertin in experimental *in vivo* thrombosis *743*
West, Clark D. See CHEEK and WEST *763*
Weston, Raymond E., Isaacs, Marian C., Rosenblum, Robert, Gibbons, Donald M., and **Grossman, Jacob.** Metabolic effects of an anabolic steroid, 17-alpha-ethyl-17-hydroxy-norandrostenone in human subjects *744*
Wettstein, Albert. See NEHER and WETTSTEIN 800
Wheeler, H. O., Combes, B., Childs, A. W., and **Bradley, S. E.** Distribution of splanchnic circulation times in cirrhosis *744*
Whipple, N. See HLAD, HUFFMAN, WHIPPLE, and ELRICK *712*
White, Colin. See KLEEMAN, EPSTEIN, and WHITE 749
White, H. L. See SURTSHIN and WHITE 267
Whitney, Elinor. See GORDON, PATTERSON, and WHITNEY 200
Whittington, Richard M. See HARRIS, PRICE, WHITTINGTON, WEISMAN, and HORRIGAN *709*
Wiggins, Hugh S. See HENLEY, WIGGINS, and POLLARD *710*
—. See HIRSCHOWITZ, WIGGINS, LONDON, and POLLARD *711*
Wilber, Joseph A., and **Brust, Albert A.** Pressor potentiation of nor-epinephrine by tetraethylammonium chloride and atropine *744*
Will, John J., and **Vilter, Richard W.** An inhibitor of desoxyribonuclease obtained from human white blood cells *745*
Williams, T. F. See HOLLANDER, WINTERS, WILLIAMS, HOLLIDAY, OLIVER, and WELT *713*
Wilson, Charles B. See KILBOURNE, WILSON, and PERRIER 362
Wilson, William P. See HICKAM, WILSON, and FRAYSER 601
Wilson, W. R. See THORNTON, HODGES, LUBIN, WILSON, and DAUM *739*
Winters, R. W. See HOLLANDER, WINTERS, WILLIAMS, HOLLIDAY, OLIVER, and WELT *713*
Wintrobe, M. M. See BUSH, ASHENBRUCKER, CARTWRIGHT, and WINTROBE 89
Wisseman, Charles L., Jr. Mechanisms of antimicrobial action by chloramphenicol *745*
Witten, T. A. See HLAD, ELRICK, and WITTEN 1139
Wolf, Stewart. See JOHNSON, RICHMOND, CAPUTTO, and WOLF *716*
Wolff, Harold G. See STUNKARD and WOLFF 954
Wong, S. See STAMLER, DREIFUS, MARCUS, WONG, HASBROUCK, SHERIDAN, MAIER, and ELLIS *737*
Wood, Earl H., Woodward, Edward, Jr., Swan, H. J. C., and **Ellis, F. Henry, Jr.** Detection and estimation of mitral regurgitation by indicator-dilution technics *745*
Wood, J. Edwin, and **Eckstein, John W.** Peripheral venous and arteriolar responses to moderate reductions in effectively circulating blood volume in man *746*
Woods, Wilna A. See LIPSON, ROBBINS, and WOODS *722*
Woodward, Edward, Jr. See WOOD, WOODWARD, SWAN, and ELLIS *745*
Woolf, L. I. See COCHRANE, PAYNE, SIMPKISS, and WOOLF 411
Wotkyns, R. S. See EISEMAN, MALETTE, WOTKYNS, SUMMERS, and TONG 940
Wróblewski, F., Friend, C., Nydick, I., Ruegsegger, P., and **LaDue, J. S.** The mechanism and significance of alterations in serum glutamic oxaloacetic and serum glutamic pyruvic transaminase in liver and heart disease *746*
Wu, Nancy. See MILLER, JOHNSON, and WU *724*
Wyman, Stanley M. See ATKINSON, KRAMER, WYMAN, and INGELFINGER *687*
Wyngaarden, James B. See PETERSON and WYNGAARDEN 552

Y

Yalow, Rosalyn S., and **Berson, Solomon A.** The effect of irradiation damage of albumin-I^{131} on the rate of its *in vivo* metabolism with special reference to the validity of biologic studies with I^{131} labeled proteins *746*
—. See BERSON, YALOW, BAUMAN, ROTHSCHILD, and NEWERLY 170
Yonemoto, Robert H. See JANDL, GREENBERG, YONEMOTO, and CASTLE 842
Young, Philip C., Burnside, Charles R., and **Knowles, Harvey C., Jr.** The effect of the intragastric administration of whole blood on the blood ammonia, blood urea nitrogen and non-protein nitrogen in patients with liver disease *747*

Yü, T. F., Paton, Bruce C., Chenkin, Theodore, Burns, J. J., Brodie, Bernard B., and Gutman, Alexander B. Effect of a phenylbutazone analog (4-[phenylthioethyl]-1,2-diphenyl 3,5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects. Evaluation as uricosuric agent 374

Z

Zalesky, M. See Braude and Zalesky *693*
Zarafonetis, Chris J. D. See Steiger, Zarafonetis, Miller, Seifter, and Baeder *737*
Zierler, Kenneth L., and **Andres, Reubin.** Movement of potassium into skeletal muscle during spontaneous attack in family periodic paralysis *747*
—, and **Andres, Reuben.** Carbohydrate metabolism in intact skeletal muscle in man during the night 991
—. See Andres, Cader, and Zierler 671
Ziff, Morris, Kibrick, Andre, Dresner, Ellis, and **Gribetz, H. Joel.** Excretion of hydroxyproline in patients with rheumatic and non-rheumatic diseases 579
—, **Gribetz, H. Joel,** and **Lospalluto, Joseph.** Effect of extracts of leucocytes and of synovial membrane on a mucoprotein from cartilage *747*
Zimmerman, H. J., and **Weinstein, H. G.** Lactic dehydrogenase in human serum *748*
Zoll, Paul M., Linenthal, Arthur J., Gibson, William, Paul, Milton H., and **Norman, Leona R.** Termination of ventricular fibrillation in man by externally-applied electric countershock *748*
Zuckerman, Seymour. See Brandt, Zumoff, Castleman, Ruskin, Jones, and Zuckerman 1080
Zumoff, Barnett. See Brandt, Zumoff, Castleman, Ruskin, Jones, and Zuckerman 1080
Zweifach, Benjamin W. See Thomas and Zweifach *739*

SUBJECT INDEX

(Page numbers in italics refer to abstracts)

A

Abdomen
contents, pull of and body position, 909
gas
compression, versus in lung, 343
volume, 664–670
volume, versus thoracic, 336
Abortion
septic, and renal failure, 1095
thyroxine binding in sera of, 1270–1275
Acetanilid, and erythrocyte defect, *690*
Acetazoleamide
acidification and alkalinization after, 1376
and electrolyte excretion in aldosteronism, 1359, 1361
Acetoacetic acid
and isovaleric acid, 419–420
in phenylalanine conversion to tyrosine, 623
Acetone
and oxygen consumption in diabetes mellitus, 1209
narcotic action of, 1297
Acetylcholine
cardiac responses to, 646
potassium and sodium contents after, 300
Achalasia, of sphincter, *687–688*
Acid-base balance
and Diamox®, 20–29
dietary effects on, *734*
and meralluride, 157–162
and posture, during sulfate diuresis, 308–312
and potassium depletion, 763–773
after sodium bicarbonate infusion, 246–252
and sulfate diuresis, 308–312
Acidity
titratable
after Diamox®, 1370
and dl-alanine, 229
after Thiomerin®, 311
of urine
and aldosteronism, 1361
and ammonia excretion, 223
after Diamox®, 27
after dl-alanine, 228–229
and low potassium diet, 157–158
pH, and Thiomerin®, 310–311
and posture, 310–312
versus pH of arterial blood, or serum bicarbonate changes, 309
Acidosis
and ammonium chloride ingestion, 1207
and Diamox®, 20–29, 308–312, *707–708,* 1370
as diabetogenic agent, 498
diabetic
insulin resistance during, *703–704*
radiosulfate distribution in, 1124
and insulin, 1209
and mercurial diuretics, 158, 162
and oxygen consumption, 1206, 1210
postoperative
and electrolytes in hypoaldosteronism, 1359
and potassium, serum concentration, 935–938
respiratory
and bicarbonate, 482, 486
and chloride, 481–487
in sickle cell disease and Diamox®, *707–708*
after sodium bicarbonate, 226
Acromegaly, in diabetic. 185
ACTH
and aldosterone, *726*
urinary, *689, 725–726*
and body fat, 1045–1053
and/or cortisone, blood sugar levels after, 414
and hydrocortisone synthesis, 557–560
and 17-hydroxycorticosteroid, 489–491
17-ketosteroid excretion after, 219–220
and Paget's disease, *719*
and peptic ulcer, *707*
regulation of salt-retaining hormone, 257–259
remission after, and platelet bound radioactivity, 966
and thyroid hormone uptake, *709*
and tyrosyluria of premature infant, 1092
and pregnanetriol in urine, 218–219
Actin, polymerization of and digitalis, 319
Addison's disease
and adrenal steroid therapy, *707*
cortisone, desoxycorticosteroid acetate, and ethyl alcohol, 388–393
and delta 1-9 fluorohydrocortisone, *721*
peptic ulcer in, *707*
water excretion in, 756
Adenosine
conversion to inosine
ammonia as side product of, 662
and reversal of storage lesion, 658
and erythrocyte preservation, 562–567, 659
hypotensive properties of, 662
red cell utilization of, 661
reversal of phosphate partition by, 1408
triphosphate, in energy exchanges of erythrocyte, 1404
Adrenal gland
and adrenocorticotropin, 559
aldosterone release by, *731*
and chlormerodrin, 35
cortex of
and ACTH, 257–259
edema formation, 902
and failure of compound F synthesis, 218
salt-retaining hormone, metabolism by liver slices, 254–259
secretory activity, *711,* 1042
and serum pH, *703–704*
and hydrocortisone
miscible pool and turnover, 557–560
production, and plasma level, 560
influences on stomach, *707*
insufficiency, and sodium conservation, 1299
medulla
block with epinephrine, norepinephrine, 577–578
and urinary hormone excretion, 1278–1283
response to, in familial hypoglycemia, 420
virilizing hyperplasia, 213–221
Adrenalectomy
and body composition, *736*
Adrenocorticotropin. *See* ACTH
and delta 1-9 fluorohydrocortisone, *721*
salt-retaining effect of estrogen after, 428
and uropepsin excretion, *707*
Adrenalin. *See* Epinephrine
Afibrinogenemia, congenital, 53
Agammaglobulinemia
congenital, 53–54
serum protein deficiencies in, 1199–1201
Age
lipoprotein, study, 983
breathing capacity decrease with, 1010
and cardiopulmonary diseases, 913
and cholesterol, total serum, and habitual work, 1176–1177
in beta lipoprotein fraction, 1178
and coronary atherosclerosis, *699–700*
and exchangeable chloride versus total body content, *703–704*
and glucose-6-phosphatase activity of liver, 1092
and hormone metabolism, 1034
and hydroxyproline excretion, 581, 585–586
and hypermetabolism, radiothyroxine, 808
maternal, and virilizing adrenal hyperplasia in child, 218
and myocardial infarction, *689*
and oxygen uptake by liver, 1091
and protein catabolism, 1103
and pulmonary
diffusing capacity, 1009
emphysema, 913, 1287
and relative viscosity of synovial fluid, 1421
and total content of sodium, potassium and chloride, 599, *703–704*

Agglutination
and erythrophagocytosis, 1154
in vitro, 738
of leucocytes, 1150–1160
and erythrocytes, *in vitro, 738*
platelet-erythrocyte, *in vitro, 738*
Agranulocytosis
and leukocyte collections, 289–290
and mercaptomerin, 776–777
Alanine
and ammonia excretion, 228–229
blood sugar concentration after, 418
reabsorptive pattern for, 890–895
Albumin
affinity of, for hydrocortisone, 1429, 1430, 1435
bilirubin in serum bound to, 537–550
at hydrogen ion levels, 548–550
catabolism of, 48–49, 54
chloride concentration after infusion of, 1375
concentration
in electrophoretic distribution of serum proteins, 986
in maternal sera, 1272
in neonatal sera, 1272
different half-lives for and methods available, 1161
diffusion rate in flowing plasma, 1391
electrophoretic mobilities of, 546–547
pH for, 1267
fraction, 54
pigment in, 540
turnover rate, 55
and hypoproteinemia in children with nephrotic syndrome, 44–55
iodinated plasma in plasma protein metabolism study, 44–55
ion-binding capacity of, 821–822
plasma
after anti kidney serum, 525–527
deficiency, in nephrotic hypercholesteremia and hyperlipemia, 522–530, *732*
plasma
metabolism in nephrotic syndrome, 44–55
radioiodinated
disappearance study, 46
in lymphatic flow study, *713*
in protein metabolism, *705–706*
red cell uptake, 121–123
species variation in response, 1169–1171
turnover rate, 1161–1170
and sodium balance in hypoproteinemia, *688–689*
solubility of and electrophoretic concentration, 1214
space, in total blood volume, 1388
and Dextran space, *715*
in synovial fluid, 814–823
and thyroxine-binding protein, thyroxine distribution between, in pregnancy, 1265–1275
and uptake from saline solution, *698*
versus total protein urinary excretion, 1280–1282
Albuminuria
and gout, in nephrosclerosis, *376*
in nephrotic syndrome, 798
and hypoalbuminemia in children, 53, 55
Alcohol
and antidiuretic hormone secretion, *392–393, 732*
Aldosterone
after dehydration, *688,* 1309, 1310
and edema, 1299
and glomerular filtration rate, 1358
and hypertension, *706,* 1360
and myocardial function, 1304
after Pitressin®, *688*
and potassium, after Mercuhydrin®, 1310
and potency of sodium-retaining hormone, 255–258
and renal blood flow, 1357, 1358
secretion of, *725*
and amphenone, *731*
and extracellular fluid volume, *688,* 1299–1305, 1306–1314
and sodium
balance, 1306
deprivation, *688*
intake, *726*
retention, 1299, 1313
urinary excretion, 1308
urinary, *688,* 800–805
and body weight, 1307
excretion of, *725–726,* 1300–1305
Alkalosis
and desoxycorticosterone in potassium free diet, 773
hypochloremic
and urine pH, aldosteronism, 1359
hypokalemic
due to sodium glutamate, 197–198
and urine pH, 1357
metabolic
mercurial diuretic response to, 155–162
respiratory compensation in, 261–266
after sodium bicarbonate infusions, 247, 252
and potassium depletion, 155–162
respiratory, 601–605
and salt-depletion, 1313
and serum potassium concentration versus total body, 935–938
Alloxan, and diabetes mellitus, 1205–1211
Alternans, in single ventricular fibers after l-thyroxin, triiodothyronine, *718*
Altitude, flying and precipitation of sickle cell crises, 1005
American Society for Clinical Investigation, proceedings of forty-eighth annual meeting
abstracts of papers, *687–748*
Presidential Address, 683–686
Amino acid
and ammonia
excretion, 228, 233
levels, *690*
in blood and gelatine, 415
clearance and glycine, 892, 895
concentration, and Cedilanid®, 316–319
excretion, hydroxyproline content in, 582
familial hypoglycemia precipitated by, 411–421
intracellular concentration of, 228, 233
as major substrate for resting muscle, 680
myocardial metabolism of and lanatoside-C, 314, 316
and nitrogen after dietary casein, 414
Aminophylline, renal hemodynamics after, 1367
Aminopterin
teratogenicity and toxicity of, *727–728*
and urinary excretion of folic acid, *697*
Aminopyrine, and reactions to typhoid vaccine, 947–952
Ammonium
and adenosine
release from, 659
as side product, 662
blood, and amino acids, *690*
chloride
acidosis due to, 1207
balance, and extracellular pH changes, 937
urinary excretion after, 1366
concentration
and glutamate, 192–198
gradient for, 231
excretion of, 223–234
after acetazoleamide injection, *227*
after dl-alanine infusion, 228–229
after potassium chloride, *227,* 234
after sodium bicarbonate, 226
metabolism, in cirrhosis, *701–702*
plasma, effect of, on coma, 191–198
production of, and postural changes, 308–312
urinary
in aldosteronism, 1361
and Diamox®, 21–29
Amphenone, and aldosterone secretion, *731*
Amphetamine
and blood glucose values, 629
and food intake, 631–632
Amylase, serum levels in pancreatic diseases, 1325–1330
Anabolism, after burns, 72–73
Androgen
and erythrocytosis, *717*
metabolism of, 1041
Anemia
aplastic
congenital, and serum iron, 589
aplastic
and hormone metabolism, 1034
urine concentration in, 1003
of cancer, 1248–1261
and Cedilanid® therapy, 315–320
Cooley's, 850, 853–854, 860
and gastric contractions after glucose, 957–962
hemolytic, *715, 721*
acquired, 858–859, 860
congenital, 846–847, 860
hemolysis of erythrocytes from, 453–457
hypochromic, nutritional, *713*

of infection, erythrocyte production and bone marrow in, 93–95
iron half-life and serum values in, 1259
paroxysmal nocturnal hemoglobinuria, 453–457, 851–852, 860
red cell sequestration sites in, 842–866
urine concentration in, 1003, 1005
hypochromic
antifibrinolytic activity in, 355–361
nutritional, *713*
and pyridoxine, *709*
and/or hypoferremia in cancer, 1256
hypoplastic of ferritin serum iron, 589
of infection, iron metabolism in, 89–95
and iron metabolism
in cancer, 1248–1261
platelet function in, 356–361
of liver disease, 854
and androgen therapy, *717*
red cell survival in, 860
macrocytic
in Laennec's cirrhosis, 854
myeloid, and androgen, *717*
pernicious, 855, 857, 860
desoxyribonuclease in sera of, 1326
and ferritin serum iron, 589
iron half-life and serum values in, 1259
red cell survival in, 860
and vitamin B_{12}, *733*
and pyridoxine, *708–709*
sickle cell, 843–846, 848–853, 860
sickle cell
alkali in treatment of painful crises, *707–708*
hyposthenuria in, 998–1006
red cell survival in, 860
of uremia, 856
red cell survival in, 860

Anesthesia
and hematocrit whole body-peripheral ratio, 129
hypothermia as adjunct to, 940
hemodynamic effects of, *731–732*
and quinidine, *692*
plasma volume and pressure responses to, 126–128

Angina pectoris, blood lipoprotein patterns in, *700*

Antibody
absorption by white cell, 1156
antigen reaction
in loiasis, *702–703*
in plasma, 1199–1203
proenzyme, *720*
of group O plasma, 1156
to insulin
detection of, 458–461
transportation, 187–188
levels and poliomyelitis, *722*
and phosphate partitioning of erythrocytes, 1404–1411
specific action, on fetal erythrocytes, 1404–1411
toxoplasma and properdin system, *702–703*
and vascular purpura, *692*

Anticoagulant
and antifibrinolysin activity, 359
antithromboplastin and proteolytic inhibitor, *735*
electrophoretic separation of, from Hemophilia A and B plasma, *712*
in plasma thromboplastin component deficiency, *707*
platelets with activity of, *736–737*
in serum, and adsorbed plasma, *707*

Antifibrinolysin, platelets as source of, 355–361

Antigen
antibody reactions
in loiasis, *702–703*
in plasma, of agammaglobulinemia, 1199–1203
parasitic, hypersensitivity to, *702–703*
proenzyme, *720*
release, and Hetrazan®, *702–703*
serum analysis in agammaglobulinemia, 1199–1201

Antipyrine, versus deuterium in edema studies, 779–791

Antistreptolysin-O, identification and titration of, 816–823

Antitoxin, diphtheria, identification and titration of, 816–823

Anxiety
and catecholamine excretion, *738*
and gastric contractions after glucose, 955–962

Aorta
aneurysm of
gastrointestinal potassium content in, 517
and gastrointestinal sodium content, 507
atherosclerotic
cholesterol content, 1023
epiphasic carotenoids in, 1243–1247
and potassium iodide, 1021, 1024
vascular segments mixing in, *697*

Appetite, and hyperglycemia, 627–632

Arginine
identification of, 1078
reabsorptive pattern for, 890, 893, 895

Arteriosclerosis
$alpha_2$ lipoproteins, size variations, 643
cerebral, gastrointestinal content
of potassium in, 517
of sodium in, 507
mercaptomerin in tissues of, 776–777
pulmonary, volume of trapped gas in, 666–667
and serum electrolyte concentrations, 1300–1305

Arthritis
gouty, and phenylbutazone analog, 374–385
as prophylactic agent, 381
rheumatoid
adrenal cortical function in, *711*
and collagen break down, 585
desoxyribonuclease activity in sera of, 1326
and excretion of hydroxyproline, 581, 583
hyaluronic acid concentration and synovial fluid viscosity of, 1419–1427
synovial fluid from, fractionation of
rheumatoid, 817–818, 823
traumatic, 819–820

Ascites
albumin, iodinated, disappearance study in, 45–49
and antidiuretic hormone, 897
and aldosterone, urinary excretion of, 1301–1305, 1313
and congestive heart failure, *727–728*
in diabetes insipidus, 897
and/or edema, and ethyl alcohol, 388–393
and estrogen, 435, 438, 439
and hydrocortisone pool, 560
in nephrotic children, 53–55
and protein pool turnover rates, 1170
and weight, 1301–1305
response to sodium loading, *728*

Ascorbic acid, and oxidate activity of tyrosine, 240, 243

Asolectin
and proaccelerin assay, 146–149
and proconvertin separation, 371–373

Asparagine, in phenylpyruvic oligophrenia, 619–625

Aspartic acid
ammonia excretion after, 228
blood levels of, 622
blood sugar after, 418

Asthma
airway resistance in, 332
life span of platelets in, 965
respiration in, and serotonin, *724*
and serotonin, *724*

Atabrine®, and ammonia excretion study, 227

Atherosclerosis
aortic
cholesterol content, 1023
epiphasic carotenoids in, 1243–1247
and potassium iodide, 1021, 1024
coronary, in middle-aged American men, *699–700*
grading of, criteria for, 1243–1244
in nephrotic syndrome, and lipid alterations, 1381
and potassium iodide, 1015–1024
and serum lipoprotein
abnormalities, 980–989
alpha, sources on distribution of, 988
ultracentrifugal analysis in
in plasma and Cohn fractions, 140–143
in serum, with electrophoresis, 987

Atropine
and arterial pressure, 127
benzyl analogue of and block of respiratory response, *724*
and pulse rate in primary autonomic insufficiency, 1416
and serotonin, *712*

Atropine (*cont'd*)
protoveratrine after and cardiac responses, *727*
Azaserine, teratogenic effects of, *727*

B

Benadryl®, and serotonin in asthma, respiration after, *724*
in hypertension, *712–713*
Berylliosis, and hypercalcuria, 1229
Bicarbonate
acid-base changes in arterial blood after, *246–252*
excretion of
and Diamox®, 21, *27*, 309–312, 1370
after dl-alanine, *229*
and hyperchloremia, 481–487
and postural changes, 310–312
and respiratory acidosis, 482
and Thiomerin®, 310–311
and extracellular pH changes, 937
plasma concentration
and Diamox®, *25–27*
and meralluride, 157–162
during respiratory acidosis, 482
during sodium infusion, 483
serum, and urine acidity, 309
reabsorption of, 482–483
renal, 481
Bile
acid
concentrations, *695–696*
dihydroxy-trihydroxy ratio, *695–696*
and hepatocellular function, *696*
cholesterol content in, 15–16
bilirubin content, 833
chloride content after potassium iodide, 1018
cholesterol excretion in, 16
flow and bilirubin output, *697*
estrogen excretion and sodium chloride, water retention, 440
fistula
and hormone metabolism, 1037–1042
and manganese excretion, 832–836
and testosterone metabolism, 1331–1339
obstruction, hypercholesteremia induced by, 1021–1022
versus urine, unconjugated steroids present in, 1338
Bilirubin
absorption spectrum, 539–541
and albumin
affinity for, 545–546
pH level for binding, 547–550
and alpha$_1$-globulin of Fraction V-1, 545
electrophoretic mobilities, 546–550
in Laennec's cirrhosis, 542
in obstructive jaundice, 539–540
globin binding and denaturation, 544–545
protein linkages in serum and van den Bergh reaction, 537–550
total serum in hepatocellular disease, 590–591
variable behavior of pigment, 550
Bleeding. *See* Hemorrhage
Blood
acetone, in diabetes mellitus, 1209
acid-base changes and sodium bicarbonate, 246–252
ammonia levels, *690*
antidiuretic substances, 392
antifibrinolytic activity in, 361
capillary and venous viscosity of, and thrombus, *707–708*
carbon dioxide tension and breathlessness, *729*
cerebral, potassium removal from, 604
cholesterol level, 1024
and congesting pressure, loss of cholesterol and fluid, 281–284
coagulation, and thromboplastin, 534–535
cord and adult, phosphorus fraction of erythrocytes, 1404–1411
defibrinogenation, in post-partum female, *714*
ferritin in, and serum iron, 589
glucose, 1141–1149
alpha amino nitrogen levels, 497–499
and amino acids, 415–418
and casein, 414–421
and dietary intake, *627–632*
and glucagon, 498, *757–762*
and hunger contractions, *962*
and insulin, 570, *576*, 758
interaction of glucagon and insulin on, *757–762*
and isovaleric acid, 420
and lactic acid, 569–572, *576*
and leucine, 414–421
and protein, 414–421
after tyrosine, 415
group A specific polysaccharide of, 1156
and hydrocortisone, 556, *697*
in paroxysmal nocturnal hemoglobinuria, 453, 456
in hyposthenuria, 999–1006
and ion exchange resin, 1184
incompatible, renal failure due to, 1095
intrapulmonary, after mitral valvulotomy, 1013
ketones
in diabetes mellitus, 1209
lead concentration and urine coproporphyrin output, 1135, 1137
lipoprotein patterns in coronary artery disease, *699–700*
maternal, amniotic fluid, fetus, exchange of water between, 634–640
metabolites in, concentration of, *672–673*
normal, 843–845
hydrogen ion, and globin complex, 550
oxygen. *See* Oxygen
specific activity of hydrocortisone in, 556
pH
in cardiopulmonary disease, 913
and Diamox®, *21*
and hemoglobin S reactivity, *708*
and metabolic alkalosis, *262–266*
and potassium equilibrium, 936
in vivo, *707–708*
unesterified fatty acid in, 206–212
spherocytic, metabolism of hereditary, *701*
in splanchnic region, serum potassium in, 604
storage of
in acid-citrate-dextrose-inosine, 660–661
and adenosine as supplement, 562–567
incubation for, 566, 659
phosphate partition of erythrocytes in, 1404–1411
with purine nucleosides, 562–567
survival, post transfusion, 562
and acid-citrate-dextrose-inosine, 661
thromboplastin formation, 533
trapping of, and venous hydrostatic pressure, 910
venous
admixture, and diffusing capacity, 1010–1013
return, and endotoxin, 1194
serum potassium in, 601
whole blood buffer base during hyperventilation, 605
Blood flow
of bone, estimation for, 673
cerebral
and metabolism, *700–701*
unesterified fatty acid differences in, 211
cholesterol passage from, and capillary changes, 284
coronary
and anastomosis of aorticocoronary sinus, 302–307
fatty acids removed from, 318
in thyrotoxicosis, 275
and endotoxin from microorganisms, 1191–1197
enterohepatic, and hormone metabolism, 1037, 1041
and epinephrine, 569–571
fetal, thyroxine-binding protein in, 1273
ferritin in, in viral hepatitis, 592
forearm, 674
diurnal variation, 991–992
of hand, and lactate concentration, 678
in heart failure, *725*
and estrogen, 451
hepatic, in heart disease, 829
of insulin-treated subjects, 170, 187
intercoronary collateral, 302, 306–307
mortality rates, 306
of liver
bromsulphalein versus radiogold methods and values, 825–829
cirrhosis, 440
in diabetes mellitus, 1205, 1209–1210
and estrogen, 451
and oxygen consumption, 1210
maternal
and amniotic fluid, water exchange in, 634–640
thyroxine-binding protein in neonatal serum, 1273
thromboplastin in and hypertension, *714*
measurement of, in skeletal muscle, 671–672

and norepinephrine, 569–571
peripheral
glucose in, 498
and hyperglycemic glycogenolytic factor, 494–500
portal, in absorption from intestine, 1041
pulmonary
hematocrit of, 1385–1392
and hydrostatic pressure, 907, 910
and pulmonary volume, in mitral stenosis, 1393–1403
from tagged red cells and plasma albumin, 1386
and venous admixture total, 396
after pulmonary artery branch occlusion, 1401
quantitation of venous return, 1192, 1194
renal
and aldosterone, 1357, 1358
autonomy of, 1357
and electrolyte reabsorption, 952
and hypertensive disease, 872
and vascular disease, 872
and weight of kidney, 1340–1344
and resorption of bone due to tumors, *698*
skin, of forearm, 674
splenic, in vivo measurement of, *725*
and vascular
engorgement, *693*
resistance, in fistula, *695*
velocity through glomerulus and protein transport, 1277, 1283–1285
to volume ratio of pulmonary bed, 1395, 1399

Blood pressure
in aldosteronism, 1360
arterial
and adrenal medullary hormones, 1278–1279
during pyrogenic reaction, 948
after typhoid vaccine, 948–952
and epinephrine, 569–571, 574, 1282
in ferritinemia, 592
during insulin hypoglycemia, 574
after l-norepinephrine, 573, 574, 1282, 1367–1368
after hexamethonium, 872
and orthostatic hypotension, 1369
after vasopressin, 1416
and protoveratrine after atropine, *727*
and serotonin, *712*
in thyrotoxicosis, 274–275

Blood volume
calculation of, 1–9, 1248
central, 1388
pulmonary, 1385–1392, 1393
circulating
and anesthesia, 130
and isotonic expansion of extracellular fluid volume, 1377
in kidney, 525
in orthostatic hypertension, 1369
removal of manganese from, 836
splanchnic, in respiratory alkalosis, 605
in viral hepatitis and ferritinemia, 592
pooled, after endotoxin, 1195–1197
in hepatic and cardiac dysfunction, 826
pulmonary
in mitral stenosis, 1393–1403
versus cardiac output, 1399
and pulmonary vascular hypertension, 1398

Body
calcium content, 763–773, 883
composition
in acute renal function, 1094–1107
after burns, 71–74
in cancer of breast, *736*
and compounds A and F, 1048
and Compounds A and F, 1048
and chloride, potassium, and sodium study, 596–600
and potassium restriction, 763–773
chloride content, 598, 599, *703–704*, 773
cholesterol handled by, 405
and circulating red cell volume, 1–9
density
and circulating red cell volume, 1–9
measurement of corporal, *735*
fat
and Compounds A and F, 1045–1053
estimation of, 1050–1052
of tissues, 598–599
hematocrit
and in large vessels, 1393
and spleen size, *705–706*
hydrocortisone in reservoir of, 552
magnesium content, 763–773
mercury distribution in, as function of time, 1063–1064
nitrogen content, 763–773
oxygen consumption, basal total, 1205–1211
perfusion, and endotoxin, 1194–1195
plethysmograph, for gas volume
in thorax, *322–326*
trapped in lungs, 664–670
position. *See* Posture
potassium, *703–704*
and aldosterone, 1307–1314
distribution in tissues, 598–599
and extracellular pH, 938
sodium, 598, 599, *703–704*, 763–773
and extracellular fluid volume, 1303
and Pitressin®, 1308
restriction, *773*, 1110
secretions, 506
specific gravity, 1047–1051
surface area
and adrenal medullary hormones, 1278–1279
in hypermetabolism, 808
and pulmonary diffusing capacity, 1009
in thoracic gas volume study, 665–667
after typhoid vaccine, 948–952
in thyrotoxicosis, *274*, 808
in thyroid study, 808
and oxygen consumption, 1011
and water diuresis, 749–756
temperature, after typhoid vaccine, 948–952
tissue
aldosterone in, 800–805
and insulin, 458
total composition of, 598

Boeck's sarcoid, volume of trapped gas in, *666–667*

Bone
anti-anabolic effect of cortisone on, 1234
and calcium
as source, 1238–1241
turnover rate, 885
marrow
in anemia of cancer, 1248–1260
in anemia of infection, 93–95
metastases to hematological and radioiron data, 1249, 1251, 1255
in hypochromic anemia, *713*
electrolyte and water content, 99–100
marrow
and iron storage, in cancer, 1256
and leukocytes, *289–296*, *691*
replacement by lymphosarcoma, 1255
reserve, and leukopheresis, 294
sacral, 93
sickle cells in, reversibility of, 999
toxic depression, in cancer, 1248
uptake, and availability of iron, *693*
pain, and estrogen, 1258
resorption
in lung carcinoma, *698*
and vitamin D, 1241
sarcoid involvement of, *1229*
sodium content, 767–773
sodium in, and potassium depletion, 768–773

Bowel
in gastrointestinal content study, 506, 508, 519
sodium and water absorption from, *730*

Bradycardia
and protoveratrine, *727*

Brain
metabolism of oxygen and glucose in, *676*
tissue
and oxidation of fat, *211*
sulfate penetration of, 1125

Breast
carcinoma of
hematological and radioiron data on, 1249–1251
and hormone metabolism, 1034

Breathing
capacity
and airway resistance, *322*
and diffusing capacity, 1010–1013
and dyspnea, *728–729*
and heart failure, 402
methods for estimating, *322–326*
obstruction to
energy cost after, *705–706*
and ventilatory response to carbon dioxide, 1286–1290
in pulmonary emphysema
capacity, 402, 1287
mechanics for, and body position, 912–920

Breathing (*cont'd*)
test results in thoracic gas volume study, 666
Bromsulphalein
method, versus radiogold for liver blood flow values, 825–829
retention in hepatocellular disease, 590–591
Bronchiectasis, and airway resistance, 332–333
Bronchitis, in breathing studies, 332, 913
Bronchodilator
and hematocrit ventilatory function, 1287
nebulized
breathing after, 395, 398–403, 1288
ventilatory capacity, 1286–1290
Bronchopneumonia
and paralysis agitans, 507, 517
Brucella melitensis
endotoxin derived from, 1191
immunization against, *687*
Buffer
base
in acidosis, 1286–1290
in alkalosis, 602–603
and sodium bicarbonate, 247, 252
total decrement, due to Diamox®, 28–29
Burn
body composition changes after, 62–77
chemical, of lungs volume of trapped gas in, 666–667

C

Calcium
balance
after burns, 73
and potassium deficiency, 773
in pseudohypoparathyroidism, 1240
bone as source for
in hypercalcemia and hypercalcuria, 1238–1241
and turnover, 885
edathamin disodium in childhood lead poisoning, 1131–1138
fecal
and cortisone therapy, 1233
and intake, *710–711*
and hyperthyroidism
loss, 886
pool, 884
oxalate and phosphate in urinary calculi study, 1069–1078
metabolism of
in children, 78–87
and cortisone, 1232–1241
in sarcoidosis, 1241
and thyroid disease, 874–886
serum
in lung carcinoma, *698*
vitamin D action on, 1241
and thromboplastin, 533
total body and fat free dry solid content, 763–773
and tubule absorption of sodium and chloride, *721*
urinary excretion of
after burn, 73
and compound F therapy, 1050–1051
and phosphate mixed in oxalate renal calculus, 1070
plasma concentration and chelating agent, *721*
Calculus, renal
incidence, after burns, 73–74
mucoprotein matrix of, 1067–1078
Capillary
alveolar, diffusion gradients, 1011
blood glucose
arteriovenous difference in hyperglycemia, 498
and food intake, 628
after insulin, 758
and glucagon, 759
in gas exchange, 1008
hematocrit, 1385
membrane, passage of corticosteroids across, 1432
myocardial and coronary sinus retroperfusion of, 307
oxygen tension gradient, 1011
permeability
to cholesterol, 281–284
to protein, *732,* 1284–1285
pulmonary
hematocrit of, 1401
venous difference, after glucose injection, 955
and viable cells in urinary calculi, 1071
walls
cholesterol lost through, 282
passage of protein molecules through, *719–720*
Caproate
narcotic action of, 1293–1294
recovery from plasma, 207
urinary glucose after, 1296
Caprylic acid
and heat stability of protein, 1215, 1219
recovery from protein, 207
Carbaminocholine, for air passage, 669
Carbohydrate
dietary intake, 1110
in glucostatic theory test treatments, 629–630
metabolism
and glucagon in normal, 494–500
in heart, and Cedilanid®, 319
and hypoglycemia, 411
oxidative, by skeletal muscle, 671–681
stores
depletion as stimulus for hunger, 962
and glucose utilization, 954
Carbon dioxide
and extracellular pH changes, 937
in forearm, 674–680
nocturnal, 992–997
production, 676, 680
inhalation of and ventilatory response in obstructive diseases, 1286–1290
and oliguria, 1098, 1106
oxidation, 498
and potassium depletion, 768–773
and sodium
bicarbonate, 247–252
chloride, 483
reabsorption, 482, 484
tension, of extracellular fluid, 481
in acidosis
hypokalemic, 195–198
respiratory, 602–603
anhydrase inhibitor, 309
Carcinoma
of breast
and hormone metabolism, 1034
bronchial, breathing study, 913
bronchogenic, radioiron concentration in, 1255
of gall bladder, and hormone metabolism, 1034
and glucose metabolism, *722–723*
of liver, metastatic, 591–594
of lung
and gastrointestinal electrolyte content, 507, 517
hypercalcemia associated with, *697–698*
volume of gas trapped in, 666–667
of pancreas
amylase in sera of, 1326
desoxyribonuclease I activity in sera of, 1326
and protein catabolism, 1103
and renal failure, 1095
of tongue, and hormone metabolism, 1034
Cardiac output
and digitalis, 314–320
and endotoxin, 1193–1194
after epinephrine, 574
and exercise, 977
in mitral stenosis, and pulmonary diffusing capacity, 1013
in myocardial transfer of sodium and potassium, 1221–1227
and norepinephrine, 574
after occlusion of pulmonary artery branch, 1401
in peripheral arteriovenous fistula and heart failure, *695*
and pulmonary blood volume in mitral stenosis, 1395–1401
in rheumatic mitral valvular disease, *697*
and salt retention in congestive heart failure, 979
and strophanthidin, 1225
in thyrotoxicosis, 274
Cardiomegaly, and congestive heart failure, *727–728*
Cardiovascular system
alterations in, due to endotoxin, 1191
and arteriovenous fistulae, *695*
hypertensive disease
and ethyl alcohol, 391
gastrointestinal electrolyte content, 507, 517
sodium excretion in, 971–972
Carotenoid
and aorta, *692*
epiphasic, in atherosclerotic lesions, 1243–1247
pigment, absorption spectrum, 1243
solubility of, in lipids and mobility, 1247
Casein, and blood sugar in types of hypoglycemia, 414–421
Catheterization
combined heart, *706–707*
four chamber, *709–710*

placement of catheter, and hepatic vein flow, 829
Cation exchange
in acidosis due to Diamox® ingestion, 28
in arterial wall, and noradrenalin, 297–301
and cardiac performance, 1227
myocardial, after acetyl strophanthidin, 1223
resin
carboxylic, and electrolyte concentration, 1300–1305
for fecal sodium extraction, 509
serum accelerator globulin adsorption to, 111–112
and urinary aldosterone excretion, 1300–1305
Cedilanid®, and myocardial metabolism, 315–320
Cerebrovascular accident
arteriovenous concentration after hyperglycemic glycogenolytic factor, 496
radiosulfate distribution after, 1124
Ceruloplasmin, identification and determination of, 816–823
Chelation
with edathamil calcium disodium for lead poisoning in children, 1131–1138
with ethylenediamine tetraacetic acid, 11–18
Chloramphenicol, and response to leukopheresis, 287–289
Chloride
balance
and calcium intake, 1231
and extracellular pH changes, 937
and intake, in renal failure, 1097–1102, 1106
postburn, 70–71
in renal failure, 1101–1102
in respiratory acidosis, 481–487
after sodium restriction, and testosterone, 1112–1119
and bicarbonate reabsorption, 481–487
body total content, 596–600
and fat-free dry solid content, 763–773
after potassium restriction, 773
of bone cortex, in acidosis, 99–105
clearance
in gouty arthritis, 374–385
concentration
after albumin, 1375
in aldosteronism, 1359
and meralluride, 157–162
and oliguria, 1098, 1106
ratio of, in radiosulfate distribution, 608–610
after sodium chloride infusion, 483
excretion
and aminophylline, 1367
and bicarbonate infusion, 482
and estrogen, 424–451
fecal, in renal failure, 1097, 1106
after hydrocortisone, 1370
after hypotonic expansion, 1372
after isotonic expansion, 1372
and meralluride, 157–162
and orthostatic hypotension, 308–312, 1369
and pyrogen activity, 1083
in renal failure, 1097, 1106
in respiratory acidosis, 482
after sodium chloride intake, 483, 1376
in supine position, 308–309
and respiratory acidosis, 482
after venous congestion of lower extremities, 1371
metabolism, and estrogen
in cardiac and renal disease, 443–451
in hepatic disease, 430–441
in normal, 423–429
and nitrogen balance, and extracellular pH changes, 937
reabsorption
after acidotic stimuli, 100
and bicarbonate and chloride infusions, 482
and estrogen, in cirrhosis, 433–439
restriction
and testosterone, 1109–1116
retention, and Diamox®, 309–312
space, in potassium depletion, 768–773
total exchangeable, 599
and chest circumference, 596
in infant and adult, *703–704*
tubule absorption of and calcium, *721*
Chlormerodrin
distribution study
intracellular, in kidneys, 38–42
plasma and tissues, 31–36
and dithiopropanol, 34, 1058–1068
diuresis and plasma regression study, 1055–1065
half time of, 1058
Chlorpromazine
and necrotizing effect of adrenalin, *739*
and respiration, in asthma, *724*
Cholate
cholesterol relationship, 11–18
after nephrectomy, 1383
Cholesterol
absorption of
and esterification of sitosterol, *700*
intestinal, 12–13, 1015–1017, 1024
lymphatic, 1041
and anti-kidney injections in nephrotic hypercholesteremia, 525–528
biliary
excretion, 16
and potassium iodide, 1018
biliary excretion of, 16
capillary permeability to, 281–284
and carotenoid, in ulcerated calcified plaque, *692*
concentration
of esterified, 139, 143
in connective tissue, 1125
after nephrectomy, 1382
in nephrotic syndrome, 792–798
population study of, 1173–1180
content
of atherosclerosis of thoracic aorta, 1244–1247
and basal metabolic rate, 792
in criteria for grading atherosclerosis, 1244
in hepatocelluiar disease, 590–591
of intestinal lymph, 406–410
of liver, 15–18, *700*, 1015
of lipoproteins, and fractions of, 980–989, 1177–1180
serum, and fluid filtration rate, 283–284
dietary
and exercise or physical labor, 1173–1180
and gastrointestinal exchange variations, *696*
and nephrotic syndrome, 522
and plasma total lipid, 1020
and renal failure, 1097, 1106
esters in lymph chylomicra, 1027
excretion of and potassium iodide, 1024
extraction, from intestinal lymph, 406–410
filtration rate, 283–284
fractionation in body fluids, 405–410
synovial, 818–821
in hyperlipemia, 152
metabolism
and ethylenediamine tetraacetic acid, 11–18
in kidney and liver, *688*
and nephrotic syndrome albumin deficiency, 522–530
and potassium iodide for atherosclerosis and hypercholesteremia, 1015–1024
phospholipid ratio in biliary cirrhosis, 135
synthesis, and disodium ethylenediamine tetraacetic acid, 15–18
and tocopherol serum levels in thyroid diseases, 1349–1353
Choline
and oxygen consumption in diabetes, 1208–1211
serum esterase and fatty liver in infants, 348
and sweating, stimulation of, 114–120
Christmas disease
and factor V, 533
and hemophilia, 1316–1322
Chromatography
extracts of aldosterone in urine, 800
Compound F, 491
for isolation of serum accelerator globulin activity, 107–112
Chylomicra
cholesterol in, 409
metabolism of, 1025–1031
Circulation. *See* Blood flow
Cirrhosis
and alcohol diuresis, 386–393
anemia of, 854
and aldosterone, 1299
ammonia metabolism in, *701–702*
biliary
composition and distribution of lipoproteins in, 133–143
ferritin in blood of, 592
serum vitamin B_{12} levels, *716–717*
and bilirubin, 539–542
desoxyribonuclease in sera of, 1326

Cirrhosis (*cont'd*)
dihydroxy and trihydroxy in bile acids, *696*
ferritin in blood of, 592
and folic acid uptake, *697*
of heart disease, and body water, 785–791
metabolism in, and estrogen, 430–441
radiosulfate space and water metabolism, 1124
renal excretion of sodium in, *728*
and serum electrolyte concentrations, 1300–1305
and sodium glutamate, 191–198
steroid levels in, 560
urinary aldosterone in, 1313
water excretion of, 756
zinc concentration, *688*
Citrate-dextrose-inosine acid, and blood preservation, 562–567, 657–662
Clotting
of hemophilic plasma, 1317–1322
one-stage, after hemophilia extract, 533
promoting activity of glass, 1183–1189
system, in hemolysis of erythrocytes, 453–457
Clotting time
and trypsin, *735*
Coagulation
and heparin in prothrombin conversion, 533–535
and platelets, *695*, *736–737*
and transfusion therapy, *706*
Cobalt, in sickle cell anemia, 1002
Collagen disease, and hydroxyproline excretion, 579–586
Colon
cancer of, hematological and radioiron data on, 1250
gastrointestinal tract content, 502–509, 512–520
gas volume in, 325, 338–342
radiomercury distribution in, 776–777
spastic, and gastric contractions after glucose, 955–962
Coma
hepatic
and hepatocellular necrosis, 592
and sodium glutamate, 191–198
and vitamin B_{12} concentrations, *716–717*
method for evaluating depth of, 191–193
and urinary coproporphyrin excretion, 1136
Connective tissue
and hydroxyproline, 579
muscle, chloride concentration in, 1125
Cooley's anemia, red cell survival in, 850–854, 860
Coproporphyrin, excretion and lead poisoning in children, 1131–1138
Coronary artery
blood flow
and Cedilanid®, 316
oxygen content of retrograde, 303
disease
blood lipoprotein patterns in, *700*
left, occlusion of circumflex branch of, 302
Cor pulmonale
and alcohol, 389
mercaptomerin in tissues of, 776–777
and pulmonary emphysema
breathing study, 913
trapped gas volume in, 666–667
sodium excretion in, 972, 973–975
Corticosteroid
aldosterone differentiated from, 801–805
binding, by plasma proteins, 1428–1433, 1434–1438
clearance, 1431
after cortisone, 1432
Corticosterone
metabolism, tracer study of, 1037–1039
radioactive and electrophoresis, 1434–1438
species difference in responses to, 1033, 1042–1043
Cortisone
blood sugar levels after, 414
for bone metastases, hematological and radioiron data after, 1251
and disseminated myocardial necrosis, 362–370
and hepatic excretory function, *696–697*
and hypercalcemia, 1232–1241
and hyperphosphatemia, 1232–1241
metabolism of, versus hydrocortisone and corticosterone, 1033–1036, 1040–1041
and muscle potassium in periodic paralysis, *708*
in nontropical sprue, *730*
and response to alcohol, 388–393
and sarcoidosis, 1231
serum calcium, phosphorus and magnesium balances after, 1234
total hydroxyproline excretion after, 583
and transmissibility, 365
Creatine, urinary excretion in renal failure, 1097, 1106
Creatinine
after chlormerodrin, 1055
in diabetes insipidus, 749
in study of homotransplanted kidney, clearances, 1364–1380
postural effects on, 269
during sulfate diuresis, 308–312
renal excretion patterns and mercurial diuretics, *696*
and sodium
bicarbonate, *226*
chloride intake, 1376
depletion, 1308
after steroid, cortisone or probenecid loading, 1430, 1431
after water intake, 1308
Cyclopropane, plasma volume changes after, 126–130
Cyst
pancreatic
amylase in sera of, 1326
desoxyribonuclease activity in, 1326
pulmonary, with trapped gas in thorax, 664–670
survival of skin homografts in, *699*
Cystine
and amino acid loading, 889–891, 895
labelled in albumin turnover study, 1161–1170

D

Dehydrocorticosterone, and total body fat, 1045–1053
Demicolcin, in leukemia, or lymphosarcoma, *701*
Deoxyadenosine, and storage of blood, 565–566
Dermatosis, and fatty liver in infants, 348
Desoxycorticosterone
and body composition in potassium depletion, 768–773
and hypertension, 300
metabolite of and virilization, *693*
and responses due to ethyl alcohol, 388–393
retention of sodium in chloride space due to, 773
and tension, in cardiac muscle, *708*
Desoxyribonuclease
activity
in pancreatic disease, 1325–1330
specific for phosphorus, 292–293
Deuterium
versus antipyrine, 779–791
versus Tritium in maternal water exchange, 636–640
Dexedrine, and food intake, 631
Dextran
in prevention of non-specific clumping of white cells, 1157
and radioiodinated albumin spaces in edema, *715*
Dehydration
extracellular, and mercurials, *688*
in infant malnutrition, *723–724*
and kwashiorkor, *723–724*
by Pitressin® withdrawal in diabetes insipidus, 1309
and urinary aldosterone, *688*, *725–726*
Diabetes
alloxan and narcotic action of fatty acid anions, 1296, 1298
Diabetes insipidus
and alcohol, 392
aldosterone secretion in, *688*
and antidiuretic hormone, 901
and ascites, 897–903
dehydration in, by Pitressin® withdrawal, 1309
filtration rate, and reabsorption of water, 755–756
water-sodium exchanges in, *737*
Diabetes mellitus
amelioration of, by hypophysectomy, 1209
blood non-sugar reducing substances in and leucine or casein, 420
and coronary artery disease blood lipoprotein patterns in, *700*
ferritin iron in the serum of, 591
and gastric contractions after glucose, 956

hepatic function in, 1211
and insulin, antibody detection, 461–465
insulin resistance and acidosis, *703–704*
and metabolism
of hormone, 1034
and oxygen consumption, 1205–1211
phlorhizin and oxygen consumption in, 1206
radiosulfate distribution in, 1124
radioinsulin
binding to gamma globulin, 185
radioelectrophoretograms, 179–184
tocopherol levels in
and serum cholesterol, 1353
and total body oxygen consumption, 1210
Diamox®
acidosis due to
metabolic effects of, 20–29
in sickle cell disease, *707–708*
effects of in heart failure, *27*
and electrolyte excretion
in aldosteronism, 1359, 1361
and quiet standing, 308–312
urinary excretion after, 1370
Diarrhea
in infant malnutrition, *723–724*
and kwashiorkor, *723–724*
of nonbacterial gastroenteritis immunity in, 200–204
Dicumarol®, and thyroid hormone uptake, *709*
Diet
isocaloric
and compounds A or F therapy, 1049
and fat decomposition, 1049
low in purines and fats and phenylbutazone analog, in gout, 380
in metabolic effects of testosterone, 1109–1116
pantothenic acid in responses to, *739–740*
phenylalanine in and darkening of hair and skin, 619
population study of, 1173–1180
protein in, 1110
creatinine clearance and urinary flow after, 755
metabolism of, *705–706*
therapy with in renal failure, 1103
and water diuresis and/or clearance, 751–754
Digitalis
analogues, inotropic effect of, 1227
direct action of, on contractile protein, 1226
and electrolyte changes, 1225
inotropic effect of and internal ionic content, *710*
and metabolism of heart, 314–320
and pulmonary diffusing capacity, 1009
Dihydrotachysterol, and hypercalcemia, 1240–1241
Diiodotyrosine
and butanol-extractable organic iodine, 795–796
and iodine exchange, 1169–1171
Diisopropylfluorophosphonate, and platelet survival time, 964–969
Dinitrophenol, heart failure induced in heart-lung preparation, 320
Dinitrophenylhydrazine, reaction to thyroxine metabolism, *687*
Diphtheria, antitoxin, identification and measurement of, 816, 822–823
Diuresis
alcohol, 386–393
in hyponatremic edematous states, *726*
and Diamox®, *27*
in edema due to heart disease, 784, 786–787
and glomerular filtration rate, in sickle cell anemia, 1001
mannitol osmotic
in ammonia excretion study, 225–226
in primary aldosteronism, 1358–1361
mercurial
and aldosterone excretion, 1307
and alkalosis, 155–162
as blocking agents, 31
chlormerodrin distribution, 38–42, 1055–1065
tissue response to Mercaptomerin, 775–778
and transit times of sodium and of creatinine, *696*
nitrogen and cortisone dosage, 1234
noradrenaline, 871
after hexamethonium, 872
pyrogen, 1080–1087
and Pitressin,® 1084
and steroid therapy, *689*
sulfate, electrolyte and acid-base excretion during, 308–312
water
and alcohol ingestion, *732*
in ammonia excretion study, 224
failure of, *690*
and hydropenia, 1366
and Pitressin®, and pyrogen, 1084
solute excretion and glomerular filtration effect on, 749–756
and testosterone, 1114
urine flow during, 269
and pH, 230
in sickle cell anemia, 1005
Dysphagia, neuromuscular, pharyngeal swallowing in, *687–688*
Dyspnea
breathing capacity in, *728–729*, 1287
cardiac and lung changes, 611
and pulmonary diffusing capacity, 1009
sodium excretion, 970–979

E

Edema
and congestive heart failure, *727–728*, 979
and aldosterone, 1299
and ethyl alcohol, 388–393
extracellular fluid volume and aldosterone, 1299–1305
of heart disease, *713*
exchangeable sodium and body water in, 781–791
hyponatremic, *726*
hypoproteinemic, *713*
in infant
and fatty liver, 348
malnutrition, *723–724*
of nephrotic syndrome, 443–451, 783–791
in children, 45–49, 54–55
of liver diseases
body water versus weight in, 791
portal cirrhosis, 1299
lymphatic flow in, *713*
pulmonary
methoxamine induced, in mitral stenosis, 1400
and renal failure, 1095
and sodium
depletion, 1313
exchange, 509
loads, *728–729*
retention, 779, 1303–1305
subcutaneous, and body weight, 1301–1305
thrombophlebitic, *713*
total exchangeable sodium and body water content in, 779
of upper extremity, *713*
EDTA. *See* Ethylenediamine tetraacetic acid
Effusion
fluid, rheology, and viscosity measurements, 1419–1427
pleural
breathing study in, 913
gas, volume trapped in, 666–667
intra-esophageal and intra-pleural measurements in, 905–910
Electrocardiogram
in Cedilanid®, cardiac metabolism of, 315
of electrolyte imbalance, *700*
of seven-electrode lead system, in heart diseases, *734–735*
T-wave in
and insulin hypoglycemia, 573
in periodic paralysis, *708*
and QT interval after epinephrine, 571
Electroencephalogram, during unconsciousness due to fatty acids, 1297
Electrolyte
balance
and body composition changes, 771
and carboxylic cation exchange resin, 1300–1305
in diabetes insipidus, 897–898
and Diamox®, 21–29
and distribution of weak, 233
and hydrocortisone, 1370
in renal failure, 1105–1106
concentrations of
in extracellular fluid in edematous states, 779
and estrogen metabolism, 423–451
exchanges in renal failure, 1099
excretion
in aldosteronism, 1359
after aminophylline, 1367
and calcium, *720–721*
after Diamox®, 21–29, 1370
fecal, *711*
in hypertension, *698*
after meralluride, in alkalosis, 157–162

Electrolyte (*cont'd*)
after norepinephrine, 1368
and orthostatic hypotension, 310–312, 1369
after sodium chloride intake, 1376
by transplanted kidney, 1377–1379
urinary, during pyrogenic reaction, 948, 950, 1084
and urine pH, 232–234
and venous congestion of lower extremities, 1370
total body
and fat-free dry solid content, 763–773
and serum concentrations, 763
Electrophoresis
of accelerator globulin, 110–112
of bilirubin-protein, 538–540
in corticosteroid binding, 1434–1438
fractions
Cohn and plasma, in biliary cirrhosis, 135–136
lipoproteins, 641–647
in insulin determinations, 174–182
of serum
agammaglobulinemic, 1200–1202
carotenoids and lipid, 1247
lipoproteins, 980–989
maternal and neonatal, 1272
from pregnant women, 1265–1270
whole, and separated in ultracentrifuge, 643
in matrix of urinary calculi, 1075–1076
in proteinuria, 1281
of synovial fluid, 815, 822–823
Emphysema
and airway resistance in, 332
alveolar wall damage and loss of elasticity, 401–403
volume of trapped gas in, 664–670
obstructive
physical properties of lung in, 394–403
ventilation during hyperpnea, *705–706*
pulmonary
breathing, and body position, 912–920
sodium excretion in, 971–975
Encephalopathy
gastrointestinal sodium content in, 507
lead, and edathamil calcium disodium, 1134–1137
Eosinophil
in loiasis, *702*
polymorphonuclear, in calcigerous stones, 1070–1071
Epinephrine
airway resistance after, 332, 333
in cardiac ganglia, species variation, 649–654
circulatory and metabolic effects of, 576
and endotoxin shock, *739*
and hexamethonium, 571
and hyperglycemia after glycine, 419
in hyperventilation, 604
and non-esterified fatty acid, 152–154, 208, 210
in hypoglycemia
familial, 413, 420
insulin, 568–577
in plasma, by ethylenediamine condensation method, 837–841
and pheochromocytomas, 577
and protein transport, 1277
pulse rate and blood pressure responses to, 569–571
and redistribution of leukocytes in vascular compartment, 294
renal hemodynamics after, 1279, 1282
after splenectomy, 289–290
urinary excretion of
in anxiety states, *738*
proteins after, 1279, 1282
Erythroblastosis fetalis, bilirubin study, 539–542
Erythrocyte
and adenosine
and hypotension, 566
osmotic fragility after, 564
binding of thyroid hormones by, 476–479
hemolysis, *690*
and hemagglutination, 458–461
non-specific, 470
and paroxysmal nocturnal hemoglobinuria, 453
in type O plasma, 1156
life span determination
with diisopropylfluorophosphonate, 964–969
with radioiron, in anemia, 91–95
of transfused, 1256–1257
linkage of sensitized virus to, *727*
and membrane concentration ratios across, 609–610
mixing of, and concentration, 129
phosphate
esters of, 659
partition, in infants, 1404–1411
sodium potassium gradient, 564
stroma, binding of thyroid hormones, 476–479
tagged, plasma volume changes measured with, 126
potassium specific activity, 515
storage, with purine nucleosides, 562–567, 657–662
sulfate distribution across membrane, 607–610
survival, *721*
in anemia of cancer, 1248, 1252
post-transfusion, 564, 660–662
total concentration and bone marrow metastases, 1248
uptake of
diisopropylfluorophosphonate, 968
of iodinated thyroid hormones, *698*
of l-thyroxine, 123
water, radiosulfate concentration in, 608
Erythromycin, and staphylococcal infections, *723*
Erythrophagocytosis
agglutination *in vitro, 738*
and leucocyte agglutinins, 1154–1159
Erythropoiesis
and anemia
of infection, 95
of neoplastic disease, 1261
induced by androgenic hormones, *717*
and iron half life, 1259
radioiron plasma disappearance half-time as index of, 1253
Esophagus
basal pressure in, *687*
and gas measurement
abdominal, 341
compressible, in thorax, 665
Estradiol
and extracellular fluid volume, 428
urinary excretion of, *689*
Estrogen
for bone metastases hematological and radioiron data after, 1251
and electrolyte metabolism
in cardiac disease, 443–451
in hepatic disease, 430–441
in renal disease, 443–451
excretion of as estriol, estrone and estradiol, *689*
and fluid retention of liver disease, 440, 451
metabolism, in myocardial infarction, *689*
therapy in cancer, 1249–1251, 1258–1261
and water metabolism, 423–429
Ethanol. *See* Alcohol
Ethionine
amylase serum levels after, in pancreatic diseases, 1328
desoxyribonuclease I activity in sera after, 1328
Ethyl Alcohol. *See* Alcohol
Ethylenediamine method, 837–841
Ethylenediaminetetraacetic acid, and plasma cholesterol, 11–18
Exercise
and cardiovascular functions, in heart disease, 970, 977–979
diet, and serum cholesterol, 1173–1180
diffusing capacity during, after valvulotomy, 1008, 1012–1013
and inulin clearance, 977
and para-aminohippurate clearances, 977
pulmonary blood volume responses to, 1400
pulmonary and peripheral resistance after and heart failure, *695*
and redistribution of leukocytes in vascular compartment, 294
and renal hemodynamic functions in heart disease, 970, 977–979
tolerance
and congestive heart failure, *727–728*
postoperative, 1008, 1012–1013
Extremity, venous congestion of lower, 1371

F

Fat
absorption and metabolism, 1025
body changes
and burns, 72–73

and compounds A and F, 1045–1053
depot, yellow color of and carotenoids, 1243
exchangeable, versus total body content in infant and adult, *703–704*
dietary intake
in glucostatic theory test treatments, 629–630
population studies, 1173–1180
hydration density equation for estimation of, 1050–1052
in renal failure, 1099–1104, 1106
liver content of in malnourished infant, 346–353
neutral, 646–647
after nephrectomy, 1382
in plasma, 154
recovery of, in biliary cirrhosis, 135
oxidation, and diabetes mellitus, 1210
response of unesterified fatty acids to, 207, 211–212
triglyceride, of hyperlipemia, 152
total, in body composition, 598, *735, 767–773*

Fatty acid
and Cedilanid® therapy, 316, 318
as energy source in diabetes, 1210
fraction, as substrate in muscle, 680
and glucose metabolism, 150–154
in lymph chylomicra, 1027
myocardial metabolism of, 314, 316
narcotic action of short chain, 1291–1298
new method for measurement, 150–151
triglyceride, specific activity, 1025
unesterified, 151–154, 206–212

Feces
loss of iodine in, in nephrotic syndrome, 798
radioactivity excreted in
in biliary fistulas, 1037–1040
in calcium metabolism, 81–87
chelation and manganese excretion, 832–836
testosterone metabolism, 1331–1339

Ferritin, and hepatocellular disease, 588–595

Fetus
activity of tyrosine transaminase in, 1091
and 17-hydroxycorticosteroid plasma levels, 492
intact, and water exchange studies, 636–638
in water exchange studies, 634–640
selective injury to by antimetabolites, *727–728*
and tyrosine oxidizing activity, 1090–1092
thyroxine passage to, 1274

Fibrillation
auricular, sodium excretion in, 971, *972*
and pulmonary diffusing capacity, 1009
ventricular protection of heart against, 302, 307

Fibrin, formation of, 533

Fibrinogen
clot promoting activity of, and contact with glass, 1186–1189
identification of, 816, 821–823
thrombin interaction to produce fibrin, 533
reactivity of, for proaccelerin assay, 146–149

Fibrinolysin
activation of, *735*
and ferritin serum iron, 589
systemic, and streptokinase, *703–704*
and thrombocytopenic bleeding, 355

Fibroelastosis, media and adventitia proliferation, 305

Fibrosis
pancreatic desoxyribonuclease activity in duodenal juice of, 1329

Fistula
biliary
and manganese excretion, 832–836
and steroid hormone metabolism, 1033–1044
and testosterone metabolism, 1036, 1039, 1043, 1332
bronchopleural, body position and intrapleural pressure, 907
peripheral arteriovenous and congestive failure, *695*
thoracic duct, labelled hormone metabolism in, 1037, 1043–1044

Fluid
accumulation of liver or renal disease, 786
amniotic
in fetus and maternal blood and water exchange, 634–640
and pulmonary hypertension, *714*
ascitic
affinity for corticosteroids, 1432
and anterior-pituitary activity, 902
and plasma concentration, 780
radioactivity in, 795, 1124, 1127
salt loads in, *728–729*
body
electrolyte composition, 1094
expansion of and urinary aldosterone, 1306–1307
in gain of weight, 1307
hydrogen ion and collagen solubility, 585
insulin, in tissues, 458
and hyponatremia, 1307
in malnutrition, *723–724*
in potassium depletion, 768–773
in renal failure, 1094–1107
volume of, by single injection method, 921–933
cell isotonic versus hypertonic, *694*
cerebrospinal
sodium in, 508–509
sulfate penetration of, 1125
and cholesterol loss correlation between, 283
dialysis, after nephrectomy, G42
and electrolyte changes in renal failure, 1105–1106
edema
and plasma concentration, 780
sulfate equilibration with, 1125
extracellular
and acidosis, 102–105
accumulation, 790
and aldosterone secretion, 1308
antipyrine concentration in, 783
calcium content, 883
carbon dioxide tension of, 481
and electrolytes, 502, 779
and edema, 788
exchangeability of components in, 502
pH changes in, and chloride-nitrogen balance, 937
uptake, after sodium bicarbonate, 247
variability of space, *730*
extracellular expansion
hypertonic salt poor albumin, 1375
hypotonic, 1372
isotonic, 1373, 1374
and kidney transplant, 1364
in nephrotic syndrome, 798
versus intracellular contraction, 1308
extracellular volume
and aldosterone, *688*, 1299–1305
change in, and responses to, 1377–1379
and circulating red cell volume, 6–9
and diuretic response, 1065
and Pitressin,® 1307–1314
and radiosulfate, 609–610, 1119
single injection method for, 921–933
and sodium chloride storage, 428
and thiocyanate space, 428
extravascular
concentration of antipyrine in, 780
exchangeable sodium in, 783
radioactivity in, 48
interstitial
calcium concentration, 883
potassium in, 519
intracellular
accumulation, and excess sodium, 790
cerebrospinal, 509
electrolyte structure, 502
uptake by, after sodium bicarbonate, 247
intrapleural, and hydrostatic pressure, 907, 910
joint
and plasma fractioned simultaneously, 817
protein components of, 814
traumatic, fractions from, 821–822
metabolism and electrolyte balance, 599–600
pleural
effusion, and body position in pressures, 908
and plasma concentration, 780
rate of hydrodynamic flow of across capillary wall, 1284–1285
retention of
and cirrhosis, 451
and compounds A or F therapy, 1049
and estrogen, 451
and ethyl alcohol, 387

Fluid (*cont'd*)
hepatic circulatory factors in, 451
sulfate equilibration, 1125
synovial
proteins, 815
rheologic studies on, 1419–1427
viscosity determinations, 1419–1427
viscosity in diagnosis of joint diseases, 1426
therapy, in renal failure, 1104
transcellular
potassium versus water in, 520
volume of, 502
Fluorohydrocortisone
and delta 1–9 fluorohydrocortisone, *721*
and sodium "space," *712*
Folic acid, metabolism, *697*
Forearm
arteriovenous oxygen difference in blood of, 674
blood flow through skin of, 674–680
capillaries of,
exchange of permeable substances across, *704–705*
fluid and cholesterol filter through, 282–284
metabolism of muscles in, 671–681
Fructose, osmotic diuresis due to and ethyl alcohol, 388–391
Fumaric acid, in phenylalanine conversion to tyrosine, 623
Fumarylacetoacetic acid, in phenylalanine conversion to tyrosine, 623

G

G–25671
defined, 384
renal clearance after versus phenylbutazone, 375–385
side effects of, 381, 385
Galactose, in matrix of urinary calculi, 1077–1078
Galactosemia, specific enzymatic defect in, *714–715*
Gall bladder, carcinoma of and hormone metabolism, 1034
Gallop sound, and pressure levels, *719*
Ganglion, blocking agents
and transmission block, 576
and vasopressin pressor effects, 1416
Ganglionectomy, cervico-thoracic, 649–654
Gas
alveolar
and blood gas, 670
nitrogen in, 668
in esophagus, 665
after mitral valvulotomy
diffusion of, 1008
intrapulmonary volume, 1013
trapping phenomenon, 669
volume of
in gastrointestinal tract, 336–345
in lung, measurement of, 322
trapped in lungs or pleural space, 664–670
Gastroenteritis, diarrheal nonbacterial immunity against, 200–204
Gastrointestinal tract
contraction, after glucose injection, 955
exchangeable potassium in, 512–520
gas volume in, 336–345
d-glucuronolactone absorbed from, 279
hemorrhage in, and renal failure, 1095
intracellular gastric juice sodium in, 509
versus in plasma, 512, 518
motor activity of, *739*
sodium content in, 502–509
specific gravity ratios, 508
Gaucher's disease, red cell survival in, 862
Gelatine
hypoglycemic effect after casein, 415
total urinary excretion of hydroxyproline after, 583
Globulin
accelerator
nomenclature, 106
purification of serum, 106–112
as trace substance, 112
and adrenal medullary hormone, 1281
alpha
absorption of pigment by in bilirubin-protein study, 539–540
in plasma and synovial fluid, 823
alpha$_1$
of Fraction V–1, combining with bilirubin, 545–546, 550
mobility of, 795
urinary excretion, 1282
alpha$_2$
in bilirubin-protein study, 540
mobility of, 795
urinary excretion of, 1282
antihemophilic, 533, 535
beta
absorption of pigment by, 539–540
and ferritin, 593–594
identification of, 1203
interaction with gamma, 1201, 1203
urinary excretion of, 1282
coating and slow mixing of tagged cells, *725*
cold insoluble
concentrated in Fraction I, 821
identification of, 816, 823
and diazotization of bilirubin, 543
electrophoretic mobility of, 550
gamma
basic fraction of and flocculation, *704–705*
and beta interactions, 1201–1203
in bilirubin-protein study, 544
binding of iodinated insulin to, 180–187
catabolism rate, 48–49
deficiency of, 1203
insulin antibodies in, 463
isolation of, 823
in loiasis, *702*
metabolism of, in nephrotic syndrome, 44–55
in plasma and synovial fluid, 821–823
serum, and thymol turbidity, *704–705*
urinary excretion of, 52, 1282
versus unadsorbed horse antiserum, 1201
iron-binding, 44–55
insulin-transporting in blood of insulin treated subjects, 170
measurement of by paper electrophoresis, 986
solubility of, 544, 550, 821
staining of, 546
thyroxine-binding, 477, 1272
Glomerular filtration rate
and adrenal
insufficiency, 1303–1305
medullary hormone, 1278–1283
and aldosterone
tumors, 1313
and aldosteronism, 1357–1363
after amino acid infusions, 890
after aminophylline, 1366
after chlormerodrin, 1058
chloruretic effect of meralluride, 157
and corticosteroid clearances, 1431
and epinephrine, 1283
in denervated homotransplanted kidney, 1364–1380
and diuresis in sickle cell anemia, 1001, 1004
and hexamethonium, 872
and hyperemia, 948–952
in kidney homotransplantation, 1364–1380
in malnourished infants, *724*
and norepinephrine, 871–872, 1283, 1368
and posture in sulfate diuresis, 311
after pyrogen, 1081–1087
during vasoconstrictive phase, 952
in respiratory acidosis, 482–484
in sickle cell anemia, 1001–1006
and sodium
excretion, *691–692*
reabsorption, 1313
retention, 979, 1303–1305
and steroid therapy, *689*
and urinary osmolarity, 755
and vasoconstriction, 1283
after vasopressin in orthostatic hypotension, 1416
after venous congestion of lower extremities, 1371
and water diuresis, 749–756
failure of, *690*
Glomerulonephritis
blood flow and weight of kidney, 1343
skin homografts, survival of, *699*
Glottis, stenosis of and airway resistance, 332–333
Glucagon
and blood glucose concentration, 498
in familial hypoglycemia, 413, 420
and insulin
antiserum, 468–469
glucose levels after, 757–762

isolation of from pancreas into blood stream, 494–500
and sodium "space," *712*
Glucocorticoid, and uropepsin secretion, *707*
Glucose
arterial concentration, 1141–1149
and Cedilanid®, 314–320
in forearm blood, 674–675
after glucagon, 498
arteriovenous difference
in basal state, 674–680
changes due to, 627–632
and glucagon, 495
in muscle of forearm, 674–675
peripheral, 627–632
negative, and hexose phosphate, 996
from test meals, 629
and turnover rates, 679
blood level
in diabetes mellitus, 1209
and epinephrine, 569–572, 576
interaction of glucagon and insulin on, *757–762*
and nor-epinephrine, 570–573, 576
and serum potassium concentration, 604
of stored blood, 660
versus hunger, appetite and food-taking, 627–632
in body metabolism of oxygen, *676*
and butyrate or caproate, 1296
glycogen, conversion to, 1092
metabolism
myocardial, and lanatoside-C, 314, 316
in neoplastic diseases, *722–723*
produced by ingestion of food, 631
and non-esterified fatty acid extraction, 211
in plasma, 150–154
response to, 208–211
and octanoate, 1296
osmotic diuresis due to and ethyl alcohol, 388–391
oxidation of and oxygen uptake, 993–997
and phenylpyruvic acid, 619–625
and phosphatase, activity in premature liver, 1092
and potassium gradient in periodic paralysis, *708*
and propionate, 1296
receptor, in central nervous system, and food intake, 627–632
and sodium "space," *712*
tolerance, *739–740*
in familial hypoglycemia, 413
tubular maxima for and pyrogen, 1084
uptake of
by forearm, 676, 992–997
uptake
and lactate production, 674, 677–678, 993–997
rate of, 680
utilization of, 1143, 1146
after glucagon and/or insulin, *761*
and hyperglycemicglycogenolytic factor, 498
kinetics, 1139–1149
and serum inorganic phosphate, 498
specific rate constant for, 1141–1149
and status of carbohydrate stores, 954
and valerate, 1296
volume of distribution, 1141–1149
Glucostatic theory, of regulation of food intake, 627–632
Glucosuria
and insulin, 1209
and oxygen consumption, 1210
Glucuronate, sodium, and glucuronolactone, 277–284
Glucuronic acid, urinary excretion, of, 278
Glucuronidase
hydrolysis of metabolites, 560
Glucuronolactone, and sodium glucuronate, 277–284
Glucuronide
17-OH corticosteroids plasma protein binding of, 1429–1433
Glutamate
in cirrhosis of liver, 191–198
in phenylpyruvic oligophrenia, 619–625
Glutamic acid
blood levels of, 622
blood sugar concentration after, 418
and glutamine blood levels, 620–622
Glutamine
ammonia excretion after infusion of, 228
in phenylpyruvic oligophrenia, 619–625
blood levels, 620–622
reabsorption patterns, 890, 893, 895
urinary excretions of acids after, 620–621
Glutathione, red cell, stability of, *690–691*
Glycine
blood sugar concentration after, 418–419
and filtered load of amino acids, renal responses to, 888
reabsorptive pattern for, 890, 893, 895
excretion, 891–892
of ammonia, 228
phenylpyruvic acid, 619–625
Glycogen
arteriovenous glucose difference and formation of, 498
in fatty liver, 350, 352
muscle
and lactate production, 677
as oxidizable substrate in basal state, 679
storage
and carbohydrate substrate, 679
disease of liver, 1092
Glycoprotein
of low molecular weights
isolation of, 823
proven by electrophoresis, 821
in synovial fluid fractions and plasma, 821
in urine, 1078
Glycosides
cardiac
and energy, 319–320
and tension in muscle, *708*
Glycosuria, and cortisone, 1232
Goiter
nontoxic nodular, radioiodine uptake in, 57
toxic diffuse, tocopherol serum levels in, 1350, 1351
Growth hormone, and synthesis of chondroitin sulfate, *733*
Guanosine
and phosphate esters of stored erythrocytes, 659
resynthesis of, 565–566
as substrates for enzymatic reaction, 662

H

Heart
and acetylcholine, 646
and adrenaline, 649–654
alternans in ventricular fiber, *718*
beat transmission and body position, 918
catheterization
four chamber, *709–710*
left and right, simultaneously, *706–707*
and Cedilanid®, 314–320
and composition of tissues of total body, 598
congenital malformation, 315
dysfunction, bromsulphalein concentration in, 826
expiratory quotient of and Cedilanid® therapy, 316
failing, and ionic transport, 1226
gallop sound, and intracardiac pressure, *719*
ganglionectomy, responses to, 649–654
insufficiency, and edema, 975
intraluminal sodium content in, 504–509
metabolism of oxygen
and glucose in, 676
in thyrotoxicosis, 275
mercury concentration in after chlormerodrin, 32, 35
and noradrenaline, 649–654
in pleurodynia virus and cortisone induced myocarditis, 362–370
potassium content, 514
protection to against ventricular fibrillation, 302
rate
and epinephrine, 1282
of hypotension, with endotoxin, 1194–1197
and norepinephrine, 1282
and protoveratrine after atropine, *727*
and pyrogenic reaction, 948
and shock precipitated with endotoxin, 1196
size, and pulmonary blood volume, 1398
sympathectomy, species variation in responses after, 650–654
uptake of amino acids, 680
work, and digitalis, 314–320

Heart failure
and aldosterone, 1301–1305
excretion, 1302, 1313
and body
position, 910
weight, 448
circulation in, *725*
and protoveratrine, *727*
congestive, 315
antidiuretic substances, 392
capillary permeability to protein in, *732*
and Cedilanid®, 315–320
and ethyl alcohol, 389
and digitalis, 319
and ethyl alcohol, 387, 391
hemodynamics of, *695*
and hydrocortisone, *727*
and liver diseases, *727–728*
in mentally confused, *700–701*
and myosin, *727–728*
and peripheral arteriovenous fistula, *695*
and prednisone, *728*
salt retention, 979
water excretion of, 756
and Diamox®, 27
edema caused by, 779
and aldosterone, 1299
and estrogen
electrolyte metabolism in, 447–451
extracellular fluid volume, 448
and pleural effusion, breathing study in, 913
and pulmonary
diffusing capacity, 1009
emphysema, 396–403
and reduction of venous pressure, 1304
and rheumatic valvular disease, 315
thiocyanate space in, 448
and sodium
dietary, 1305
urinary excretion of, 448
and water balance, 448
Heart-lung preparation
cardiac output and efficiency in, and digitalis, 314–320
and endotoxin, 1194
Hematocrit
after albumin infusion, 527
of anemia in cancer, 1249–1251
circulating, in kidney, *721–722*
in constrictive pericarditis, 444
after hypotonic expansion, 1372
large vessel
and central, 1391
and mitral stenosis, 1395–1401
and pulmonary, 1391
of lesser circulation, 1385–1392
measurement of in skeletal muscle, *672*
and nocturnal metabolism of muscle, 995
pulmonary
calculated values, 1393–1403
diffusing capacity, 1009
in mitral stenosis, 1393–1403
values, in sickle cell anemia, 1001
of venous blood
and adrenal medullary hormones, 1278–1279
and body size, *705–706*
in cardiac failure, 446
and estrogen, 425, 428, 446
in nephrotic syndrome, 449
Hematuria
and aldosteronism, 1360
idiopathic, and steroid therapy, *689*
Hemochromatosis, iron in serum, 592
and half-life of, 1260
Hemodynamics
and anesthesia, 125–130
cerebral after exercise in aortic stenosis, *717–718*
of congestive failure and peripheral arteriovenous fistulae, *695*
after endotoxin, 1191–1197
and epinephrine, 574
of hyposthenuria in sickle cell anemia, 1001–1006
in mitral stenosis, 1013
catheterization for, 1395
in myocardial transfer of sodium and potassium, 1222–1227
and norepinephrine, 574
pulmonary, and number of circulating leucocytes, 289
and pulse deformation, *729*
renal
and adrenal medullary hormones, 1277–1283
in aldosteronism, 1357, 1358, 1360
after aminophylline, 1366
after hypertonic albumin expansion, 1375
and isotonic expansion of fluid, 1373, 1374
and norepinephrine, 1368
after pyrogen, 948, 1081–1087
receptor-effector mechanisms influencing, *737*
and renal nerves, 1377–1379
after sodium chloride-load, *698*
after typhoid vaccine, 948–952
and venous congestion of lower extremities, 1371
responses to hypothermia, *731–732*
after vasopressin in orthostatic hypotention, 1412–1418
Hemoglobin
in anemia
of cancer, 1249–1260
sickle cell, 998–1006
C disease
red cell survival in, 860
urine concentrations, 1001, 1003
Hemoglobin
concentration
and bone marrow metastases, 1248, 1257
relation to counts, 129
after sodium bicarbonate infusions, 247
glomerular permeability to, *719–720*
plasma, and electrolyte changes, 1225
production, in anemia, 860
and red cell survival, 847
radiochromium labelled for red cell sites of sequestration, 842–866
reaction to incompatible blood, renal failure, and, 1095
sickle cell
intravascular, and hyposthenuria, 998–1006
reactivity of, and blood pH, *708*
in red cell deoxygenation, *707–708*
in sickle cell trait, 1005
synthesis genetic defect of, *708*
Hemoglobinemia
and red cell
autoagglutination, 857
incompatible, removal of, *738*
sickle cell, reversibility of, 999
urine concentration defect in, 1001
and kidney function, 1005
paroxysmal nocturnal
hemolysis of erythrocytes from, 453–457
red cell sequestration site study in, 851–852, 860
Hemolysis
in anti-D disease, erythrocytic phosphate partition in, 1404–1411
of erythrocytes, *690*
non-specific, 470
and hemagglutinins, 458–461
in type O plasma donors, 1156
paroxysmal nocturnal hemoglobinuria, and properdin system, 453
during postburn period and nitrogen balance, 73
Hemophilia
anticoagulant activity, *712*
antihemophilic factor, 533, 1322
carrier state in, 1316–1322
and Christmas disease, 1316–1322
clotting
one-stage time, 533
in plasma, 1317–1322
promoting activity of glass contact, 1186–1189
Hemophilia
prothrombin activity removal with asolectin, 371–373
Hemorrhage
and antibrinolytic activity of platelets, 355–361
gastrointestinal
and renal failure, 1095
Hemosiderosis
absence of ferritin in, 589, 591
of lungs, volume of trapped gas in, 666–667
Heparin
and necrotizing effect of adrenalin, *739*
removal of chylomicron from plasma, 1025
urinary, 1078
Hepatitis
activity of desoxyribonuclease in sera of, 1326
bilirubin study, 539–542
dihydroxy and trihydroxy bile acids in, *696*
and estrogen, 430, 435–441
ferritin, iron in blood of, 590–592
iron half-life and serum values in, 1259
liver damage due to serum B_{12} concentrations, *716*
Heredity
in coronary artery disease, *700*
of Graves' disease, *714*

hemoglobin synthesis defect, *708*
of hemophilia, 1316–1322
of urine concentration defect, in sickle cell anemia, 1003
of virilizing adrenal hyperplasia
autosomal recessive gene, 220–221
fertility of carriers, 217–218
frequency of gene, 215–216
Hexamethonium
block of respiratory response by, *724*
and epinephrine, norepinephrine, and hypoglycemia, 570–576
and hypertension, 870
pressor responses to noradrenaline after, 868–873
and serotonin, *712*
and tetraethylammonium, 576
Hexosamine, and hexose
in synovial fluid protein, 821–822
in urinary calculi, 1077–1078
Histamine, and change in potassium or sodium content, 300
Histidine, reabsorption, capacity and pattern, 890, 893–895
Hodgkin's disease
desoxyribonuclease in sera of, 1326
ferritin in blood of, 591–593
Homogentisic acid, in phenylalanine conversion to tyrosine, 623
Homograft, survival, *699*
Hunger
and glucostatic theory, 954–963
neural activity leading to sensations of, 627–632
Hyaluronic acid
concentration, of synovial fluid, 1422
Hydrocortisone
assay of, with phenylhydrazine, 554
binding of by albumin, 1436
by plasma protein fractions, 1429, 1430
and congestive failure, *727–728*
and fluorohydrocortisone in hypocorticoidism, *721*
half-time of, 556–557
and hepatic excretory function, *696–697*
for idiopathic nephrotic syndrome, *689*
kidney responses to, 1370
measurement of production, 559
metabolism of, in bile fistula, 1037–1042
species difference, 1033
miscible pool and turnover rate of, 552–560
oral versus intravenous, 1040
plasma clearances and urinary excretions after, 1370
and sarcoidosis, 1235–1241
and sodium "space," *712*
specific activity of, 555
synthesis after adrenocorticotropin, 557–560
versus corticosterone, species difference in, 1042–1043
concentration
in erythrocyte, 609–610
and body position, 308–309
exchange of and bicarbonate reabsorption of, 481
urinary excretion of
and Diamox®, 25–29
in supine position, 308–309
urine flow, versus osmolar clearance, 1086
and water conservation in aldosteronism, 1361
Hydroxybutyrate, beta
in diabetes mellitus, 1209
and lactate, convulsions after, 1295–1297
Hydroxycorticosterone, 17-
levels, in maternal and cord plasma, 491
placental passage of, 488–493
renal excretion, 1303
diurnal pattern, *711*
synthesis of and virilization, 218, *693*
and total body fat, 1045–1053
Hydroxyindole acetic acid, as hypertensive agent, *713*
Hydroxylamine, and glucuronic acid after glucuronolactone, *278*
Hydroxyphenylpyruvic acid
liver production of, 1091
premature versus adult, 241–243
urinary excretion of in infants, 1089
Hydroxyproline, in rheumatic diseases, 579–586
Hydroxytryptamine. *See* Serotonin
Hyperaldosteronism, and sodium metabolism in hypertensives, *706*
Hypercalcemia
associated with lung carcinoma, *697–698*
and cortisone therapy, 1232–1241
and hypophosphatemia, *698*
idiopathic, sodium phytate for, 1241
polyuria and salt depletion of, *720*
in sarcoid, 1229
Hypercalcuria, and vitamin D, 1238–1241
Hyperchloremia
and bicarbonate reabsorption, 481–487
radiosulfate distribution in, 1124
Hypercholesteremia
and anti-kidney serum, 530
cholesterol in serum of, 409–410
and disodium ethylene diamine tetra acetic acid, 13–14
and xanthomatosis, 282
nephrotic, *732*
and albumin, 522–528
and potassium
chloride, 1018, 1020
iodide, 1015–1024
and thyroid function, 792
and Triton, 17, 1021–1022
Hyperferremia, in hepatocellular disease, 588–595
Hyperglobulinemia, in sarcoid, 1229
Hyperglycemia
and diabetes, 497–498
and food intake, 627–632
and oxygen consumption, 1210
Hyperkalemia
with acidosis and changes in extracellular pH, 935–938
due to hyperventilation and arterial serum potassium, 605
Hyperlipemia
and albumin, 522–530
and anti-kidney serum, 530
cholesterol in serum of, 409–410
in nephrosis, *688, 732*
and hypercholesteremia, 522
and renal function, 1381–1384
plasma lipids of, 152
and potassium intake chloride versus iodide, 1018, 1020
physical activity and diet in prevention of, 1173–1180
response of unesterified fatty acids to heparin in, 210
Hypernatremia, radiosulfate distribution in, 1124
Hyperparathyroidism, and sarcoid, 1229
Hyperphospholipemia, and nephrosis, *688*
Hyperphosphatemia, and cortisone therapy, 1232–1241
Hyperplasia
in bone marrow
megakaryocytic, 966
normoblastic, *717*
islet cell, hypoglycemia due to, 414–421
marrow myeloid, 296
virilizing adrenal, 213–221
recessive hypothesis, 215
Hyperproteinuria, due to hyperglobulinemia and sarcoid, 1229
Hypertension, arterial
antidiuretic substances in, 392
circulatory effects of protoveratrines, *727*
and coronary artery disease blood lipoprotein patterns in, *700*
coronary sinus and intimal proliferation, 307
and desoxycorticosterone, electrolyte pattern, 300
and gastrointestinal content
of potassium, 507
of sodium, 517
and hexamethonium
and/or noradrenaline, 870
and renal vascular bed, 872
and hyperaldosteronism, *706*
and isolated heart, plasma versus steroid action on, *708*
pulmonary
and pulmonary compliance, 617
and release of thromboplastin into blood stream, *714*
and pulmonary emphysema breathing study, 913
and serotonin, *712, 724*
and sodium
chloride, 1359
metabolism, *706*
Hyperthyroidism
and calcium metabolism, 874–886
and triiodothyronine
antithyroid drugs and, 58–59
disease activity after, 57–61
desoxyribonuclease in sera of, 1326
and plasma-thyroid hormone tissue relations, *708–709*
specific activity of serum and urine, 886
versus time for, 880
during puerperium, 1274
and tocopherol serum levels, 1345–1356

Hypertocopherolemia, with hypercholesterolemic disorders, 1352–1354
Hyperventilation
and arterial serum potassium concentration, 601
and epinephrine effects on serum potassium and blood glucose, 604
and pepsin concentrations, *712*
Hyperuricemia, and calcium metabolism, 874–875, 878, 883–884
Hypoalbuminuria, in nephrotic syndrome
in children, 53–55
lipemia of, 522–530
Hypoferremia, in anemia of cancer, 1248, 1259, 1261
Hypogammaglobulinemia, in nephrotic syndrome in children, 54
Hypoglycemia
familial, precipitated by amino acids, 411–421
and gastric acidity in primary autonomic insufficiency, 1416
induced by insulin and gastric hunger contractions, 962
insulin, epinephrine, and nor-epinephrine, 568–577
intermittent and oxygen consumption, 1210
and l-leucine and/or casein, 416, 420
and protein, dietary, 421
Hypogonadism, and testosterone, 1109
Hypohidrosis, postural hypotension and impotence, 1416
Hypokalemia
and acetylcholine, *708*
with alkalosis, and changes in extracellular pH, 935–938
and potassium gradient in periodic paralysis, *708*
serum potassium concentration in aldosteronism, 1359
Hyponatremia
and delta 1–9 fluorohydrocortisone, *721*
edema, and antidiuretic hormone, *726*
and gain of weight, 1307
and sodium loss, *734*
and urinary aldosterone, 1307
water loading in antidiuretic activity of plasma during, *726*
Hypoparathyroidism
and calcium metabolism, 874–875, 878, 883
Hypophysectomy, and oxygen consumption in diabetes mellitus, 1208–1211
Hypoproteinemia
aldosterone secretions in, *688*
in children, with nephrotic syndrome, 44–55
and edema
and ethyl alcohol, 388–393
and lymph flow, *713*
and steroid therapy, *689*
Hyposthenuria, in sickle cell anemia, 998–1006
Hypotension
orthostatic
antidiuresis evoked by versus electrolyte excretion, 1377–1379
and posterior pituitary hormone, 1412–1418
Hypothalamus
assays of, for antidiuretic hormone, 901
Hypothermia
antifibrinolytic activity of plasma after, 358, 360
circulatory changes due to, *731–732*
and pneumococcal peritonitis, 940–945
and radioactive iodine uptake by red cells, 477
Hypothyroidism
and gastric contractions after glucose, 957–962
and tocopherol serum levels, 1345–1356
Hypoxanthine, in blood stored in adenosine, 657–659, 662

I

Infant
exchangeable chloride in, *703–704*
hemolytic disease in, phosphate partition of erythrocytes, 1404–1411
idiopathic hypercalcuria, sodium phytate for, 1241
malnutrition in, *723–724*
fatty liver in, 346–353
neonatal, composition of sera from, 1272
premature
liver of, 239–240, 346–353, 1089–1092
tyrosyluria of and ACTH, 1092
tyrosine oxidizing system in fractions of liver, 239–240
in premature, 1089, 1091
Rh negative, phosphate partitioning of erythrocytes in, 1408
sickle cell disease, urine concentration defect in, 998–1006
thyroxine binding by sera of, 1270–1275
Infection
anemia of, and erythrocyte production, 93–95
experimental pneumococcal and hypothermia, 940–945
filarial, positive complement-fixation test, *702*
genito-urinary tract, and sickle cell anemia, 1004
immunity to
endotoxins, *687*
in gastroenteritis, 200–204
and insulin antibodies, 463–464
intermittent fever during, *693*
intestinal, of family contacts of poliomyelitis, *722*
pyogenic, leukopenia of, 295
in renal failure, 1103
staphylococcal, penicillin-resistant, *723*
Injury
thermal, to respiratory tract, 669
traumatic, proteins of synovial fluid, and, 823
Inosine, and stored blood, 658–659, 662
resynthesis of phosphates in erythrocytes of, 565–566
Insulin
and acidosis, *703–704*, 1209
antibodies to, 458–465
antiserum
cross-reactivity of, 470
hemolytic titration, 460
specificity of, 467–473
and blood glucose
changes in, versus with hexamethonium, 574
and glucagon, *757–762*
in neoplastic diseases, *723*
and glycosuria, 1209, 1234
in sarcoidosis, 1231
and hexamethonium, 574
hypoglycemia, 573–577
action of, 472
epinephrine and norepinephrine in, 568–577
and hyperglycemia
after glycine, 419
infantile idiopathic, 420
immunological assay of microgram quantities of, 458–465
and intracellular carbohydrate metabolism after isovaleric acid, 420
iodinated, metabolism of, 170–188
and isovaleric acid, 420
and ketonemia, 1209
and oxygen consumption
basal total body, 1205
beef pancreas, 1211
and choline, 1211
in control of diabetes, 1211
in diabetes mellitus, 1207
and pantothenic acid, potassium study, *739–740*
and potassium gradient in periodic paralysis, *708*
secretion
and dietary intake, 186
by islets of Langerhans, 420
sensitivity in pantothenic acid and potassium, *739–740*
and unesterified fatty acid concentration, 152–154
myocardial, 211
Intestine
absorption
calcium from, and vitamin D, 1237, 1241
hydrocortisone and testosterone, 1041
distension of and visceral pain, *722*
Inulin
clearance
and aminophylline, 1360
and epinephrine, 1277
and exercise, 977
during mannitol and Pitressin®, 1366
and norepinephrine, 1277, 1368
and orthostatic hypotension, 1369
protein ratio, and adrenal medullary hormones, 1278–1279

serial, in kidney homotransplantation, 1365
after vasopressin, 1416
after venous congestion in lower extremities, 1371
space, and radiosulfate, 1124
volume of distribution single injection methods for, 926–933
Iodide, potassium, in hypercholesteremia and atherosclerosis, 1015–1024
Iodine
amount and exchange of in behavior of iodinated protein, 1169–1171
metabolism
in Graves' disease, *714*
during pregnancy, 1263
in thyroxine
metabolism, in nephrotic syndrome, 792–799
turnover studies, in thyroid diseases, 806–812
protein bound, 875
and tocopherol serum levels in thyroid diseases, 1349–1353
Iron
absorption and vitamin D, 1240
and anemia
of cancer, 1248–1261
of infection, 89–95
nutritional hypochromic, *713*
colloidal saccharate disappearance rates, 827
ferritin, in hepatocellular disease, 588–595
passage and transport of, *693*
Isoagglutinin, identification and measurement of, 816, 822–823
Isohemagglutinin, of agammaglobulinemia, 1203
Isoleucine
blood sugar concentration after, 418
reabsorptive pattern for, 890–895
Isoniazid
inactivation of, *691*
irreversible binding of, *719*
Isopropylnoradrenaline, recovery of, by ethylenediamine method, 838–839
Isovaleric acid, and hypoglycemia blood sugar level, 416–421

J

Jaundice
and anti-A hemolytic disease in newborn, 1409
liver damage due to, trihydroxydihydroxy bile acid ratio in, *695–696*
obstructive
bilirubin study by filter paper electrophoresis, 539–542
and estrogen, 435–441
thorazine, iron, ferritin and serum in, 590–592
Joint
carpal and knee
hyaluronic acid concentration in, 1422
synovial fluid viscosity of, 1419–1427
diseases of, rheologic findings in diagnosis, 1426
and synovial fluid, fractionation of proteins, 814–823

K

Ketoglutarate
and tyrosine oxidizing system, 1091–1092
urinary excretion of, after glutamine, 620–621
Ketone
and Cedilanid® therapy, 316
in diabetes mellitus, 1210
and hyperglycemic glycogenolytic factor, 496
as major substrate for resting muscle, 680
myocardial metabolism of and digitalis, 319
and lanatoside-C, 314, 316
urinary, 1296
Ketonemia
as diabetogenic agent, 498
insulin and oxygen consumption in, 1209
Ketosis, diabetic, and oxygen consumption in, 1206, 1210
Ketosteroid
excretion of, *711*
and sodium-retaining hormone regulation, 257–258
in virilizing adrenal hyperplasia, *693*
and ACTH, 219–220
Kidney
amyloid disease, 443, 447–451
anti-serum, hypercholesteremic effects of, 523–524
blood flow through
and electrolyte reabsorption, 952
estimation of, 1340–1344
cancer of hematological and radioiron data on, 1249
and chlormerodrin, mercury concentration after, 31–42, 1062
in cortex, 1060
in diseased, 775–777
and diuresis, 1055, 1061
and dithiopropanol, 34
clearance
of folic acid, *697*
damage
in gout and phenylbutazone analog, 380–381
and plasma albumin, 522–530
denervated
and functional capacity, *694*
responses to volume changes, 1364–1380
water-sodium exchanges in, *737*
disease
anemia of, 857–858
and estrogen production, 440
and hypertension, *708*
and norepinephrine and epinephrine, 1277–1285
and protein transport, 1277
total exchangeable sodium and body water in edematous, 779–784
excretion
creatinine, *696*
sodium, and glomerular filtration rate, *691–692*
and estradiol action, 428–429
and fatty acid, 1295
fatty degeneration of and hyperlipemia, 1381
fetal, and amniotic fluid formation, 634
filtration fraction and adrenal medullary hormones, 1278–1279
filtration rate in one and osmolar concentration of urine from other, 756
failure
body composition in, 1094–1107
electrolyte and fluid changes in, 1105–1106
and serum potassium concentration, 938
function
and aldosteronism, 1357–1363
and benzyl analog of serotonin, *713*
in cirrhotics with ascites, 440
in gout after phenylbutazone analog, 380
and hyperlipemia, 522, 1381–1384
and manganese uptake, 831
during pyrogenic reaction, 948
in sickle cell anemia, 1001–1006
and structure, in lupus nephritis, *717*
and Thiomerin, 766–777
in transplanted, denervated kidney, *694*, 1364–1380
and urine concentration, 158
hematocrit of, *721–722*
homotransplantation of in identical twin, 1364–1380
iodinated insulin study in, versus in plasma, 182–183
metabolism of oxygen and glucose in, 676
and noradrenaline during hexamethonium action, 869–870, 872
phospholipid content, *688*
plasma flow
and hyperemia, 948–952
and mercury clearance, 1063
protein transport within, 1277
pyrogen action on, and solute excretion, 1084–1085
red cell
number, after anemia correction, 1003
shunting, *721–722*
resistance to Pitressin®, 1005
response to
calcium metabolism, 886
to amino acid mixture, 888
removal of
and hypercholesteremic effect of anti-kidney serum, 523–524
and renal albumin loss, 528
reversibility of hyposthenuria, 998
sickling in intravascular, 1005
slices
and inactivation of salt-retaining hormone, 259
in vitro conversion of thyroxine to triiodothyronine by, 812
and staphylococcal septicemia, *736*
tissue
culture, myocarditis in, 366–367
mercaptomerin distribution in, 775–778

Kidney (*cont'd*)
transplant prehydration and excretion of isotonic saline, 1364
weight
calculation of, *in vivo*, 1340–1344
Kimmelstiel-Wilson syndrome, and hormone mtabolism, 1034
Kyphoscoliosis
breathing study in, 913
volume of trapped gas in, 666–667
Kwashiorkor
causes of, *723–724*
fatty liver in, in malnourished infant, 346

L

Lactate
and Cedilanid® therapy, 316, 318
concentrations of in basal state, 674–680
convulsions produced with, 1295–1296
and fatty acids propionate and butyrate, 1295
and forearm, 674–680
nocturnal production, 992–997
and hexamethonium, 570, 576
and insulin hypoglycemia, 570, 576
in muscles of forearm, 674–675
myocardial metabolism of and lanatoside-C, 314, 316
oxidation to and arteriovenous glucose difference, 498
and extracellular pH, 937
reactions to, 1297
Lead poisoning, and urinary coproporphyrin, 1131–1138
Leucine
and hypoglycemia blood sugar level, 416–421
identification of, 1078
reabsorptive pattern for, 890, 893, 895
Leukemia
antifibrinolytic activity in, 355–361
and body composition, *736*
desoxyribonuclease in sera of, 1326
ferritin iron in, 591
after folic acid, *697*
and glucose metabolism, *722–723*
granulocytic, lactic acid and oxygen consumption, *695*
hypermetabolic and hydrocortisone, triethylene melamine in, 808–809
leukocyte production and delivery in, *691*
and mercaptopurine, *701*
lymphatic, 356–361
mercaptomerin in tissues of, 776–777
metabolic and cytochemical changes in, *701*
myeloid, 356–361, 965–969
and platelet
function, 356–361
life span, 965–969
red cell destruction in, 1248
remission of and hemolysis, *699*
Leukocyte
agglutination, 1150–1160
in vitro, *738*
antigenic composition of, *738*
isolation from peripheral blood, 966
leukemic, glutathione reductase of, *729*
leukopheretic study of, 285–296, *691*
photomicrography in, 1152–1153, 1158
segmented polymorphonuclear in calcigerous stones, 1070–1071
uptake of diisopropylfluorophosphonate, 968
in loiasis, *702*
Leukopenia
after hemolytic transfusion reactions, *738*
Lipemia
clearing factor and fat transport, 1025
disappearance of and lipolysis, 1030
nephrotic, hypoalbuminemia in, 522–530
and unesterified fatty acids
in plasma, 153
response to glucose, *210–212*
Lipid
after albumin infusion, *527*
and carotenoid, *692*, 1247
content, of liver biopsies, 1210
dietary
and atheromatous plaques, 1243
and infiltration of aortic wall, *692*
and nephrotic syndrome, *522*
fraction in blood unesterified fatty acids as, *211–212*
in liver
fatty, 350–352
and rates of splanchnic bed metabolism, 1210
total, in diabetes mellitus, 1209
oxidation of by muscles, 680
and protein pattern changes, *688*
plasma, 135
after anti-kidney serum injection, *524–528*
fractions after nephrectomy, 1382
mobilizing factor, *737*
total, and potassium iodide, 1016–1020
Lipoprotein
alpha
in serum
extractability of cholesterol, 405–410
and fat-soluble tocopherols, 1349
sources on distribution of, in atherosclerosis, 988
in serum lipoproteins, 1028
of myocardial infarction, 982–989
total binding capacity, 981
staining, versus cholesterol elution procedure, 982
tests for, in matrix of urinary calculi, 1075
alpha$_2$ defined in atherosclerosis, 641–647
blood patterns in coronary artery disease, *699–700*
characterization of, 143
and cholesterol
in myocardial infarction, 981, 983
in protein, 409
lipase
in metabolism of chylomicra, 1025–1031
and unesterified fatty acids, 211
lipid distribution in, 982
measurement of in synovial fluid fractionation, 816–823
metabolism, in nephrotic syndrome, *706*
nomenclature, 1026
in plasma
of biliary cirrhosis, 133–143
electrophoresis of, in atherosclerosis, 980–989
idealized distribution of, 646
and steroid binding, 1432
Liver
absorptive process in of testosterone and hydrocortisone, 1041
alcohol effects on, *710–711*
anaplastic cancer metastatic to hematological and radioiron data on, 1251
and anemia of kidney disease, 856
blood flow by bromsulphalein and radiogold methods, 825–829
and chlormerodrin mercury concentration after, *32–36*
cholesterol
content, 15–18, *688*, *700*, 1015
and disodium EDTA, 14–18
and potassium iodide intake, 1019
secretion, in plasma, 405
cirrhosis of
desoxyribonuclease in sera of, 1326
effect of glutamate on coma due to, 191–198
water excretion of, 756
and congenital hemolytic anemia, 846–847
and Cooley's anemia, 850
damage and antidiuretic substances, 392
desoxyribonucleic acid content of, 346–353
disease
anemia of, and red cell sequestration sites, 854–860
and congestive heart failure, *727–728*
edema in, and body water, 779
and estrogen, 430–441
exchangeable sodium and body water in, 784
ferritin in the peripheral blood of, 588–595
and fluid retention, 423
granulomatous and neoplastic, 591–593
and vitamin B_{12}, *716–717*
fatty
enlargement due to, 348
in malnourished infant, 346–353
and oxygen consumption, 1211
function of
and cortisone or hydrocortisone, *696–697*
in loiasis, *702*
and manganese uptake, 831
after nephrectomy, 1383
and Gaucher's disease, 862
glucose release from and peripheral utilization, 500

glycogen storage disease, glucose-6-phosphatase activity in, 1092
and hemolytic anemia, 858–859
and homozygous C disease, 853
and hydrocortisone, *697*
hydroxyphenylpyruvic acid production by, 1091
in premature versus adult, 241–243
and hypoglycemia after glycine, 419
and iodinated insulin metabolism study, 182–183
iron storage in, in cancer, 1256, 1259, 1260
and nutritional hypochromic anemia, *713*
lipids
and rates of splanchnic bed metabolism, 1210
total, in diabetes mellitus, 1209
and macrocytic anemia, 854
mercaptomerin in, 776–777
and splanchnic oxygen uptake, 1210
and paroxysmal nocturnal hemoglobinuria, 851
and pernicious anemia, 855
phospholipid content, *689*
radioiron pooling
in anemia of infection, 93
in lymphosarcoma, 1255
and rates of splanchnic bed metabolism, 1210
and regulation of plasma lipids, 1383
and removal of active steroid hormones, 255–259
serum dihydroxy-trihydroxy bile acid ratio, *695–696*
and sickle cell anemia, 848–849
and spleen, ratio of radiochromium distribution, 860
tyrosine oxidizing system in, 239–240, 1089–1092
uptake of mercury by, 32–37
and BAL, 34
and uroporphyrin conversion to coproporphyrin and to protoporphyrin, *689*
and hypotension due to endotoxin, 1196–1197
and Thiomerin®, *776*

Loiasis, host-parasite relationship in, *702–703*

Lung
atelectasis of aneurysm of aorta with, 913
axial streaming of red cells in capillaries, 1390, 1391
blood in
flow, after occlusion, 1401
and surface tension, 910
volume, calculated values, 1393–1403
cancer of, hematological and radioiron data on, 1249–1251
chemical burns of, 666–667
and hypercalcemia, *697–698*
compliance
and body position, 907, 912–920
and capillary pressure, 614
defined, 904
and duration of inspiration on, 397
and intra-pulmonary mixing, 919
and non-elastic pulmonary resistance, 669
in pleural effusion, 907
in pulmonary emphysema, 918
and resistance of, 904, 920
and respiratory rate, 910, 916
and vascular pressure, 611–618
and vital capacity, 615, 616
and composition of total body, 598
compressible gas in cardiopulmonary disorders, 664–670
congestion
in emphysema and/or heart failure, 401–403
and renal failure, 1095
respiratory effects of, *692*
dead space
and diffusing capacity, in mitral stenosis, 1010–1013
ratio to tidal volume, 396
disease
and abdominal gas, 341–343
anemia of, 1249–1251
fetal, and amniotic fluid formation, 634
function of
and airway resistance, 333
and body position, 910
as pulmonary compliance, 617
gas volume
Boyle's law in measurement of, *322*
trapped, *664–670*
plethysmographic method for measurement of, *322–326*
hemodynamic alterations in, 289
hemosiderosis of, *666–667*
mercaptomerin in, radiomercury labelled, 776–777
obstructive emphysema and energy cost of breathing, *705–706*
physical properties of in emphysema and/or heart failure, 394–403
red cell volume, calculated values, 1395
resistances, in respiratory system, 394
reversibility of diffusion impairment, 1008–1013
and staphylococcal septicemia, *736*
stiffening, redistribution of blood to periphery after, *693*
as source of circulating unesterified fatty acids, 211
tidal volume and body position, 914–917
tuberculosis of, desoxyribonuclease activity in sera of, 1326
vascular engorgement, respiratory and circulatory effects of, *692–693*
ventilation
and bronchodilator, 395, 1287
vessels, blood volume in, in mitral stenosis, 1393–1403
vital capacity of
and airway resistance in, 332
and bronchodilator, 1287
versus blood-gas exchange, 1010–1013
volume, ratio of residual to total, 396

Lupus erythematosus, desoxyribonuclease in sera of, 1326

Lymph
absorption, from intestine, 1041
cholesterol and total lipid, and potassium iodide, 1016
chylomicra, composition of, 1027
fatty acids in, as phospholipids, or triglycerides, 1025
flow, *713*
hydrocortisone and testosterone radioactivity, 1037
tuberculosis of, and isoniazid, *718–719*

Lymphedema, lymphatic flow in, *713*

Lymphocytes, in body of urinary calculi, 1072

Lymphoma
and glucose metabolism, *722–723*
red cell destruction in, 1248

Lymphosarcoma
hematological and radioiron data on, 1250
metabolic and cytochemical changes in, *701*

Lysine, reabsorptive pattern for, 890, 893, 895

M

Macromolecules, elongated hydrophilic and red cell sensitization, *715–716*

Magnesium
absorption and vitamin D, 1240
balance
and calcium intake, 1231
and fecal magnesium excretion after burn, 74
fecal excretion and intake, *710–711*
and paroxysmal nocturnal hemoglobinuria hemolysis, 455
and potassium deficiency, 773
in stone matrix, 1075
total body, and fat free dry solid content, *763–773*

Malnutrition
causes of and intracellular edema, renal adjustments in, *723–724*
composition of liver in infants, 346–353

Manganese, excretion after ethylenediaminetetraacetic acid, 831–836

Mannitol
diuresis, and ammonia excretion mechanism, 230
osmotic diuresis induced by and Pitressin®, 1366
plasma clearance, in aldosteronism, 1358
and single injection methods, 922, 926–933

Matrix, of urinary calculi, 1067–1078

Meningitis, meningococcic, mercaptomerin in tissues of, *776–777*

Meralluride
and acid base metabolism, 157–162
binding to plasma proteins, 36

Mercaptomerin®, tissue distribution of radiomercury labelled, 775–778

Mercuhydrin®
and extracellular fluid, 1310
regression rates after, 1055
basal rate
in myxedema, 808
in nephrotic syndrome, 792, 799
of pregnancy, 1263
and radiothyroxine in hypermetabolism, 808
in thyrotoxicosis, 274–275, 808
in bile fistula and hydrocortisone, 1037–1042
and body surface area, 808
and extrathyroidal organic iodine pool, 808
and thyroid function, 792
thyroxine, *687, 737, 738*
in nephrotic disease, 792–799
in thyroid disease, 811–812
Methamphetamine, and responses to environmental stimuli, *694–695*
Methionine
labelled, in albumin turnover studies, 1161–1170
reabsorption pattern, 890–895
Mitochondria
capacity for manganese uptake, 831
and thyroxine metabolism, *687*
Mitral valve
area, in pulmonary volume estimation, 1396
closure and vibration, atrial versus ventricular pressure in, *719*
insufficiency of
hemodynamics during, 1396
left heart, enlarged mixing chamber, *697*
and pulmonary pulse pressure, *719*
sodium excretion in, 971–972
stenosis of
and body position, 910
breathing study in, 913
catheterization in, *706–707, 709–710*
diffusing capacities, 1008, 1013
pulmonary blood volume in, 1393–1403
pulmonary vascular resistance, 1008
Morphine, plasma volume changes after, 126–128, 130
Mucoprotein
of calculus matrix, 1075–1078
serum, and cortisone, 1233
Mumps, and pancreatitis, amylase and desoxyribonuclease in sera of, 1326
Muscle
and chloride concentration, 610
electrolyte and water content, 99–100
function, and ventilation, *729*
heart, and cardiac glycosides, 1225–1227
intracellular volume in and acidosis, 101–105
membrane potential and potassium gradient, in periodic paralysis, *702, 708*
metabolism of oxygen and glucose in, *676*
potassium uptake by in periodic paralysis, *708*
skeletal
carbohydrate metabolism in during night, 991–997
in oxidative metabolism, 671–681
smooth and norepinephrine, 297–301
in urinary calculi, 1071–1072
stretch, and cardiac output, 1226
tone and activity, and fatty acids, 1294–1295
total body, 598
uptake of mercury by, 32–35
and BAL, 34
Muscular dystrophy, and tocopherol deficiency syndrome, 1354
Myleran, in leukemia or lymphosarcoma, *701*
Myocarditis, pleurodynia virus and cortisone induced, 362–370
Myocardium
contraction and ionic changes, 1226
electrolyte arteriovenous difference, 1224
focal areas of scarring, 305–307
infarction of
and cholesterol, 983
desoxyribonuclease in, 1326
gastrointestinal content in, 507, 517
lipoproteins in, *700,* 983–989
mercaptomerin in tissues of, 776–777
in women, *689*
internal ionic content and inotropic effect of digitalis analogues, 1227
prevention of lesions of, 365–367
retroperfusion of, 302
after coronary sinus arterialization, 306–307
transfer of sodium and potassium, 1220–1227
uptake of lipid by, 680
and unesterified fatty acids, 211
Myosin, and cardiac failure, *727–728*
Myxedema
and calcium metabolism, 874–886
hydrocortisone turnover in, 560
and myotonia and pseudomyotonia, *716*
protein synthesis rate in, effect of l-triiodothyronine on, 164–169
radiothyroxine turnover studies in, *737,* 806–812
triiodothyroacetic acid for and tocopherol serum level, 1352

N

Narcosis, hypothermia after and peritonitis, 940–945
Neo-Antergan®
and serotonin, *712*
and respiratory block, *724*
Neohydrin®. *See* Chlormerodrin
Neoplasm
disseminated and abnormal hemolytic system, *698–699*
and glucose metabolism, *722–723*
malignant and anemia, 1248–1261
Neostigmine
depolarizing action of and potassium chloride, *708*
and primary autonomic insufficiency, 1416
Nephrectomy
and anti-kidney serum
hypercholesteremic response to, 523–524
and plasma cholesterol, 527
excretory function after and hyperlipemia, 1382
hyperlipemia after, 1381–1384
and narcotic action produced by fatty acid, 1298
Neohydrin® clearance after, 1057
Nephritis
glomerulo, 443, 447–451
renal structural changes and function after, *717*
Nephrocalcinosis, and tubular damage, *720–721*
Nephrosclerosis
and hypertensive state of aldosteronism, 1360
mercaptomerin in tissues of, 776–777
Nephrosis
in adults, *689–690*
and aldosterone, 1299, 1313
diabetic blood flow and weight in, renal, 1343
ferritin, iron in serum of, 590–592
lipid in serum of and cholesterol, 409
and plasma albumin
deficiency, *732*
and lipids, 527–528
and thyroid function, 792
thyrotropic activity in, 792
and thyroxine
binding, *730*
metabolism, 792
total and protein-bound radioactivity in, 796–798
Nephrotic syndrome
atherosclerosis in and lipid alterations, 1381
basal metabolic rate, 799
desoxyribonuclease in sera of, 1326
estrogen effects on electrolyte and water metabolism in, 443, 447–451
and ethyl alcohol, 388–393
extracellular fluid volume in, 449
with hypoproteinemia in children, 44–55
idiopathic and steroid therapy, *689*
metabolism in
lipoproteins, *706*
phospholipid, *688*
plasma proteins, 44–55
and plasma albumin deficiency, 522
and renal fatty degeneration, 1381
response of pituitary-thyroid axis in, 799
thiocyanate space, 449
Nerve
adrenergic, nor-epinephrine produced by, 568
renal
and efferent limb of fluid volume control system, 1364–1380
and renal hemodynamics, 1377–1379
total body, 598

Nervous system
central "glucoreceptors," 627–632
parasympathetic and sympathetic in primary autonomic insufficiency, 1416
Neurodermatitis, and gastric contractions after glucose, 955–962
Neutrophile
and lymphocytes, 290–291
and reserve of leukocytes, 295
Newborn
at delivery 17-hydroxycorticoids in cord plasma, 490
hemolytic disease of intra-erythrocytic phosphate partition, 1404–1411
liver of, tyrosine oxidizing activity, 1091–1092
thyroxine binding by sera of, 1270–1275
total electrolyte and water content, *703–704*
Nitrogen
absorption, and vitamin D, 1240
alpha amino in plasma and whole blood, 497
in alveolar gas, 670
balance
after burns, 62–77
and calcium intake, 1231
during cortisone, in sarcoidosis, 1231
and extracellular pH changes, 937
in hyperthyroidism, 886
metabolic, and thyroid disease, 875
in myxedema, 166
and total electrolyte, in renal failure, 1098, 1106
and body weight in adult tissue, 1115
excretion
and body fat, 1050–1051
fecal, *710–711*
in renal failure, 1097, 1106
glycine tagged with in protein synthesis, 164–169
in kidney fractions after chlormerodrin, 38–39
and necrotizing effect of adrenalin, *739*
non-protein plasma concentrations, after nephrectomy, 1381–1384
nuclear-cytoplasmic ratios of, *701*
phospholipid, in biliary cirrhosis, 138–139
retention and body weight, 1109
and testosterone, 1109–1119
after potassium restriction, 1116
after sodium restriction, 1112–1119
total body and fat free dry solid content, 763–773
urea and hyposthenuria in sickle cell anemia, 999–1006
and water, total body versus fat free dry solid, 765
and potassium deficiency, 773
Nitrous oxide, flow curve for renal blood flow, 1341
Noradrenaline. *See* Norepinephrine
Norepinephrine
blood pressure and pulse rate after, 571–573
and cardiac ganglia, 649–654
cation shifts in arterial wall due to, *297–301*
concentration in plasma, 837–841
and/or hexamethonium renal responses to, 869–872
and hypertension, 870
and insulin hypoglycemia, 568–577
and nodal premature contraction, *572*
and protein transport, 1277
and pulmonary vascular compliance, *692–693*
recovery of by ethylenediamine method, 838–839
renal hemodynamics after, 1278–1283, 1368
urinary protein excretion after, 1278–1283
Nose, secretions containing inhibitors, and viral infections, *715*
Nucleic acid, in liver of malnourished infants, 346–353
Nutrition
and carotenoid content of aortic atherosclerosis, 1246–1247
and circulating concentration of unesterified fatty acids, 210–211
hypochromic anemic, *713*
at onset of oliguria and protein catabolism, 1103

O

Obesity
and caloric intake, 1053
and coronary artery disease, blood lipoprotein patterns in, *700*
effect of on red cell and plasma volumes, 4–9
and gastric contractions after glucose, 955–962
in population study of diet and physical activity, 1173–1180
non-esterified fatty acids in plasma, 151–153
and turnover rates of blood, 9
Obstruction
airway
and breathing capacity, 1286–1290
and ventilatory response to carbon dioxide, 1286–1290
of biliary passages, 435–441
extrahepatic, and bile acid concentrations, *696*
respiratory, 329
and bronchodilator drugs, 333
venous, in hepatic disease, 443, 447–451
Octanoate
injection site of, and response, 1296
narcotic action of, 1293–1294
Oligophrenia, phenylpyruvic, amino acid administration in, 619–625
Osmolarity
of body fluids in malnourished infants, *724*
concentration of serum and water diuresis, 753
urine plasma ratio
after albumin infusion, 1375
after hydropenia and Pitressin®, 1366
after isotonic expansion, 1373
during mannitol and Pitressin®, 1366
postural effects on, 268–269
urinary
after pyrogen, 1081–1087
and serum and water diuresis, 749–756
and water conservation in aldosteronism, 1361
Osteitis deformans
and calcium metabolism, 874–875
phosphatase alkaline levels in, *719*
Osteoarthritis
and gastric contractions after glucose, *956*
hyaluronic concentration and synovial fluid viscosity in, 1422–1425
Ouabain, and oxygen consumption of cardiac muscle slices, 314–320
Oxygen
arterial
and exercise, 977
in heart disease, 972–979
hepatic venous difference in diabetes, 1209
in metabolic alkalosis, 264–266
in respiratory alkalosis, 602–603
in thyrotoxicosis, *274*
and venous concentration in basal state, 674–680
arteriovenous difference
and exercise, 977
in heart disease, 972–974
in muscles of forearm, 674–675
nocturnal, 992–997
and renal weight, 1342
in thyrotoxicosis, *274*
breathing and nitrogen, in alveolar gas, *670*
capillary-mixed venous difference, 1011
cardiac metabolic rate for in thyrotoxicosis, *275*
cerebral utilization in mental confusion, *701*
consumption
in acidosis, 1206
and alloxan, 1206
basal total, 1205–1211
and compound F, 1050, 1053
in diabetes mellitus, 1205–1211
and digitalis, 314–320
and exercise, 977
and glucosuria, 1210
in heart disease, 972–974
in ketosis, 1206
and lactic acid production, 675–676
in mitral stenosis, 1011
in phlorhizin diabetes, 1206
after Pitressin®, *720*
and protoveratrine after atropine, *727*
and renal weight, 1342
splanchnic, in diabetes mellitus, 1205, 1209
in thyrotoxicosis, 274
after vasopressin, 1415
content of blood
aortic-coronary sinus, 302–307
and capacity, during storage, 564
in pulmonary artery, 303

Oxygen (*cont'd*)
diffusion
capacity of lungs in mitral stenosis, 1008–1013
in emphysema and/or heart failure, 402
fraction of consumption and oxidation of glucose, 677–678
myocardial extraction and Cedilanid®, 314–320
rate of uptake of, in metabolism of forearm, 674–680
and respiration in pulmonary emphysema, 1289
saturation
of bilirubin, 543
of blood in cardiopulmonary disease, 913
in mitral stenosis, 1011
of peripheral glucose, 498
and respiratory alkalosis, 602–603
tyrosine, in liver, 249–253
of unesterified fatty acid, 209–212
tension
alveolo-capillary, 1011
arterial, 1009
and hemoglobin concentration, 1005
uptake of
by forearm, 676
and glycosides, 314–320
and lactate production, 674, 677
nocturnal, of forearm, 992–997
and oxidation of glucose, 993–997
uptake and tyrosine oxidizing system, 1091
Oxytocin, and pressure in autonomic insufficiency, 1414, 1415

P

Paget's disease
and adrenocortical hormones, *719*
and calcium metabolism, 874–882
Palmitic acid
recovery of from plasma, 207
for tagging chylomicra in fat transport study, 1025–1031
Pancreas
carcinoma of
and amylase, desoxyribonuclease in sera of, 1326
mercaptomerin in tissues of, 776–777
crude fraction of and insulin antiserum, 469
disease of, and desoxyribonuclease I, 1325–1330
and fatty acid metabolism, 1205
hyperglycemic-glycogenolytic factor, 494–500
juice
sodium in, 508–509
manganese excretion in, 831
and oxygen consumption in diabetes mellitus, 1208–1211
sodium secretion in, 506–509
Pancreatitis, amylase and desoxyribonuclease in sera of, 1325–1330
Panhypopituitarism
and ethyl alcohol, 387, 392
and aldosterone excretion, *688*, 1309
water excretion of, 756
Para-aminohippuric acid
clearance
in aldosteronism, 1357
and aminophylline, 1367
and epinephrine, norepinephrine, 1278–1280
and exercise, 977
and G-25671 versus phenylbutazone, 374–385
after kidney transplant, 1365
and l-norepinephrine, 1368
and orthostatic hypotension, 1369
and pyrogen, 1080, 1083–1087
serial, in kidney homotransplantation, 1365
in sickle cell anemia, 1005
after typhoid vaccine, 948–952
after vasopressin, 1416
for measurement of renal blood flow, 1340–1344
reaction, in matrix of urinary calculi, 1072–1075
tubular maxima for during pyrogenic effect, 1084
Paralysis
periodic, and cortisone, *708*
potassium and sodium concentration in, 507, 517
Pelargonate
and induced unconsciousness, 1294
injection site of, and response, 1296
Penicillin, and penicillin-resistant staphylococcal infections, *723*, *736*
Peptic ulcer
in Addison's disease after cortisone therapy, *707*
ferritin iron in the serum of, 591
gastric content from fractionation of, *716*
symptoms of and disordered motor activity, *739*
Pepsin, regulation by local mucosal changes in pH, *712*
Periarteritis
due to virus and/or cortisone, 365
constrictive, and estrogen, 443–447, 450–451
and renal failure, 1095
Peritonitis
mercaptomerin in tissues of, 776–777
pneumococcal and prolonged hypothermia, 940–945
and renal failure, 1095
Pharynx
swallowing mechanism in dysphagia, *687*
and testosterone, 1111
Phenylacetylglutamine
excretion of
after glutamine, 620
phenylpyruvic oligophrenia, 619
in phenylalanine conversion to tyrosine, 623
Phenylalanine
blood sugar concentration after, 418
conversion of
to phenylpyruvic acid, 619
to tyrosine, 623
reabsorptive pattern for, 890, 893, 895
Phenylbutazone, as uricosuric in gout, 374–385
side effects of, 381, 385
Phenylhydrazine, assay of hydrocortisone, 554–560
Phenylketonuria, in phenylpyruvic oligophrenia after amino acid, 619–625
Phenyllactic acid, excretion after glutamine, 620–621
Phenylpyruvic acid, excretion of and amino acids, 619–625
4-(Phenylthioethyl)-1,2-diphenyl 3,5-Pyrazolidinedione. *See* G-25671
Phonocardiogram, in rheumatic heart disease and mitral insufficiency with gallop sound, *719*
Phosphate
and glucose in venous blood from skeletal muscle, 996
organic esters, 660
resynthesis of, 661
partition of erythrocytes, 1404–1411
after adenosine, 564
in stone matrix, 1075
urinary output and estrogen, 424–451
in hepatic disease, 430–441
in renal and cardiac disease, 443–451
Phosphatase
alkaline
in hepatocellular disease, 590–591
in osteitis deformans, *719*
serum, and sarcoid, 1229
Phospholipid
fractions, in chylomicron metabolism, 1027–1028
in hyperlipemia, 152
metabolism in liver and kidney, *688*
plasma
cholesterol in biliary cirrhosis, 135
concentration after nephrectomy, 1382
Phosphorus
balance
after burns, 68–73
and calcium intake, 1231
during cortisone in sarcoidosis, 1231
dietary absorption of, *710–711*
fecal excretion
and cortisone therapy, 1233
and intake, *710–711*
metabolism, 875, 1232–1241
nuclear-cytoplasmic ratios of, *701*
phospholipid uptake, *688*
serum levels
after hyperglycemic-glycogenolytic factor and glucose, 496
in lung carcinoma, *698*
during sodium phytate, 1233–1241
and vitamin D, 1241
Phosphorylase
and arteriovenous glucose difference, 498

nucleoside, 660
and rejuvenation phenomenon, 661–662
Pitressin®
and aldosterone excretion, 1307
after ACTH, *726*
and fluid volume, 1307
and pyrogen, 1084
and serum sodium concentration and osmolality, 1307
sustained, *688*
and body fluids, *688*
and renal tubule, 1080–1087
and water conservation in aldosteronism, 1361
during water diuresis
in sickle cell anemia, 1004–1006
Placenta
amniotic and maternal fluid and water exchange, 634–640
in iron transport and passage, *693*
passage of 17-hydroxycorticosteroids in, 488–493
thyroxine passage to, 1274
Plasma
and ascitic fluid radiosulfur equilibration between, 1127
pulmonary volume calculated values, 1395, 1396
and red cell transit times, 1385
from renal artery to vein, *721–722*
volume, 1–9, 126, *704–705*, 1395
in anemia of cancer, 1249–1251
in congestive failure, *725*
and estrogen, 425, 428
in polycythemia, *736*
water, versus erythrocyte, 608
Plasminogen, activation of, *735*
Platelet
antifibrinolytic activity of, 355–361
anticoagulant effect of, *736*
antigenic composition of, *738*
clotting activity of
after contact with glass, 1183–1189
after freezing and thawing, 1185, 1189
metabolic function of, *695*
uptake of diisopropylfluorophosphonate, 964–969
Plethysmograph
airway resistance, 327–334
thoracic gas volume, 322–326
versus dilution method, 664–670
Pleura
calcified right, breathing study in, 913
effusion of, and gas volume, 666–667
measurement of, 905–910
thickening of and pressure gradient across lung, 617
Pleurodynia virus, and cortisone, myocardial lesions due to, 362–370
Pneumoconiosis, and airway resistance in, 332
Pneumonia
and urinary concentration of hydroxyproline, 580
Pneumothorax
intra-esophageal and intra-pleural measurements in, 905–910
volume of trapped gas in, 666–667
Poikilocytosis
and nutritional hypochromic anemia, *713*
of stored blood, and adenosine, 564
Poisoning
lead, in childhood, urinary coproporphyrin in, 1131–1138
vitamin D, sodium phytate for, 1241
Poliomyelitis
bulbar, swallowing passive after, *687*
and hyperglycemic-glycogenolytic factor, 496
vaccine, and immunization with formaldehyde, *722*
Polydipsia, and low potassium diet, 157
Polycythemia
and androgen for metastatic breast cancer, *717*
body composition in, *736*
and ferritin serum iron, 589
and pulmonary emphysema breathing study, 913
Polycythemia vera, thrombocytosis life span of platelets in, 965, 969
Porphobilinogen, conversion of, *689*
Porphyrin
interconversion of, *689*
and edathamil calcium disodium, 1136
Posture
and breathing, 904–910
in cardiopulmonary disease, 912–920
antidiuresis of quiet standing, 308–312
and compliance, 919–920
effects on urine flow and excretion, 268
quiet standing and supine position effects, 1369
and renal tubular activity, 267–270
reabsorption of sodium ion, 309–310
and resistance in supine versus sitting, 919–920
Potassium
absorption of
and level of intake, *710–711*
and vitamin D, 1240
and aldosterone
after Mercuhydrin®, 1310
output, *726*
urinary, *689*
in arterial wall and norepinephrine, 297–300
arteriovenous difference
and acetyl strophanthidin, 1224
in periodic paralysis, *702, 708*
balance
and actomysin, 300
and calcium intake, 1231
and extracellular pH changes, 937
in gastrointestinal contents, 512–520
and nitrogen, 66–69, 1236
in renal failure, 1101–1102
and sodium balance, 772
and testosterone propionate, 1111–1119
chloride
and alkalinization of urine, *227–228*, 234
and sodium, total exchangeable, 599
clearance
and dehydration, 1309
renal, and G-25671 versus phenylbutazone, 374–385
in renal failure, 1098, 1106
deficiency
body composition and electrolyte changes due to, 768–773
and diet, *734*
after dehydration, *688*
depletion of
mercurial diuretics during alkalosis due to, 157–162
and plasma carbon dioxide tensions, 484–487
renal concentration defect in, *713*
in distal colon, 516
distribution
in body tissues, 598
ratios, after death, *739*
exchangeable
in gastrointestinal tract, 512–520
versus total body content in infant and adult, *703–704*
excretion
and aldosterone, 1361
in human sweat, 114–120
and body position during sulfate diuresis, 308–312
and Diamox®, 1370
fecal, 516, 1097, 1106
during pyrogen activity, 1083–1084
after typhoid vaccine, 948–952
gradient, during neuromuscular function, *708*
intake
and preservation of homeostasis, 771
in renal failure, 1097, 1106
intracellular
and extracellular pH change, 935–938
measurement of, 519
and serum concentration, 935–938
intraluminal gastrointestinal content, 514–520
iodide and hypercholesteremia in atherosclerosis, 1015–1024
loss
and aldosteronism, 1357–1363
and salt-depletion, 1313
and neurogenic dysfunction of bowel, 519
nuclear-cytoplasmic ratios of, *701*
after Pitressin®, *688*
plasma concentration
after albumin infusion, 1375
in acidosis, 482–484
in aldosteronism, 1359
during pyrogenic reaction, 948–951
serum concentrations
and hypokalemic alkalosis due to sodium glutamate, 195–198
and kidney failure, 938
and pantothenic acid, *739–740*
and potassium depletion, 763–773

Potassium (*cont'd*)
and respiratory alkalosis, 601–605
and sodium depletion, *688*, 1300–1305
of water and dialysate, 608–610
and sodium, *726*, *739*
myocardial transfer of, 1220–1227
restriction, and testosterone, 1115
and tubule reabsorption, 312
total body content, 596–600
species difference, 519
and extracellular concentration, 935–938
and extracellular pH changes, 938
urinary excretion
and acetazoleamide, 1359, 1361
after albumin, 1375
and aldosterone, *726*, 1304, 1307, 1313
in aldosteronism, 1357–1361
and compound F therapy, 1050–1051
after hydrocortisone, 1236, 1370
after isotonic expansion, 1372
during pyrogenic reaction, 947–952
in renal failure, 1097, 1106
after sodium depletion, 1308
after typhoid vaccine, 948–952
after water intake, 1308
and fat free dry solid content, 763–773
after sodium chloride intake, 1376
and estrogen, 424–451
after typhoid vaccine, 948–952
Prednisone
and hydrocortisone, 558–560
for nephrotic syndrome, *689*
Pregnancy
electrophoretic composition of plasma proteins, 1263
sera of thyroxine binding of, 1263–1275
and thyroid hormone
production and release, 1274
uptake, *708–709*
and tyrosine oxidizing activity, 1090–1092
Pregnanetriol
excretion, and virilization, *693*
urinary, and ACTH, 218–221
Progesterone, and tension in cardiac muscle, *708*
Pressure
alveolar
airflow measurement, 327–334
and carbon dioxide after sodium bicarbonate, 245–252
arterial
and aldosteronism, 1360
and endotoxin, 1191–1197
and anesthesia, sedation, 127–130
and noradrenaline, 872
and vasopressin, 1412, 1418
pulse wave distortion, and hemodynamics, *729*
atmospheric, breathing against, *692*
atrial patterns caused by movement of atrioventricular ring, *710*
basal in pharynx, *687*
brachial arterial after oxytocin or vasopressin, 1414
central venous
and G-suit inflation, *692*
and pulmonary compliance of, *692*
congesting, and capillary permeability to serum cholesterol, 282
coronary artery, peripheral, 303–307
diastolic
and sodium excretion, 973
and systolic, 572
end expiratory and body position, 912–920
femoral artery
and endotoxin, 1194–1195
systolic, *729*
glomerular capillary and protein output, 1284–1285
gradient, and pulmonary compliance, 614
intracardiac and gallop sounds, *719*
intraesophageal end expiratory and body position, 914–917
in emphysema and heart failure, 399
in mitral stenosis, 1393–1403
and norepinephrine after hexamethonium, 872
pulmonary artery
and blood flow, *710*
and exercise, 977
in heart disease, 975
after occlusion, 1401
after vasopressin, 1415
versus compliance, 614
pulmonary capillary
and pulmonary blood volume, 1395
and pulmonary compliance, 614
in mitral stenosis, 1013
and compliance, vital capacity, 616
in rheumatic disease and mitral insufficiency, *719*
and sodium excretion in heart disease, 973
pulse, T-wave changes in and epinephrine, 569–571
rectal, and gas escaped, 341
right atrial and body position, 910
transpulmonic and pulmonary viscous resistance, *725*
vascular, and pulmonary compliance in heart disease, 611–618
venous, 979
hydrostatic, in blood trapping, 910
myocardial response to, 1304
sedation and anesthesia effects on, 127–130
ventricular filling and cardiac output, 1226
end-diastolic filling and congestive heart failure, *727–728*
systemic arterial in heart disease, 975
Proaccelerin
asolectin adsorbed plasma as substrate for assay of, 145–149
clot-promoting activity of and glass, 1186–1189
nomenclature, 106
Probenecid, corticosteroid and creatinine clearances after, 1432
Proconvertin
asolectin
proaccelerin assay, 146–149
separation from prothrombin, 371–373
clot-promoting activity of and glass, 1186–1189
nomenclature, 106
Proline
reabsorption pattern for, 890, 893, 895
total urinary excretion of hydroxyproline after, 583
Properdin, and hemolysis of erythrocytes paroxysmal nocturnal hemoglobinuria, 453–457
Propylthiouracil
antithyroid therapy with in thyrotoxicosis, 808
Prostate, cancer of
hematological and radioiron data on, 1249–1251
with bone metastasis, and estrogen, 1258–1261
disseminated, 1256
and hormone metabolism, 1034
Protamine, and removal of intravenously chylomicron from plasma, 1025
Protein
and accelerator globulin activity, 109
balance, and caloric intake during renal failure, 1103
beta-metal-combining, identification and measurement, 816–823
bilirubin-linkage in serum, 537–550
binding capacity of, 475–479
mercury, 41
thyroxine, 812, 1263–1275
capillary permeability to, *732*
catabolism
and compounds A or F therapy, 1049
and fat decomposition, 1049
rate calculation, 168
in renal failure, 1103
carotenoid affinity for, 1247
content of, in liver in malnourished infant, 346–353
contractile, of failing heart muscle and glycosides, 319
in diffuse toxic goiter, *708–709*
and fat storage, 1049
fractions
and pigment peaks by direct densitometry, 539
separation of, 1213–1218
host tissue metabolism and tumor growth, *722–723*
iodinated and albumin turnover, 1169–1171
and insulin antisera, 469–470
assay, 473
pancreatic, 468–469
intake
blood sugar and amino nitrogen after, 414–418
and fatty liver, in Kwashiorkor, 346
in glucostatic theory test treatments, 629–630
and hypoglycemia, 416–421

liponeogenesis from total body fat, 1053
lymph
chylomicra, 1027
intestinal, 409–410
metabolism
N-15 glycine technique, 164–169
labelled albumin, *705–706*
labelled plasma versus amino acid, 1168–1171
in nephrotic syndrome, 44–55
molecules passage of, through capillary walls, *719–720*
output
and renal vasoconstriction, 1284–1285
pattern changes in and in lipid pattern, *688*
plasma, 135, 525–527
in agammaglobulinemia, 1199
after albumin infusion, 527
and anti-kidney serum injection, 525–527
binding of corticosteroids by, 1428–1433, 1434–1438
heat stability of, 1213–1218
labelled, for plasma volume measurement, 126
and tissue uptake of thyroid hormone, *709*
of platelets reaction of diisopropylfluorophosphonate with, 964–969
portion of molecule in stone matrix, 1078
tests for, 1076
postural effects on, *269*
precipitation
for lipoprotein separation, 988
radiocystine labeled for albumin turnover, 1167–1171
serum
and adrenal medullary hormones, 1277–1279
in cardiac failure after estrogen, 446
and estrogen, 425–428, 444, 449
and fatty livers, 348
measurements with labelled radioiodine, *704–705*
nomenclature, 1026–1027
results of electrophoresis, 1233
total, in pregnancy, 1270
size and specific activity of pool, 1170–1171
sodium restriction and testosterone propionate, 1110
of synovial fluid, characterization of, 814–823
synthesis, and l-triiodothyronine, 164–169
total
after hypotonic expansion, 1372
measurement of by paper electrophoresis, 986
transglomerular capillary transport of, in renal disease, 1277, 1283
urinary excretion
and adrenal medullary hormones, 1278–1283
in aldosteronism, 1359, 1360
after estrogen, 431–441
values for metabolic mixture and body surface area, 1099–1100

Proteinuria
and aldosteronism, 1360
after anti kidney serum injection, 525
and iodinated plasma albumin, 45–49
and protein transport, 1277
Prothrombin
asolectin
and proaccelerin assay, 146–149
and proconvertin separation, 371–373
clot-promoting activity of and glass, 1186–1189
consumption and trypsin, *735*
and heparin, 533–535
removal of from oxalated plasma, 1187–1189
retention in hepatacellular disease, 590–591
serum activity in hemophilia, 1317–1318
Protoveratrine, and hypertension with left heart failure, *727*
Pseudohypoparathyroidism, hypercalcemia, due to vitamin D, 1240–1241
Pseudomyotonia, and myxedema, *716*
Pulmonary artery
disease
and ethyl alcohol, 389
and volume of abdominal gas, 341
insufficiency and sodium excretion in heart disease, 973
pressures
in heart diseases, 975
in mitral stenosis, 1013
in thyrotoxicosis, *274*
after vasopressin, 1415
structure, and diffusing capacity, 1008, 1012–1013
Pulse rate
and adrenal medullary hormones, 1278–1279
after carotid sinus massage in primary autonomic insufficiency, 1416
and exercise, 977
in ferritinemia, 592
in heart disease, 973–975
in myocardial transfer of sodium and potassium, 1221–1227
and norepinephrine, 573
in viral hepatitis, 592
Purpura
idiopathic thrombocytopenic antifibrinolytic activity in serum of, 356–361
nonthrombocytopenic passive transfer of, *692*
Pyelogram, retrograde, in matrix of urinary calculus, 1068–1075
Pyelonephritis
blood flow and weight reproducibility of renal, 1343
mercaptomerin in tissues of, 776–777
polysaccharides, containing aminosugars in, 1078
red cell survival in, 856
skin homografts survival of, *699*
Pyridoxine
and hypochromic anemia, *708–709*
and tyrosine oxidizing system, 1091–1092
Pyrogen
reaction, to typhoid vaccine, 947–952
salt and water excretions after, 1080–1087
Pyruvate
myocardial metabolism of, 314–318
oxidation to, and arteriovenous glucose difference, 498

Q

Quinine
and ammonia excretion, *226–234*

R

Radiocalcium, in calcium metabolism study, 78–87
Radiocarbon
palmitic acid labelled chylomicra, for metabolism study, 1025–1031
steroid hormones labelled with
for corticosteroid-protein binding, 1434–1437
testosterone metabolism, 1332–1339
for steroid tracer study, 1033–1044
Radiochloride, chromic, in red cell sequestration site study, 842–866
Radiogold, versus bromsulphalein method for liver blood flow values, 825–829
Radioiodine
albumin labeled, for protein metabolism, *705–706*
turnover studies, 1161–1170
hyperthyroidism treatment and triiodothyronine, 58–61
insulin labeled for insulin metabolism, 170–188
sodium iodide labelled with, in serum tocopherols of thyroid disease, 1345–1356
for thyroxine
metabolism in nephrotic syndrome, 792–799
triiodothyronine binding, 475–479
uptake
by thyroid gland, 57
in thyrotoxicosis, 274
Radioiron, in anemia
of cancer, 1249–1260
of infection, 89–95
Radiomanganese, excretion of and chelation, 831–836
Radiomercury, in distribution studies
of chlormerodrin, 31–42
mercaptomerin, 775–778
Radiophosphorus, desoxyribosenucleic acid labeled with for leukocyte growth study, 291–296
Radiopotassium, equilibration of in gastrointestinal contents, 512–520
Radiosodium, equilibration of in gastrointestinal contents, 502–509

Radiosulfate
in distribution of sulfate ion across semi-permeable membranes, 607–610
disappearance of from body, 1119–1128
Radiothyroxine
disappearance curves in thyroid disease, 808
red cell uptake, 476–479
in thyroxine-binding serum protein study, 1263–1275
turnover studies in, 806–812
in hypermetabolism, *737*
Rectum
distention of pain relieved, 341
sodium content, 506
Red blood cell
in anemia
of cancer, 1248–1261
Cooley's 850, 853–854, 860
dissemination of metastases, 1257–1258
hemolytic, 846–860, 1404
homozygous C disease, 853
sickle cell, *707–708*
uremia, 856
autoagglutination of in peripheral blood and hemoglobinemia, 857
axial streaming of and lowering of small vessel hematocrit, 1385
binding capacity of, 475–479
chlormerodrin entrance in, 1058
chromium radiochloride in survival studies, 1252
circulating volume of versus body density, 1–9
defect, incidence and genetics of, *691*
destruction in neoplastic disease, *721*, 1257–1258
electrolyte concentration, 99–105
in erythrophagocytosis, 1154–1156
and erythrophagocyte in white cell, 1159
fetal and adult intra-erythrocytic phosphate pattern of, 1404–1406
function of, and flickering phenomenon, 564
hemolysis of, *738*
in fatty acid anions, 1295
of insulin conjugated, 470
iron turnover rate, 92–93
in anemia of cancer, 1249–1251, 1253–1254
life span, 9
diisopropylfluorophosphonate labeling for, 964–969
and slow mixing of tagged cells, *725*
and anemia of cancer, 1248
and anemia of infection, 91–95
mass, hematocrit venous level as index of total, *705–706*
metabolism
and preservation of blood, 562
nucleated
and interconversion of porphyrins, *689*
after leukopheresis, 290
and plasma transit times through kidney, *721–722*
potassium content
and digitalis, or alcohol, 1225
specific activity, 515
and pulmonary blood flow, 1386
radioactivity in, 172, 1029
autogenous, 843–846–860
hemoglobinuria paroxysmal nocturnal, 852
renewal rate in anemia of cancer, 1249–1251, 1254
sensitization
in hemolytic anemia, *715*
insulin antiserum, 463
nonspecific adherence of platelets and leukocytes to, *738*
sequestration sites, *725*, 842–866
index of, 865
S-hemoglobin in deoxygenation of, *707–708*
of stored blood, 564–567, 660–661
transfusion of, for suppression of intravascular sickling, 998
transit time through lung versus plasma, 1399–1401
uptake
thyroxine and triiodothyronine, 121–124, 476–479
radioactive labeled l-triiodothyronine, 476–479
radioiron, 92–93
after sodium bicarbonate infusions, 247
utilization of purine nucleosides, 661
of radioiron, 1249–1251, 1253–1254, 1260
viability of, 564
volume 8, 1395
in anemia of cancer, 1248–1251
and hydrogen ion concentration, *701*
in total blood volume calculation, 1385
versus body density and obesity, 3–9
See also Erythrocyte
Regitine®
benzyl analogue of and block of respiratory response, *724*
and serotonin, *712*
Reserpine, metabolism, *710*
Respiration
and airway resistance, 327–334
biphasic response to sodium bicarbonate, 250
changes in after hypertonic sodium bicarbonate infusion, 245–252
compensating in metabolic alkalosis, *262–266*
of isolated auricle and Ouabain, 314–320
minute volume of in thoracic gas volume study, 664–670
in pulmonary emphysema, 1289
pumping of air past obstructions in airways, *669*
rate
and body position, 914–917
and lanatoside-C, 314–320
versus compliance, 920
resistance during in emphysema and/or heart failure, 395–403
in tissues during pregnancy, 1274
and vascular engorgement, *693*
Respiratory quotient
and Cedilanid®, 314–320
in diabetes mellitus, 1210
of forearm muscles, 678–679
and nocturnal metabolism of muscle, 994–995
Reticulocyte
in anemia of cancer, 1249–1251, 1253
hyperactivity, and resistance to endotoxin, *687*
and hyposthenuria in sickle cell anemia, 999
and inosine due to thymidine, *733*
and sickle cell trait, 1005
Rheumatic fever
desoxyribonuclease in sera of, 1326
and pulmonary diffusing capacity, 1009
and urinary concentration of hydroxyproline, 580

S

Sarcoid
desoxyribonuclease in sera of, 1326
ferritin in, 591–593
hypercalcuria in, 1229–1241
Saliva
inhibition of agglutination and erythrophagocytosis, 1156
by leucocytes, 1151
sodium concentration in versus in plasma, 512, 518
Salmonella typhosa
endotoxin derived from, 1191
immunization against, *687*
Scleroderma
and airway resistance in, 332
breathing study in, 913
hydroxyproline excretion in, 583
volume of trapped gas in, 666–667
Sclerosis
multiple, and hormone metabolism, 1034
Septicemia
staphylococcal, *736*
Serine
identification of, 1078
reabsorptive pattern for, 890, 893, 895
Serotonin
and block
of renal effects, *713*
of respiratory response, *724*
and hypertension, *712*
Shock
endotoxin
and adrenalin, *739*
and renal failure, 1095, 1196–1197
postpartum and renal failure, 1095
Shunt
portacaval, episodic stupor in, *701–702*
vascular, and protein output, 1284–1285
Sickling, intravascular, and urine concentration defect, 998–1006
Silicosis, and airway resistance in, 332
and sodium excretion in heart disease, 974
Sinus
aortico-coronary anastomosis and coronary circulation, 302–307
carotid, massage, and autonomic insufficiency, 1416
rhythm, sodium excretion in, 971–972

Sitosterol, and liver cholesterol, *700*
Skeleton
total body, 598
turnover of calcium in, 885
Skin
during catabolic phase after burn, 74
homograft survival in uremia, *699*
involvement in sarcoid, 1229
sensitivity to insulin, 461
total body, 598
Sodium
absorption of
and level of intake, *710–711*
from small bowel, *730*
tubule, and calcium, *721*
and vitamin D, 1240
acetate, unconsciousness produced by, 1294–1295
and aldosterone, 1299–1305
and potassium intake, *726*
reabsorption, 1313
secretion, *688*, 1306
urinary, 1300–1305
arteriovenous difference and strophanthidin, 1224
balance
and calcium intake, 1231
and Diamox®, 23–25
in hypoproteinemia, *688*
and meralluride, 157–162
postburn, 70–71
in renal failure, 1101–1102
and testosterone propionate, 1111
blood-to-gut transport, 508
body composition responses to, 763–773
of bone cortex, in acidosis, 99–105
cecal mechanism for conservation of, 506–507
clearance
and adrenal medullary hormones, 1278–1279
renal, 374–385
renal, and epinephrine or norepinephrine, 1277
concentration
after albumin infusion, 1375
in arterial wall, and norepinephrine, 298
in aldosteronism, 1359
in congestive heart failure, 779
and hypokalemic acidosis due to glutamate, 195–198
and osmolality, 1307–1314
postural effects on, 268–269
in potassium depletion, 768–773
during pyrogenic reaction, 948
in renal failure, 1098, 1106
in serum water and dialysate, 608–610
after sodium bicarbonate infusion, 247
in tissue, 776–777
and unconsciousness, 1295
after dehydration, *688*, 1309
depletion of
by resin, 1300–1305
and urinary excretion of aldosterone, 1299
and water intake, 1308
in diureses, *688*, *696*
excess, in heart disease, 790
exchangeable
body total, *703–704*
in tissue composition, 598–600
and water, 779–791
and intracellular fluid
pH, 937
volume, 1299–1305
excretion, *694*
after aminophylline, 1366
after Diamox®, 1370
in heart disease, 970–979
after hypotonic expansion, 1372
and orthostatic hypotension, 1369
and phenylbutazone, 378–379
during pyrogen activity, 1080–1087
renal patterns and mercurial diuretics, *696*
in stool, 506, 1097, 1106, 1304
during sulfate diuresis and posture, 308–312
in sweat, 114–120
after venous congestion of lower extremities, 1371
and exercise in heart disease, 970
fractions of, versus creatinine excreted, *696*
gastric juice transport of, 508
gastrointestinal content in hypertensive and arteriosclerotic heart disease, 502–509
glucuronate and glucuronolactone, 277–284
glutamate, and urinary excretion of phenylpyruvic acid, 621
gradient, of erythrocyte, 564
hydroxybutyrate after injection of, 1297
iodide, red cell uptake of, 122, 476–479
intake
creatinine clearance and electrolyte excretion after, 1376
in renal failure, 1097, 1106
intracellular, and heart, 1226
loss
after acidotic stimulus, 100
in virilizing adrenal hyperplasia, *217*
losing syndrome in pulmonary and central nervous disorders, *734*
and Mercuhydrin®, 1310
metabolism
in hypertension, *706*
in malnourished infants, *723*
myocardial transfer of, 1220–1227
after Pitressin®, *688*, *720*
and norepinephrine, 300
oral loads of during water diuresis, 755
restriction
and potassium depletion, 1313
and testosterone, 1110–1119
retaining hormone effect of tissue slices on, 256
retention
and aldosterone, 1361
compound A or F therapy, 1049
and Diamox®, 309–312
and edema, 1306
and estrogen, 433–439
and failure of water diuresis, *690*
and heart failure, 1304
and peripheral edema, 979
and G-25671 versus phenylbutazone, 382–385
potassium and ammonium excretion after, 310
"space" studies, *712*
storage of in heart disease after edema free, 791
total body content, 596–600
total exchangeable in edematous states, 779–791
transcellular equilibration of radiosodium with, 509
transport
in intestinal mucosa, 502–509
and neurohypophyseal extract, *720*
urinary excretion
and acetazoleamide, 1359, 1361
and albumin, 1375
in aldosteronism, 1359
and body weight, 1307
and compound F therapy, 1050–1051
after hydrocortisone, 1370
after isotonic expansion, 1372
and posture, 308–310
and Pitressin®, 1307
during pyrogenic reaction, 947–952
in renal failure, 1097, 1106
after sodium chloride intake, 1376
urinary outputs of and estrogen, 424–451
valerate, and alloxan diabetes, 1298
and water
in edematous, hepatic, and renal disease, 791
homostasis schema, 1313
intracellular, in malnutrition, *723–724*
Spherocytosis
hereditary, 846–847, 852
erythrocyte metabolism in, 1404
and osmotic hemolysis, *701*
of stored blood and adenosine, 564
Spine
metastases to, and anemia, 1249–1251
traumatic demyelinization, 507, 517
Spleen
and anemia
congenital hemolytic, 845–854
and Chlormerodrin, 35
and Gaucher's disease, 862
hemodynamics in and number of leukocytes, 289
iron storage in cancer, 1256
and red cell destruction, 1260
and Laennec's cirrhosis, 854
and mercaptomerin, 776–777
of normal, 843–845
radioactivity distribution to, 93, 843–862
size of, and body and venous hematocrit-ratio, *705–706*
and unesterified fatty acid, 211
Splenectomy
radiochromium in prediction of need, 864
thrombocytosis after life span of platelets in, 965
Sprue, absorption of water and sodium from, *730*

Staphylococcus
infections antibacterial agents in treatment of, *723*
septicemia, *736*
viability in cytoplasm of living leukocytes, *731*
Steroid
adrenal
and peptic ulcer, *707*
urinary output in Addison's disease, *707*
adrenocortical
excretion of, 1303
function, *711*
and virilizing hyperplasia, 221
biogenesis and hypertension, *693*
delta 1–9 fluorohydrocortisone, electrolyte effects of, *721*
enterohepatic circulation of, 1041
formaldehydogenic response to by sodium retaining hormone, 257
glycogenic response to by sodium retaining hormone, 257
metabolism species difference, 1033–1044
protein binding reversible character of, 1436
therapy for nephrosis in adults, *689–690*
urinary aldosterone-like and sodium restriction, 1306
versus plasma action on isolated heart, and hypertension, *708*
Stomach
and adrenal steroid therapy, *707*
cancer of, hematological and radioiron data on, 1250–1251
equilibration of radioactive and intraluminal gastrointestinal potassium, 512–520
gas in, measurement of, 325, 338–339
gastric content fractionation of, *716*
intraluminal sodium content in, 504–509
potassium content, 514
secretion of pepsin by, *711–712*
Stone
calcigerous, matrix from, 1067–1078
renal, and hypercalcuria, 1229
Stool
calcium in vitamin D action on, 1241
excretion in
and balance study in sarcoidosis, 1231–1241
electrolyte, *711*
potassium, 516, 1097, 1106, 1304
in renal failure, 1097, 1106
sodium in, 506–509, 1097, 1106
urobilinogen, in anemia of cancer, 1249–1251, 1256, 1258
values in sarcoidosis for nitrogen, sodium, and potassium, 1237
virus 1302 passage in, 363
Streptokinase
effects of purified, *703–704*
plasminogen activation, *735*
Streptomycin
and isoniazid, *719*
and staphylococcal infections, *723*
Strophanthidin
and failing heart, *710*
and hypertension, *708*
and myocardial transfer of sodium and potassium, 1223–1224
Sucrose
and extracellular fluid spaces, *730*
as indicator for single injection method, 922, 926–933
Sulfanilamide, and erythrocyte defect, *690*
Sulfate
concentration, in serum water and dialysate, 608
distribution of across semi-permeable membranes, 607–610
exchanging pool of, 1126
growth hormone, *733*
and insulin, *733*
in stone matrix, 1078
urinary excretion
and posture, 308–312
Sulfhydryl, metabolism in leukocytic disorders, *729*
Sulfuric acid, absorption spectra of hydrocortisone, and plasma steroid, 554
Sweat
gland fatigue and secretory function, *733–734*
loss of sodium and chloride in, postburn, 71
rate of flow of and rate of excretion of sodium and potassium, 114–120
sodium reabsorption, 119
Synovial fluid
protein fractionation study, 814–823
viscosity, 1419–1427
Synovitis, traumatic
hyaluronic acid concentration and synovial fluid viscosity in, 1422
relative viscosity of effusions from, 1421
Syphilis
aortic insufficiency due to, 315

T

T-1824
disappearance of in plasma volume studies, 125–130
escapes from circulation in congestive heart failure, *725*
versus radioiodine in plasma volume measurement, 704–705
Tachycardia
and testosterone propionate, 1111
T-wave changes in and epinephrine, 569–571
Tapazole®, antithyroid therapy with in thyrotoxicosis, 808
Temperature
body, after typhoid vaccine, 948–952
and heat stability of plasma protein, 1213–1218
Testes, cancer of hematological and radioiron data on, 1251
Testosterone
metabolism, 1331–1339
after sodium and chloride restrictions, 1109–1116
and transport of, in bile fistula, 1033–1044
Tetracycline, derivatives and staphylococcal infections, *723*
Tetraethylammonium chloride
and epinephrine, 569–571, 576
and hexamethonium, 576
and/or Pitressin® pressor effects of vasopressin after, 1416
Tetrahydrocortisone
fluorescence and phenylhydrazine assays of, 554
and virilization, *693*
Tetraiodothyroacetic acid
formation of, from thyroxine, *687*
Thalassemia
urine concentration in, 1003
Thiocyanate, space
in body fat estimation, 1050–1052
and estrogen, 426
Thiomerin®
electrolyte excretion during quiet standing, 308–312
mercaptomerin labeled with, 775–778
Thorax
and duct fistula, labelled hormone metabolism in, 1037
gas volume trapped in lungs or pleural space, 664–670
pressure-volume curves and body position, 909
shape of and hydrostatic pressure, 910
Threonine
identification of, 1078
reabsorption pattern, 890–895
Thrombin
activation of accelerator globulin, 107–108
conversion of prothrombin to, 533
and paroxysmal nocturnal hemoglobinuria hemolysis, 455–457
Thrombocythemia, hemorrhagic and excess platelets, *737*
Thrombocytopenia
antifibrinolytic activity in, of serum and plasma, 355–361
platelet
deficiency in, 533
life span in, 965
red cell
hemolysis, *in vivo*, *738*
survival, 862
Thrombocytosis
antifibrinolytic activity in, of serum and plasma, 355–361
life span of platelets in, 965–966
Thromboplastin
components of
deficiency, *707*
and heparin, in prothrombin conversion, 533–535
formation, liable factor in and excess platelets, *737*
generation test in hemophilic carriers, 1318–1319
pulmonary lesions following, *714*
time
of hemophilic B plasma and asolectin, 371
Thrombosis
cerebral
and gastrointestinal electrolyte content, 507, 517
and glucagon, 495

formation of, and viscosity of capillary and venous blood, *707–708*
intravascular, and streptokinase, *703–704*
life span of platelets in, 965
and vessel occlusion, 305–307
Thyroid
activity and cholesterol levels in hyper- and hypothyroidism, 1347
cessation of desiccated therapy, 808
disease
and calcium metabolism, 874–886
tocopherols in serum of, 1345–1356
and triiodothyronine, 57–61
function
and calcium metabolism, 874–886
in nephrosis, 792
heart disease sodium excretion in, 972–974
hormone
binding by erythrocyte stroma, 476–479
and calcium metabolism, 886
calorigenically potent during pregnancy, 1274
cellular metabolic response to, 1274
components, and tissue uptake, *709*
intracellular metabolism of, *687*
peripheral degradation of, 812
plasma protein complex, *708–709*
and protein synthesis, 168–169
radioactivity from tagged red cells, 479
thyrotropic, 792
iodine function in nephrosis, 799
in myxedema, 809, 812
uptake
of radioiodine, 792
from thyrotoxic plasma, *698*
Thyroidectomy
and calcium metabolism, 874–886
remission after, and triiodothyronine, 58
Thyrotoxicosis
calcium metabolism in, 874–886
hemodynamics in, 274–275
plasma hydrocortisone turnover in, 560
in pregnant women, 1274
radiothyroxine turnover studies in, *737*, 806–812
thyroxine bound to albumin in, *698*
tocopherol depletion in, 1345–1356
Thyroxamine, identification of, *687*
Thyroxine
binding
in maternal, neonatal and newborn sera, 1272–1273
by red cells, 475
deficiency in nephrotic syndrome, 798
degradation of in Graves' disease, *714*
and electrical alternans in single ventricular fibers of heart, *718*
fractional rate of turnover during pregnancy, 1274–1275
metabolism, *687*, *737*
in nephrotic syndrome, 792–799
in thyroid disease, 811–812
and triiodothyronine, *738*
partition of, during threatened abortion, 1270–1275
plasma protein-bound, 1263–1275
and proteinuria, *730*
radio-iodine labelled
in metabolism of thyroid study, *687*
uptake of, 121–124, 476–479
Tissue
adipose, and fatty acids
short chain, 1045–1053
unesterified, 211–212
catabolized and anabolized nitrogen/magnesium ratio of, after burn, 75
deformation, resistance to, 904, 907–910
elastic, and pulmonary compliance, 617
electrolyte and water content, 99–100
embryonic teratogenic effects on, *726–727*
fluid
extracellular, 99–105
insulin in, 458
homogenate cryoscopic measurements of, *694*
homotransplantation survival of, *699*
and Laennec's cirrhosis, 854
leukemic
chemotherapeutic specificity of agents for, *701*
reservoirs of, and rate of production, *691*
in leukopenia, 285
metabolism of, *720*
of oxygen and glucose in, 676
response to thyroid hormone, 1274
myeloid growth of and leukocytosis, 285
myxedematous and protein synthesis rate, 169
and paroxysmal nocturnal hemoglobinuria, 851
peripheral uptake of glucose by after glucagon, 494–500
radiochromic chloride in for red cell sequestration sites, 843–862
and sickle cell anemia, 848–849
thyroid hormone uptake, *709*
and thyroxine metabolism
in nephrotic syndrome, 792–799
in thyroid disease, 806–812
transplantation survival in uremia, *699*
Titratable acid
excretion of
after dl-alanine infusion, 228
urinary, and Diamox®, 28
Tocopherol, concentration in sera of thyroid disease, 1345–1356
Tongue, carcinoma of and hormone metabolism, 1034
Toxemia, of pregnancy hypertension secondary to, *708*
Tracheobronchitis, airway resistance after, 332–333
Transaminase
apoenzyme concentration of, 1089
hepatic glutamic pyruvic activity of, *710–711*
tyrosine apoenzyme deficiency, 1091
Transplantation
kidney, in male twin, *694*, 1364–1380
tissue, survival in uremia, *699*
Tremor, induced by ammonium salts, effect of glutamate on, 193–197
Triglycerides
in lymph chylomicra, 1027–1030
specific activity of, 1025, 1029
and total lipid levels after nephrectomy, 1381
Triethylenemelamine
in leukemia, 808–809
or lymphosarcoma, *701*
Trichloracetic acid
and radioinsulin, 173
and radiosulfate, 1125
Triiodothyronine
binding, plasma proteins, 475
calorigenic effect of, 809–810
conversion of thyroxine to in peripheral tissue, 811
diffusibility of, 478
and electrical alternans in single ventricular fibers of heart, *718*
in myxedema, 164–169, *737*
and protein metabolism, *705–706*
radioactive red cell uptake of, 121–124, 476–479
test, in hyperthyroidism, 57–61
Trihydroxyindole method, versus ethylenediamine, specificity of, for epinephrine and norepinephrine, 837–841
Tritium oxide, passage of in amniotic fluid and maternal water exchange studies, 636–640
Trypsin, neutralization of anticoagulant effect of, *735*
Tryptophan
blood sugar concentration after, 418
and heat stability of plasma protein, 1215, 1219
reabsorptive pattern for, 890, 893, 895
Tuberculin, and isoniazid, *718–719*
Tuberculosis, of lung, desoxyribonuclease activity in sera of, 1326
Typhoid, vaccine, reactions to, and aminopyrine, 947–952
Tyrosine
hypoglycemic effect, 415–418
identification of, 1078
metabolism in young, 1089–1092
oxidizing system in liver
development of, 236–243
and postnatal feeding, 1090–1092
transaminase activity, 1089–1092
phenylalanine conversion to, 623
reabsorptive patterns for, 890, 893, 895
urinary excretion of, in infants, 1089
Tyrosyluria, of premature infant and ACTH, 1092

U

Ulcer, duodenal
or gastric, in Addison's disease, *707*
and hemorrhage, 776–777
life span of platelets in, 965

Urea
oral loads of, during water diuresis, 755
pool, calculation of, 164
Uremia
anemia of, red cell survival in, 860
hypercholesteremic response to, 525
skin homografts survival of, *699*
after transplanted kidney, *694*
Uricosuria, and phenylbutazone analog, 381
Urine
acid-base and Diamox®, 21–29
acidotic stimulus, and sodium loss into, 100
after adrenal medullary hormone infusion, 1281
protein excretion, 1278–1283
and aldosterone, 800–805
and dehydration, *688*
in heart failure, 1305
and hydration, *725–726*
and sodium, *726*, 1305–1308
and water intake, 1308
alkaline
after dl-alanine, 228
after potassium chloride, *227*, 234
after sodium bicarbonate, 226–227, 234
antidiuretic substances, 392
hormone, 902
hypertonicity due to, *690*
after anti-kidney serum injections, 525–526
bicarbonate content of, 482–483
and bladder
potassium content, 515
specific activity, 513
calcium in vitamin D action on, 1241
calculi, organic matrix of, 1067–1078
carbon dioxide in, 482
carbohydrate-protein substances in, 1077
chloride
content, in respiratory acidosis, 482
excretion, in renal failure, 1097, 1106
after sodium chloride infusion, 483
output, after estrogen, 424–451
clearance of corticosteroids and creatinine, 1431
concentration
in hemolytic anemias, 846–860, 1003
versus serum and water diuresis, 753
composition of, 1077–1078
coproporphyrin output and blood lead concentration, 1135
corticoids and hydrocortisone turnover values, 557, 560
dilute, in diabetes insipidus, 902
electrolyte excretion in
after isotonic expansion of fluid, 1373, 1374
after sodium intake, 1376
after typhoid vaccine, 948–952
excretion in
and balance study in sarcoidosis, 1231–1241
after chlormerodrin, *32–37*, 1063–1064
of cholesterol, 1097, 1106
of fat, 1097, 1106
fatty acid as ketone bodies in, 1210
after folic acid citrovorum factor, *697*
after glucuronate or glucuronolactone, *278–279*
after hexamethonium, 872
of hormone metabolites, 1041
of phenylacetylglutamine, 620–621
of phenylpyruvic acid, 622
of porphyrins, 1131
during pyrogenic reaction, 947–952
after sodium bicarbonate infusions, 247
of vitamin B_{12}, *717*
excretion of radioactivity
in biliary fistulas, 1037–1040
hydrocortisone, 559–560
of sulfate, 1119–1128
extracts, and liver slices, 255
flow
after aminophylline, 1366
and bicarbonate concentration of reabsorption, 485
after chlormerodrin, 1055–1058
effect of sodium bicarbonate on, *226*
after hypertonic salt poor albumin, 1375
after hypotonic expansion, 1372
after isotonic expansion, 1373
during mannitol and Pitressin® infusion, 1366
and noradrenaline, 871–873
and Pitressin®, 1084
postural effects on, 268, 308–312
and pH, in ammonia excretion study, 223–234
and potassium, 157
after pyrogen, 1081–1087
during respiratory acidosis, 482
and salt depletion, *720–721*
and testosterone, 1114
after typhoid vaccine, 948–952
after venous congestion of lower extremities, 1371
versus osmolar clearance in hydropenia, 1086
and water diuresis, 231, 749–756
globulins
and adrenal medullary hormone infusion, 1281
iron-binding, renal clearance of, 55
glucose in
in diabetes mellitus, 1209
after valerate, 1296
and homozygous C disease, 853
hydrogen ion
concentration during sulfate diuresis, 308–312
excretion, and Diamox®, 25–29
17-hydroxycorticoid, and
17-ketosteroid ratio, in rheumatoid arthritis, *711*
loss, due to, 1050–1051
hydroxyproline in
concentration, 580
hydrolysis, 584
hydrolysis and extraction of, 800–805
in Laennec's cirrhosis, 854
in nephrotic syndrome, 798
mannitol and sucrose in, in single injection methods, 928–933
metabolite in and virilization, *693*
of normal, 843–845
organic iodine in as thyroxine and/or diiodotyrosine, 798
osmolarity, 1080–1084
and Pitressin®, 1084
and pyrogen, 1083
and water diuresis, 749
output, in ferritinemia and viral hepatitis, 592
output, and estrogen, 424–451
in hepatic disease, 431–441
in renal and cardiac disease, 443–451
and paroxysmal nocturnal hemoglobinuria, 851
and pernicious anemia, 855
pH
in aldosteronism, 1359, 1361
after amino acid infusion, 228
and chloruretic action of mercurials, 157–162
after potassium chloride infusion, 227, 234
after sodium bicarbonate infusions, 226, 234, 247–252
phosphate output and estrogen, 434–441
phosphorus, vitamin D action on, 1241
after Diamox®, 21, 1370
and dietary potassium, 157–158
and posture during sulfate diuresis, 308–312
potassium
and acetazoleamide, 1359, 1361
after albumin, 1375
and aldosterone, *726*, 1304, 1307, 1313
in aldosteronism, 1357–1361
and compound F, 1050–1051
after hydrocortisone, 1236, 1374
after isotonic expansion, 1374
during pyrogenic reaction, 947–952
and renal failure, 1097, 1106
after sodium depletion, 1308
after typhoid vaccine, 948–952
after water intake, 1308
pregnanetriol in effect of ACTH on, 218–221
protein-bound iodine in, 792
of hydrocortisone, 1037–1040
radioactivity in after intravenous insulin-I^{131}, 172
radioactivity of steroids in, 1034–1040
radiocalcium excretion into of boys and young adults, 81–87
radiochromic chloride excretion in, 843–862
radiomanganese excretion in, 832–836
rate of loss in of albumin, gamma globulin and iron-binding globulin, 48–53

sediment counts in aldosteronism, 1360
and sickle cell anemia, 848–849, 998–1006
sodium
and aldosterone-like steroids, 1306
and aldosteronism, 1359
in cardiacs and cirrhotics, 1313
and compounds A and F, 1047
in constrictive pericarditis, after estrogen, 446
and dehydration, 1309
in diabetes insipidus, 900
and estrogen, 424–451
in heart disease, 971
during pyrogenic reaction, 952
in renal failure, 1097, 1106
after sodium depletion, 1308
after typhoid vaccine, 948–952
after water intake, 1308
solute excretion
postural effects on, *268*
variations in, and water diuresis, 749
specific gravities
in diabetes insipidus, 900
and anemia, 1000, 1003
volume
in renal failure, 1097, 1106
and testosterone, 1114
Urobilinogen, fecal, in anemia of cancer, 1249–1251, 1256, 1258
as hemolytic indices, 1248
Urokinase, plasminogen activation by, *735*
Uropepsin, excretion, in Addison's disease, *707*
Uroporphyrin, conversion of, to coproporphyrin and protoporphyrin, *689*
Uterus, thyroxine passage to, 1274

V

Vaccination, and intestinal infection of family contacts of poliomyelitis, *722*
Valerate, narcotic action of, 1292–1298
Valine
blood sugar concentration after, 418
reabsorption patterns, 890–895
Valvulitis, due to virus and/or cortisone, 365
Valvulotomy, mitral, and capacity diffusing, 1008–1013
vital, and pulmonary compliance, 615
van den Bergh reaction
of bilirubin, 537–538
and hydrogen ion levels, 550
Vaponefrin®, and ventilatory response to carbon dioxide, 1286–1290
Vasoconstriction
after epinephrine and nor-epinephrine, 574
and adrenal medullary hormones, 1283
intrarenal
and potassium excretion, 951
during pyrogenic reaction, 952
renal
in denervated kidney, 1377, 1378
and glomerular filtration rate, 1283
and noradrenaline, 872
Vasodilatation
after epinephrine and nor-epinephrine, 574
renal after transplantation, 1377, 1388
Vasopressin, in orthostatic hypotension, 1412–1418
Vena cava
inferior
pressures of, and endotoxin, 1192–1193, 1196–1197
thrombosis of, 443, 447–451
superior obstruction, 443, 447–451
thoracic, constriction of, 900
Ventilation
body position, 910
and change in compliance, 918
capacity
and carbon dioxide inhalation, 1286–1290
and pulmonary disease, *705–706*
versus blood-gas exchange, 1010–1013
pulmonary, after mitral valvulotomy, 1013
in pulmonary emphysema
and bronchodilator, 1287
rate of flow, 394–403
in respiratory acidosis
and sensitivity of respiratory center, 1286–1290
after sodium bicarbonate, 665
tidal, and measurement of lung volume, 665
Ventricle
end diastolic pressure in heart disease, 975
filling and gallop sound, *719*
left
distribution of radiomercury labeled mercaptomerin in, 776–777
stroke work, 1221–1227
vascular segments mixing in, *697*
versus atrium circulation times, *697*
Virilization
adrenal hyperplasia, 213–221
Virus
adaptation of, 1302
and myocarditis, 363
in tissue culture, 366–367
coxsackie, cardionecrotizing effects of, and cortisone, 362–370
infection of the respiratory tract, *715*
and nonbacterial gastroenteritis, immunity against, 200–204
poliomyelitis sensitized with antibody and complement, *727*
and properdin system, 456
Viscometer
capillary, for viscosity measurement, 1420
and venous, *707–708*
Vitamin
A, epiphasic carotenoid conversion to, 1243
B_{12}
absorption, *699*
in chronic myelogenous leukemia, *724*
deficiency, *733*
and liver damage, *716–717*
in pernicious anemia, *733*
D
absorption of, 1237, 1241
fecal, *710–711*
overdosage, and hypercalcuria in sarcoid, 1229
parathyroid-hormone-like action of, 1238–1241
E deficiency, and muscular dystrophy, 1346, 1353

W

Water
and amniotic fluid exchange, formation, and removal, 634–640
and antidiuretic hormone
diuresis, 749
metabolism, *392*
retention, 393
balance
and weight, 1308
and cardiac failure, 446–448
and cirrhosis, 432–436
and compounds A and F, 1047–1050
in constrictive pericarditis, 444–446
in diabetes insipidus, 897–898
and estrogen metabolism, 424–451
in nephrotic syndrome, 447–449
and sodium, 427, 1111
and testosterone propionate, 1111
and urinary output after estrogen, 424–451
body
antipyrine versus deuterium dilution methods, 782–783
in body fat estimation, 1050–1051
distribution of total, 598–600
in edematous states, 779–791
and fat-free dry solid content, 763–773
in heart disease, 784
in renal failure, 1099–1100
sodium ratio to, 791
total, 598–600, *703–704, 735–736,* 791, 1309
change, and body composition in potassium depletion, 768–773
clearance
after hypertonic salt poor albumin, 1375
after isotonic expansion, 1372
and pyrogen, 1082–1087
rate of free, and hydropenia, Pitressin®, 1358
concentration,
in erythrocytes, 609–610
in tendon, bone, and muscle, 99–105
in fatty livers, 349
connective tissue, penetration of sulfate into, 1125
conservation, in aldosteronism, 1361

Water (*cont'd*)
diuresis
and alcohol ingestion, 386–393, *732*
and body position, 268
and clearance, 749–756
excretion and concentration of ammonia after, 230
and Pitressin®, or pyrogen, 1084
in sickle cell anemia, 1005
and urinary flow, 231, 749–756
drinking, and urinary output in diabetes insipidus, 901
erythrocyte and plasma radiosulfate concentration in, 607–609
exchanges
in renal failure, 1102
versus total body content in infant and adult, *703–704*
excretion
in Addison's disease, 756
after albumin infusion, 1375
after aminophylline, 1366
in cirrhosis of liver, 756
of congestive heart disease, 756
fecal, in renal failure, 1097, 1106
after hydrocortisone, 1370
after l-norepinephrine, 1368
during mannitol and Pitressin®, 1366
and orthostatic hypotension, 1369
of panhypopituitarism, 756
and pyrogen, 1080–1087
renal patterns, and mercurial diuretics, *696*
in sweat, 116–120
extracellular, radiosulfate space as index, 1119–1128
gastrointestinal, 502–509
impaired tolerance, 386–393
intake in renal failure, 1097, 1106
intracellular
in infant malnutrition, *723–724*
and Pitressin®, 1307–1314
loading and plasma osmolality, 1377
measurement of total body, 599
metabolism of
and antidiuretic hormone of the posterior pituitary, 393
and changes in body composition, 1104–1105
in infant malnutrition, *723*
and nitrogen, total body versus fat free dry solid, 765
across placenta exchange of, 634–640
reabsorption
defect in, and aldosteronism, 1361
and hydropenia, Pitressin®, 1350
and supraopticohypophyseal system, 1313
retention in cirrhosis with ascites after estrogen, 433–439
and compounds A or F therapy, 1049
and G-25671 versus phenylbutazone, 382, 384
and heart failure, 1304
serum, equilibrium concentration of radiosulfate in, 607–610
and sodium
metabolic effects in distribution edema formation, 791
and testosterone during sodium restriction, 1115
tolerance tests, in hepatic disease, 436
See also Fluid
Weight
and airway resistance, 331
and calcium metabolism, 883
in cardiac failure, and estrogen, 446–448
in chloride, potassium and sodium studies, 596
cirrhosis without ascites and estrogen, 435–436
in constrictive pericarditis after estrogen, 444–446

X

Xanthine
paper chromatography of, 657
Xanthomatosis, hypercholesteremic, 282
Xanthosine
and phosphate esters of stored erythrocytes, 659
and resynthesis of phosphates, 565–566

Y

Yeast
cell metabolism inhibition, 1297–1298

Z

Zinc
concentration, in cirrhosis, *688*
turbidity and serum gamma globulin, *704–705*
Zymosan, and properdin system, 456